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Abstract 
 
Background: Platelets provide the initial haemostatic plug at sites of vascular injury. They 
also participate in pathological thrombosis that leads to myocardial infarction, stroke and 
peripheral vascular disease. 
The outcome of an  acute myocardial infarction depends not only on the formation  and 
stability of an occlusive thrombus, but also on the efficacy of the endogenous thrombolytic 
process,  which  allows  reperfusion  of  the  infarct  related  artery  and  prevents  recurrent 
ischaemic episodes. Various platelet function tests are available to measure the thrombogenic 
potential of an individual, but the sensitivity of these tests remain questionable as most of 
these tests use citrated blood and measure response to a particular agonist. Endogenous 
thrombolysis  has  been  a  neglected  entity,  and  its  beneficial  effects  on  cardiovascular 
outcomes has not been studied in depth in the past, possibly as until recently there has been 
no available technique to measure spontaneous thrombolytic activity in native blood. The 
Global Thrombosis Test (GTT) is a new point of care tests that allows us to measure time to 
thrombus formation (Occlusion time: OT) using native blood, avoiding the use of agonists 
and making the test results more physiological. The GTT also measures the time to lyse this 
formed thrombi without use of any lytic agents (Lysis time: LT), allowing us to measure the 
patient’s endogenous thrombolytic potential. 
 
Aim: Our aim in this study was to detect patients who are at risk of future thrombotic events 
despite dual antiplatelet therapy, either due to prothrombotic tendency or due to impaired 
endogenous thrombolysis, and to determine if these two parameters were correlated. 
 
Methods: GTT was used to assess the thrombotic and thrombolytic activity in healthy 
volunteers, and in different patient populations. 100 healthy volunteers were tested using the 
GTT, and a normal range was established. 300 patients admitted to hospital with a diagnosis 
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of acute coronary syndrome (ACS) were included in the study, and tested using the GTT after 
they had been stabilized on dual antiplatelet therapy (Aspirin and Clopidogrel). All these 
patients were followed up for a year, to determine if their baseline GTT results were a 
predictor of recurrent cardiac events. The primary endpoint of the study was major adverse 
cardiovascular events (MACE), which was a composite of cardiovascular death, nonfatal 
myocardial infarction, or stroke at 12 months. 
 
Results: All results were analysed using statistical package SPSS version 16.0 (SPSS Inc., 
Chicago, Illinois). 
The 100 healthy volunteers were all non-smokers, and were not taking any medications. 
There were 55 males and 45 females, and mean age was 38±11 years (range 22-76, IQR 11). 
OT was normally distributed with mean OT 377.80s, and using mean ± 2SD, we derived a 
normal range of 185-569s (200-550s). LT demonstrated a skewed distribution with values 
ranging between 457 – 2934s. Using log transformation, a normal range of 592 – 1923 (600- 
2000s) was established for LT. 
 
OT and LT were both prolonged in ACS patients compared to normal volunteers (p< 0.001). 
No association was observed between OT and risk of major adverse cardiovascular events. 
LT was noted to be a significant and independent predictor of MACE in a multivariate model 
adjusted for cardiovascular risk factors. LT ≥ 3000 s was the optimal cutoff value for 
predicting 6 month MACE [hazard ratio (HR): 2.48, 95% CI: 1.2-4.8, P= 0.008] and 
cardiovascular death [HR: 4.04, 95% CI : 1.3-12.0, P= 0.012   ] and 12 month MACE 
[HR:1.9, 95% CI: 1.04- 3.5,P= 0.03] and cardiovascular death [HR: 3.9,95% CI: 1.34-11.9, 
P= 0.013 ]. LT ≥ 3000 s was observed in 23% of ACS patients. 
Conclusions: Our study suggests that endogenous thrombolytic activity based on lysis of 
platelet rich thrombi can be assessed by the point of care GTT assay, which can help in  
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identification of ACS patients at high risk of future cardiac events. Prolongation of OT may 
be explained by the antiplatelet effects of Aspirin and Clopidogrel, as both these drugs 
prolong time to thrombus formation and hence increase OT. Further large studies are required 
to study factors which can reduce thrombogenic potential, and improve endogenous 
thrombolytic activity, which can be monitored using the GTT to improve cardiovascular 
outcomes.
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Objectives, Hypothesis and Outline of this thesis 
 
 
Objective 
 
The main objective of this thesis was to identify patients who are at recurrent risk of 
thrombotic events despite being on dual antiplatelet therapy, using a new point of care system 
– the GTT. It was our aim to determine if OT or LT was a significant predictor of adverse 
cardiac events, and if there was a correlation between these two variables. 
 
Hypothesis 
 
 
Among patients receiving dual antiplatelet therapy with standard doses of aspirin and 
clopidogrel following an acute coronary syndrome, those with enhanced platelet reactivity or 
impaired endogenous thrombolysis are at increased risk of future major adverse cardiac 
events. 
 
Outline 
 
 
In Chapter 1, I will discuss the mechanism and determinants of thrombus formation and 
endogenous thrombolysis, the different antiplatelet agents available, the mechanism of 
antiplatelet resistance and role of different platelet function and plasma fibrinolytic tests in 
identification of patients at risk of future cardiac events. 
Chapter 2 explains the methodology, and in Chapter 3, I will discuss the development of 
normal range for OT and LT in healthy volunteers in the Western and Japanese populations. 
Chapter 4 explores the role of ADP in thrombus formation, and its effect on OT and LT in 
healthy individuals. It also studies the effect of Aspirin on prolongation of OT, with a 
moderate effect on LT in patients with stable angina. A significant effect is observed with  
clopidogrel on prolongation of OT, with no significant effect on LT in healthy individuals, 
and in patients with stable angina. In Chapter 5, the relationship between OT and MACE,  
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LT and MACE and effect of other variables on LT and MACE in the ACS group of patients 
is demonstrated. It also studies the effect of dual antiplatelet therapy on OT and LT in 
stable angina patients, and comparison is made with healthy volunteers and ACS patients. 
C omparison is then made with the results of two platelet function tests, the GTT and the 
Verify now assay.  Chapter 6 discusses the limitations of our methodology, with future 
research ideas. This is followed by Appendices, which includes the Ethical  approval  
documents,  Case  Report  Forms,  publications  from  this  study,  and references.
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Chapter 1: Introduction 
 
Background 
 
 
 
Aspirin and clopidogrel are the antiplatelet agents most commonly used in patients with 
coronary artery disease. However, 5-60% of patients taking aspirin and 4-30% of those taking 
clopidogrel continue to experience thrombotic events despite treatment with these agents 
(Nguyen et al. 2005). Evidence from some studies suggests that reduced responsiveness or 
“resistance” to antiplatelet agents is associated with subsequent major adverse cardiac events 
(MACE). The definition of antiplatelet drug resistance largely depends on the method used to 
measure platelet function. As a result, no standard definition has been universally accepted. 
However, it remains unknown whether altering therapy based on platelet function tests is 
beneficial to patients. There are currently no guidelines for the treatment of antiplatelet drug 
resistance. Although point-of-care platelet-function testing makes screening for resistance 
feasible, routine screening has not been recommended in clinical practice due to lack of 
standardized measures of platelet function. 
Platelet function tests are used to detect patients with abnormal platelet function, which may 
be inborn or acquired, and is used to detect platelet activation in patients at risk of thrombotic 
events. They are also used to monitor the effect of antiplatelet agents such as aspirin, 
clopidogrel or membrane glycoprotein IIb/IIIa inhibitors. Incorrect blood sampling is a major 
source of error in measuring platelet function. Most tests lack sensitivity and have low 
positive predictive value for clinical events and are difficult to perform in the clinical setting. 
There has been no suitable bedside test of thrombotic function, all prior tests showing 
clopidogrel resistance have been done in a haematology laboratory, away from the patient, 
and most of these tests either used platelet rich plasma or citrate-anticoagulated blood, or 
supra high doses of agonists to induce platelet aggregation and thus were not “physiological” 
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in terms of truly representing the in vivo situation ( Zucker et al. 1978). Recent data from the 
 
Reclose 2-ACS study demonstrated high platelet reactivity to both clopidogrel and aspirin in 
 
9% of ACS patients. 1,789 patients with ACS were enrolled in the study, and tested using 
both arachidonic acid and ADP as agonists.This phenotype was known as global high platelet 
reactivity (GHPR), and GHPR was significantly associated with cardiovascular ischemic 
events and cardiac death in a Cox regression analysis (MACE: HR=1.5[1.0-2.2], p=0.02; 
cardiac death: HR= 1.9[1.2-3.2], p=0.008). These results suggest that global high platelet 
reactivity is a more effective parameter for identifying ACS patients at high risk of ischaemic 
cardiac events (Marcucci et al. 2012). 
There are various global assays of fibrinolysis, but none of the tests are really used in the 
clinical setting (Stief et al. 2007). They are time consuming, labour intensive and most 
importantly there is uncertainty with regards to which biomarker should be measured, as 
limited data is available on fibrinolytic marker levels and cardiac outcomes. Furthermore, 
most of the tests available measure clot lysis as opposed to thrombolysis. 
Thrombotic events not only depend on the propensity to thrombus formation, but also on the 
efficacy of endogenous thrombolytic activity. Endogenous thrombolysis is a protective 
mechanism against lasting arterial occlusion, and acute myocardial infarction (AMI) has been 
considered a result of failure of timely spontaneous thrombolysis.  A large number of patients 
with occluded arteries had coronary angiography weeks to months after their initial AMI, and 
patency of the culprit artery was demonstrated, suggesting endogenous thrombolysis had a 
key role to play in the dissolution of the thrombus (Swan et al. 2003). This entity has been 
neglected so far, more so because until recently, there has been no physiological test available 
to assess endogenous thrombolytic activity. 
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The Global Thrombosis Test is a point of care test that allows the measurement of dynamic 
coagulation and spontaneous thrombolysis, which is lysis of an autologous platelet–rich 
thrombus in the absence of added plasminogen activators. The test is performed on non- 
anticoagulated native blood without added external agonists. In this technique, an occlusive 
thrombus is formed using high shear stress, analogous to that in a stenosed coronary artery. 
The first phase of the test (Occlusion time: OT) is used as a marker of platelet function, the 
more reactive the platelets the faster the occlusion will occur. The restart of blood flow 
following occlusion is due to spontaneous thrombolysis (Lysis time: LT). This is a near 
patient test, which provides a result on the patient’s thrombotic and thrombolytic status, and 
is applicable to acute clinical situations, as well as more general screening (Yamamoto et al. 
2003). 
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Pathophysiology of thrombus formation 
Platelets are small discoid cells present in blood, produced by fragmentation of megakaryocytes 
and play a significant role in haemostasis. They are 1-2µm in diameter, and have a life span of 
5-10 days. Normal platelet count is 150,000-350,000 per microlitre of blood. The vascular 
endothelium is responsible for maintaining the integrity of the vessel wall. Intact 
endothelium releases nitric oxide, prostacyclin, ectonucleotidase CD39, thrombomodulin and 
tissue factor pathway inhibitor, all of which inhibit thrombus formation. CD39 is an ecto- 
nucleoside triphosphate diphosphohydrolase enzyme and an integral component of the 
endothelium. It degrades ADP by neutralizing prothrombotic releastase and thus prevents 
thrombus formation. It also reduces norephinephrine release in the heart and prevents serious 
cardiac arrhythmias (Marcus et al. 2005). 
Disruption of the endothelium by flowing blood results in exposure of prothrombotic substances  
such  as  collagen,  vWF,  fibrin,  fibronectin  and  oxidized  LDL which  activate platelet 
monocyte complex formation and activates platelets resulting in platelet aggregation. 
Neutrophils represent 40-60% of the leucocytes and monocytes represent 5% of the leucocyte 
concentration. Both neutrophils and monocytes have a very short half-life of upto 20 hours, but 
their life span increases approximately three times in inflammation. Leucocyte activation results 
in release of mediators of inflammation such as elastase, cathepsin G, lactoferrin and cytokines.  
The different types of cytokines released are interleukins, TNFα, G-CSF and GM-CSF. These 
mediators of inflammation cause leucocyte adhesion to the endothelium, initiate release of 
oxidant radicals O2 and H2O2 which result in tissue damage which in turn cause platelet 
activation and aggregation. Tissue factor is also present on the surface of monocytes and 
macrophages, which together with Factor VIIa aids in the coagulation cascade. Tissue factor 
forms a complex with Factor VIIa and converts inactive Factor X to active Factor Xa.   
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Activated Factor X then combines with Factor V in the presence of phospholipid and calcium, 
generates thrombin and results in thrombus formation (Gorbet et al. 2004). 
Collagen is a protein of the vessel wall that maintains tissue integrity, and allows matrix 
constituents to adhere to the vessel. The platelet-reactive collagens I–IV support platelet 
adhesion up to relatively high shear rates and also induce platelet aggregate formation at shear 
rates found in the small vessels upto a shear of 2000s. (Farndale et al.2004). Platelet 
accumulation on collagen at shear rates of 300s to 1250s is enhanced by coperfusion with 
plasma fibronectin (Nievelstein et al. 1988). Fibronectin is a glycoprotein dimer and component 
of the subendothelium, and helps in stabilization of the platelet aggregates after vascular injury.  
vWF is a multimeric glycoprotein synthesized in the endothelial cells and megakaryocytes. It is 
present in the subendothelial matrix, blood plasma and platelets.  It binds and transports Factor 
VIII and collagen and promotes platelet adhesion, aggregation and thrombus formation (Ruggeri 
et al. 2007). Oxidized LDL is cytotoxic to endothelial cells and enhances thrombus formation by 
free radical formation and impairment of nitric oxide synthase activity (Mehta et al. 2001). It 
also activates CD40 and increases activity of metalloproteinases. Alternative pathway involves 
tissue factor release which forms a complex with Factor VIIa and activates Factor IX and 
generates thrombin. Protease activated receptor PAR4 is the main thrombin receptor in 
platelets and thrombin is responsible for cleaving this receptor on the platelet surface resulting 
in thromboxane A2, serotonin and ADP release which help in the formation of thrombus. 
ADP is stored in the dense granules of platelets, and activates platelets by binding to P2Y1 and 
P2Y12 receptors (Fig 1). Thus thrombus formation occurs in 2 stages – initial stage involves 
glycoprotein VI and glycoprotein Ia/IIa mediated platelet activation following collagen  
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exposure, followed by stabilization of the thrombus by formation of thrombin and fibrin 
triggered by tissue factor release (Colman et al. 2006). 
Disruption of an atherosclerotic plaque results in platelet aggregation and eventually formation 
of an intra-coronary thrombus. This thrombus obstructs the lumen of the vessel, resulting in 
either partial or complete occlusion of blood flow. This imbalance in myocardial demand and 
supply results in coronary ischemia, and presents clinically as an acute coronary syndrome. The 
atherosclerotic plaque is composed of a central lipid core, surrounded by a fibrous cap. The 
plaque is composed of various inflammatory cells which result in disruption of the fibrous cap. 
Various enzymes such as metalloproteinase are also produced by the plaque, and result in further 
plaque disruption. Thin capped fibrous atheroma with fibrous cap thickness < 65 mm are more 
prone to disruption and result in acute coronary syndromes.  
Endothelial dysfunction is an important determinant of thrombus formation. Intact vascular 
endothelium release nitric oxide and prostacyclin which relax blood vessels and inhibit platelet 
activation. In endothelial dysfunction, the release of these substances is reduced resulting in 
platelet activation and aggregation, and increased amounts of thrombus formation. 
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Figure 1 – Platelet receptors 
 
 
 
 
 
 
 
 
 
 
 
Nature Reviews Drug Discovery 2, 775-789 
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Determinants of thrombus formation (Occlusion time) - Role of calcium and 
agonists in platelet aggregation 
 
 
Intracellular calcium plays an important role in the coagulation process. It activates 
phospholipase A2 which results in release of arachidonic acid, thromboxane A2 and 
subsequently enhances platelet aggregation. It plays a role in both the intrinsic and the 
extrinsic clotting pathway, as it is required for activation of Factors VII, IX, X, XI and XIII. 
It is also important for conversion of glycoprotein IIb/IIIa (GPIIb/IIIa) complex into the 
functional fibrinogen receptor, and assists in binding of fibrinogen to its receptor (Shattil et 
al. 1985). The calcium concentration required for aggregation to occur is in the range of 10- 
100µM, below which no platelet aggregation occurs (Ataullakhanov et al. 1994). Most platelet 
function tests use citrated blood and test platelet activation and aggregation. Citrate is known 
to reduce the plasma calcium concentration significantly from 0.94-1.33mM to 40-50 
µM, and hence results in suboptimal platelet aggregation. Use of trisodium citrate in citrated 
blood reduces the calcium concentration to significantly low levels (Rebello et al. 2000), 
altering the platelet response to agonists and antagonists, and   renders the tests non 
physiological by eliminating the effects of thrombin on platelet aggregation. Minimum 
calcium concentration required for platelet aggregation is 10 µM and at levels greater than 
250 µM, thrombin is generated by activated platelets and eventually coagulation occurs at 
levels over 330 µM concentration (Scarborough et al. 1999). 
 
Available platelet function tests use agonists like arachidonic acid, collagen, epinephrine and 
ADP in citrated blood. All these agonists result in release of platelet granule contents and 
subsequently increase production of thromboxane A2 which accelerates aggregation. 
Furthermore, the concentrations of these agonists in vitro are significantly higher than that 
measured in native blood. There is also intraindividual variability in release of the granule 
contents and TXA2, questioning the reliability of the results obtained. At physiological 
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calcium concentration, none of these agonists cause granule or TXA2 formation ( Gorog et 
al.2009). A study by Patel et al compared the amount of platelet aggregation using different 
quantities  of ADP  (1,  5,  10,  and  20  µM), and  no  significant  difference in  aggregatory 
response was seen with 10 µmol/l when compared to 20 µmol/l ADP. This study also 
demonstrated reduced platelet aggregation in citrate anticoagulated plasma. The non calcium 
chelating anticoagulant used in the study was PPACK (D-Phenyalanyl-L-propyl-L-arginine 
chloromethyl ketone), and platelet aggregation was measured using a Light Transmission 
Aggregometer (Patel et al. 2006). 
 
Thrombin is important in the platelet activation and aggregation pathway. It is a serine 
protease protein that cleaves soluble fibrinogen to insoluble fibrin and causes platelet 
activation and aggregation. It activates the G protein-coupled protease receptors PAR1 and 
PAR4 on platelets, which in turn activate heterotrimeric and monomeric G proteins 
leading to increase in cytosolic calcium concentration, platelet shape change and enhances 
platelet aggregation. In native blood, at physiological doses of calcium, all agonists induce 
thrombin release and activate the intrinsic coagulation system resulting in granule content 
release, platelet aggregation and thrombus formation. Thrombin converts fibrinogen to fibrin, 
which stabilizes the thrombus to the vessel wall. In citrated blood, calcium is below the 
threshold concentration of 250µM, which suggests thrombin is not generated. Hence, most 
platelet function tests do not assess the role of thrombin in platelet aggregation, and exclusion 
of such an important mediator of thrombosis makes the results of these tests unreliable in the 
clinical setting. Direct thrombin inhibitors, PAR1 antagonists such as Atopaxar and 
Vorapaxar have recently been developed to inhibit thrombosis (Brass et al. 2003, 
O'Donoghue et al. 2011, and Morrow et al. 2012). 
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The plasma protein vWF is essential for adhesion and activation of platelets, and regulates 
release of thrombin upon binding to platelet membrane receptors glycoprotein Ib-IX-V 
and IIbIIIa (Crary et al.1995).  Moake and colleagues demonstrated the binding of vWF to 
glycoprotein Ib in vitro, and this binding ultimately assists in the cross linking of platelets to 
form an aggregate (Moake et al. 1986). A study by Nishida et al revealed inverse 
correlation between vWF and occlusion time using the GTT in 132 healthy volunteers, 
suggesting vWF is essential in the formation of thrombus (Nishida et al. 2006). Inverse 
correlation was also noted between RBC, haemoglobin, haematocrit and occlusion time 
in this study. Another Japanese study by Ikarugi et al has also reported inverse 
correlation between haematocrit and occlusion times (Ikarugi et al. 2003).  
It has been mentioned that Shear stress is required for platelet activation and this stress can 
vary between 50-3000 dyne/cm
2 
depending on the degree of arterial stenosis. On activation 
by high shear of at least 250dynes/cm2, platelets release ADP and contribute to thrombus 
formation. Strony et al demonstrated that platelets are activated by high shear stress levels 
in stenosed coronary arteries, and adhere at sites of vessel wall damage eventually forming 
a thrombus (Strony et al. 1993). 
ADP is a nucleoside diphosphate stored in platelet granules and released upon platelet 
activation. It binds with the G-protein coupled platelet receptors P2X1, P2Y1 and P2Y12 
resulting in release of intracellular calcium, changes the shape of the platelet, and plays an 
important role in platelet activation and aggregation through inhibition of the enzyme adenyl 
cyclase. It also generates thromboxane A2 by hydrolysis of arachidonic acid from 
phospholipid, which enhances the aggregation process (Jianguo et al. 2002). 
Collagen is a naturally occurring protein found in the subendothelium of the vessel wall, and 
gets exposed on disruption of the vessel wall. It binds to glycoprotein VI and glycoprotein  
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Ia/IIa  receptors  on  platelets,  and  results  in  thromboxane A2  generation  which  enhances 
platelet aggregation. Glycoprotein Ib-V-IX binds to the vWF present in collagen and further 
activates platelets (Lodish et al. 2000). 
Epinephrine, also known as adrenaline is a catecholamine released by the adrenal glands 
from the amino acids phenylalanine and  tyros ine . Tyrosine is ox id ized  to  L-Dopa 
which  i s  decarboxylated to Dopamine. Dopamine β-hydroxylase converts Dopamine to 
Norepinephrine, which is eventually methylated to form epinephrine. Epinephrine binds to 
the α2-adrenergic receptor on platelets inhibiting adenyl cyclase and releases calcium ions. It 
induces fibrinogen receptor expression and fibrinogen binding and activates platelet 
aggregation (Shattil et al. 1989). 
 
Arachidonic acid is a polyunsaturated omega -6 fatty acid. It is converted to 
prostaglandin G2 and H2 and thence to thromboxane A2 by cyclooxygenase and 
thromboxane synthase. Thromboxane A2 is a potent vasoconstrictor and induces platelet 
activation and aggregation. 
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Antiplatelet agents: a review of the evidence 
 
 
 
Aspirin 
 
Aspirin, also known as acetylsalicylic acid inhibits prostaglandin and thromboxane A2 
production by acetylation of COX1, the enzyme that produces the cyclic endoperoxide 
precursor of thromboxane A2. The action of aspirin on platelet cyclooxygenase is permanent, 
lasting for the lifetime of the platelet (7-10 days) and repeated doses of aspirin produce a 
cumulative effect on platelet function. 
 
In addition to being an antiplatelet agent, it also works as an anti-inflammatory drug with 
analgesic properties. A metanalysis by the Antiplatelet Trialists collaboration analysed data 
from 25 randomized trials, and demonstrated that aspirin reduced vascular mortality by 15% 
and non-fatal vascular events (stroke or myocardial infarction) by 30% (Antiplatelet Trialists' 
Collaboration .1998). Another metanalaysis by the Antithrombotic Trialists collaboration 
examined data from from 195 clinical trials involving more than 135000 patients, and 
demonstrated a 40% reduction in cardiac events in unstable angina patients on aspirin 
(Antiplatelet Trialists' Collaboration . 2002). The ISIS-2 study showed a significant reduction 
in non-fatal reinfarction and stroke in patients with prior myocardial infarction on aspirin 
(ISIS-2 Collaborative Group.1988). 17187 patients with AMI were randomized with placebo 
control, to aspirin, streptokinase, both or none of the medications. A significant reduction in 
vascular mortality was observed in the aspirin group when compared to placebo (9.4% vs. 
11.8%, p< 0.001).  Patients admitted with myocardial infarction, on aspirin the week prior to 
admission have also demonstrated a reduction in ischaemic episodes and reinfarction rates 
(Garcia-Dorado et al.1995). In a study of 539 patients admitted with an ACS, 214 were taking 
aspirin prior to admission. AMI occurred in 52 (24%) of these patients, compared to unstable 
angina in 162 (76%), and AMI was significantly lower in the cohort of patients who had been 
28 
 
 
 
 
on aspirin prior to admission compared to those not on prior aspirin (24% vs 54%, p < 
 
0.0001). The Swedish Angina Pectoris Aspirin Trial (SAPAT) was the first prospective study 
of aspirin in stable angina patients established on a beta-blocker, demonstrating a significant 
reduction in the incidence of first myocardial infarction in patients with symptoms of stable 
angina pectoris (Juul-Moller et al. 1992). 2035 stable angina patients on sotalol were 
randomised double-blind to treatment with aspirin 75 mg daily or placebo. There was a 34% 
reduction in primary outcome events which included myocardial infarction and sudden death; 
(95% CI 24-49%; p = 0.003). In a Veterans Administration Cooperative Study by Lewis et al, 
1266 men with unstable angina were randomized to aspirin or placebo. The primary endpoint 
was death and acute myocardial infarction, the incidence of which was 51 per cent lower in 
the aspirin group than in the placebo group (5% vs. 10.1%, p = 0.0005)( Lewis et al. 1983). 
However, aspirin does have its limitations as it only inhibits TXA2 synthesis, and has little or 
no effect on other platelet agonists. It inhibits some platelet inhibitors like prostacyclin and 
important side effects include bleeding events and gastric irritation. Resistance to aspirin is 
seen in approximately 30-40% of patients who continue to experience adverse cardiac events 
inspite of being on aspirin. 
 
Clopidogrel 
 
 
Clopidogrel is a potent, oral antiplatelet agent. It is a thienopyridine derivative, and inhibits 
both exogenous ADP dependent platelet activation andaggregation.It is a prodrug oxidized by 
the hepatic cytochrome P450 system to its active metabolite, which irreversibly binds to the 
ADP-coupled P2Y12  receptor. P2Y12  inhibition thus inhibits ADP-induced platelet activation 
and resultant aggregation. Clopidogrel has been used as an “add-on” therapy to aspirin, and 
has shown significant reduction in thrombotic events in patients with atherosclerotic disease 
(MI, CVA and PVD). The   CURE study (The Clopidogrel in Unstable Angina to Prevent 
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Recurrent Events Trial Investigators.2001), showed a  20% relative risk reduction (RRR) in 
cardiovascular death, non-fatal MI and CVA in NSTEMI patients on dual antiplatelet therapy 
(aspirin and clopidogrel). 12,562 patients with NSTEMI were randomized to clopidogrel (300 
mg immediately, followed by 75 mg once daily) or placebo in addition to aspirin for 3 to 12 
months. The primary outcome was a composite of death from cardiovascular causes, nonfatal 
myocardial infarction, or stroke and occurred in 9.3 percent of the patients in the clopidogrel 
group  and  11.4  percent  of  the  patients  in  the  placebo  group.  (RR with clopidogrel as 
compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001).  The 
COMMIT (CLOpidogrel and Metoprolol in Myocardial Infarction Trial collaborative group. 
2005) and CLARITY TIMI 28 (Sabatine et al. 2005) study demonstrated a significant 
reduction in death, non-fatal MI and CVA in STEMI patients. 45,852 patients admitted with 
STEMI were randomized in the COMMIT study, and allocated clopidogrel 75 mg daily or 
placebo in addition to aspirin 162 mg daily.  A significant reduction in death was seen in the 
clopidogrel group compared to placebo group ( 9.2% vs. 10.1% , p= 0.002). In the CLARITY 
TIMI 28 study, 3491 patients with STEMI were randomized to clopidogrel (300-mg loading 
dose, followed by 75 mg once daily) or placebo. Primary endpoint occured in 21.7 % of the 
placebo  group  and  15.0%  in  the  clopidogrel  group,  p  <0.001) .  Further benefi t  
wi th  clopidogrel was seen in the CREDO (Steinhubl et al. 2002) study, with a 27% 
RRR in patients undergoing PCI. 2116 patients who were to undergo elective PCI were 
recruited and randomly assigned to receive a 300-mg clopidogrel loading dose or placebo pre 
PCI. Thereafter, all patients received clopidogrel, 75 mg/d, through to day 28. From day 
29 through 12 months, patients in the loading-dose group received clopidogrel, 75 mg/d, and 
those in the control group received placebo. Both groups received aspirin throughout the 
study. Clopidogrel pretreatment did not significantly reduce the combined risk of death, MI, 
or urgent target vessel revascularization at 28 days (reduction, 18.5%; 95% CI, −14.2% to 
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41.8%; P = .23), but significantly reduced the composite end point of death, MI, or stroke 
(relative risk reduction [RRR] 26.9% [p = 0.02; 95% CI 3.9% to 44.4%]) at one year. In the 
CAPRIE study (CAPRIE Steering Committee. 1996), there was an 8.7% RRR with 
clopidogrel in patients with atherosclerotic disease (MI, CVA and PVD). 19 185 patients 
with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent 
myocardial  infarction,  or  symptomatic  peripheral  arterial  disease  were  randomized  and 
treated with either clopidogrel or aspirin. Patients on clopidogrel had an annual 5.32% risk of 
ischaemic stroke, myocardial infarction, or vascular death compared with 5.83% with aspirin 
resulting in a  relative-risk reduction of 8.7% in favour of clopidogrel (95% CI 03—165, p = 
0.043). The MATCH (Diener et al. 2004) study was a double-blind, placebo-controlled trial 
to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic 
stroke or transient ischaemic attack and at least one additional vascular risk factor who were 
already receiving clopidogrel 75 mg/day. There was 6.4 % RRR with clopidogrel plus aspirin 
in ischaemic CVA, MI, vascular death or rehospitalization for acute ischaemia.   15.7% 
patients receiving aspirin and clopidogrel reached the primary endpoint c o m p a r e d  to 
16·7% in the clopidogrel alone group (RRR 6.4%, [95% CI −4·6 to 16·3, p= NS]. Recent data 
suggests higher doses of clopidogrel exhibit greater and more rapid onset of platelet 
aggregation. The ARMYDA-2 (Giuseppe et al. 2005) trial compared 600mg and 300 mg 
loading doses in patients undergoing PCI , and a significant reduction in the clinical endpoint 
of death or non fatal MI was seen in the 600 mg group ( 12% vs. 4%, P= 0.041) at 30 days. 
Major side effects limiting use of clopidogrel include bleeding events and intolerance in a 
small proportion of patients. Data from various studies including CREDO and CAPRIE 
recommend use of clopidogrel for at least a year in ACS patients on medical management 
and in stented patients. Table 1 summarizes different randomized controlled trials 
demonstrating reduction in MACE with clopidogrel. 
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Table 1: Randomized controlled trials demonstrating reduction of MACE with 
Clopidogrel 
 
 
 
Study Study population Trial arms Primary endpoint (%); 
 
significance 
CURE 12,562 patients with 
 
UA/NSTEMI 
Clopidogrel plus Aspirin 
 
 
vs 
 
 
Placebo plus Aspirin 
9.3 vs. 11.4 ; p<0.001 
CAPRIE 19,185 patients with 
 
atherosclerotic disease 
 
(CVA/MI/PAD) 
Aspirin 
 
 
vs 
 
 
Clopidogrel 
5.8 vs. 5.2 ; p =0.043 
CREDO 2,116 patients undergoing 
 
PCI 
Clopidogrel plus Aspirin 
 
 
vs 
 
 
Placebo plus Aspirin 
8.5 vs. 11.5 ; p = 0.02 
CLARITY 
 
TIMI 28 
3,491 patients < 75 years 
 
with STEMI presenting 
within 12 hrs of 
symptoms 
Clopidogrel plus Aspirin 
 
 
vs 
 
 
Placebol plus Aspirin 
 
 
 
15 vs. 21.7; p<0.001 
COMMIT 45,852 patients with 
 
suspected ACS with 
 
STEMI 
Clopidogrel plus Aspirin 
 
 
vs 
 
 
Placebo plus Aspirin 
9.2 vs. 10.1; p =0.002 
MATCH 7,599 patients with recent 
 
ischaemic CVA/TIA 
Clopidogrel plus Aspirin 
 
 
vs 
 
 
Placebo plus Aspirin 
15.7 vs. 16.7; p=NS 
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Ticlopidine 
 
 
Ticlopidine is a thienopyridine derivative that irreversibly inhibits the P2Y12 receptor. It is a 
prodrug that requires conversion to the active metabolite by the hepatic cytochrome P450 
enzyme. It is rapidly absorbed, highly bioavailable and has a prolonged effect. It permanently 
inhibits the P2Y12 receptor by forming a disulfide bridge between the thiol on the drug and a 
free cysteine residue in the extracellular region of the receptor and thus has a prolonged 
effect. Like aspirin it has a short half-life with a long duration of action.Maximal inhibition of 
platelet aggregation is not seen until 8 to 11 days after starting therapy (McTavish et al. 
1990).The loading dose is 500 mg followed by 250 mg twice per day. In a number of 
randomised trials like the FANTASTIC, MATTIS and the ISAR study (Martin et al. 1999), 
aspirin was compared with aspirin and ticlodipine and a reduction in recurrent cardiovascular 
events was observed in the combination group.In the STAMI trial (Scrutinio et al. 2001), 
1470 patients post AMI were allocated to receive aspirin 160 mg/day or ticlopidine 500 mg / 
day. No significant difference was seen between aspirin or ticlopidine in the rate of the 
primary combined end point of death, recurrent AMI, stroke or angina. The primary end point 
was recorded in 59 (8.0%) of the 736 aspirin-treated and 59 (8.0%) of the 734 ticlopidine- 
treated patients (p = 0.966). In another study by Tanuicchi et al, clopidogrel conferred similar 
protection as ticlopidine against subacute stent thrombosis and major adverse cardiac events 
in 1016 patients 2 weeks post coronary stenting, but clopidogrel was better tolerated than 
ticlopidine with less adverse reactions (Tanuichi et al. 2001). Within 30 days, stent 
thrombosis of the stent occurred in 1.92% of the patients in the ticlopidine group and in 
2.02% of the clopidogrel group (P=0.901). A MACE occurred in 4.60% of patients receiving 
ticlopidine  and  in  3.85%  of  patients  receiving  clopidogrel  (P=0.551).   Ticlopidine’s  
unfavourable side-effect profile with risk of bone marrow suppression has   led to the 
withdrawal of this drug in some countries (e.g. United Kingdom). 
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Dipyridamole 
 
 
Dipyridamole is a phosphodiesterase inhibitor. It increases the cellular concentration of 
platelet adenosine 3, 5-monophosphate (cAMP) levels by interfering with platelet function 
and inhibits its breakdown. This effect is mediated by inhibition of cyclic nucleotide 
phosphodiesterase and/or by blockade of available uptake of adenosine, which acts at 
adenosine A2  receptors to stimulate platelet adenylyl cyclase.  High cAMP levels lead to a 
reduction in intracellular Ca2+, and low Ca2+ levels inhibit events leading to platelet 
activation and granule excretion.In the European Stroke Prevention Study. 2, 6602 patients 
were  recruited  and  randomized  to  treatment  with  ASA  alone  (50  mg  daily),  modified- 
release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or 
placebo.   Dipyridamole plus aspirin combination resulted in a 37% reduction in stroke 
(p<0.001), compared to 8% with aspirin alone (p = 0.013); and 16% with dipyridamole alone 
(p = 0.039) (Diener et al. 1996). 
 
Cilostazol 
 
 
Cilostazol is a reversible cAMP phosphodiesterase inhibitor with antiplatelet and 
antithrombotic properties. In a review of 8 trials by Chapman et al, patients on cilostazol 
demonstrated an increase in walking distances and improved quality of life compared with 
placebo.  In  six  of  eight  well  designed  clinical  trials,  cilostazol  was  significantly  more 
effective than placebo in increasing walking distances and improving the quality of life of 
patients with moderate to severe intermittent claudication  (Chapman et al. 2003). 
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Glycoprotein IIb/IIIa Inhibitors 
 
Glycoprotein IIb/IIIa receptors on the platelet surface bind fibrinogen, and are the final 
common pathway of platelet activation. The GP IIb/IIIa receptor may be activated by any 
platelet agonist, and can be inhibited by GPIIb/IIIa receptor inhibitors, which block platelet 
aggregation. Three such agents approved for use at present are abciximab, eptifibatide and 
tirofiban. All are effective but need to be given intravenously and are only approved for 
short-term use (Lippi et al. 2007). 
Abciximab is a long acting, reversible GPIIb/IIIa receptor inhibitor with a half life of 30 
minutes. It is a monoclonal antibody and is eliminated by protease degradation. It has shown 
significant risk reduction in the 30 day composite endpoint of death, myocardial infarction, 
and need for urgent repeat revascularization procedures in various trials. In the EPIC trial 
(Marmur et al. 2006), abciximab resulted in a 35% reduction in ischaemic events at 30 days 
in 2099 high risk ACS patients undergoing PCI. Six months follow up data from this trial 
also showed a significant reduction in the rate of instent restenosis.In the EPILOG study ( 
Roe et al. 1998), abciximab was used in 2792 elective and urgent PCI patients, and resulted 
in a 68% reduction in ischaemic events at 30 days. In the EPISTENT study (T o p o l  et al. 
1998), there was a 60% RRR in mortality in the abciximab plus stent group at 1 year as 
compared to the other treatment groups. In the CAPTURE trial (Umans et al.1997) , 
abciximab showed a 29% RRR in ischaemic events in 1265 high risk unstable angina patients 
at 30 days, but this benefit was not maintained at 6 months follow up. In the RAPPORT 
study, abciximab resulted in a 48% reduction is ischaemic events in 483 STEMI patients 
undergoing PAMI. In the ISAR REACT II study (Ndrepepa et al. 2008), there was a RR of 
0.71, P=0. 02, with a significant reduction in ischaemic events in 2022 ACS patients with 
elevated troponin. Eptifibatide is another GPIIb/IIIa inhibitor, and produces a dose-dependent 
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inhibition of platelet aggregation and has been shown to reduce the frequency of acute 
ischemic complications following percutaneous coronary revascularization. In the IMPACT 
II study (The IMPACT-II Investigators.1997), eptifibatide was used in suboptimal doses, 135 
µg/kg bolus plus 0.5 or 0.75 µg/kg/min infusion. Among patients who received eptifibatide 
treatment, the reductions in the composite end point at 30 days were 22% (P = .035) and 14% 
(P = 0.178) for the 135/0.5 and 135/0.75 doses, respectively. The efficacy of increased doses 
was tested in the PURSUIT trial (The PURSUIT Trial Investigators. 1998), where a bolus of 
180 µg/kg and infusion of 1.3 µg/kg/min or a bolus of 180 µg/kg and infusion of 2.0 
 
µg/kg/min was given to patients undergoing PCI. This infusion rate was significantly higher 
than the doses used in the IMPACT II trial, and resulted in a statistically significant reduction 
in the incidence of death or MI.Similarly, in the ESPRIT study (The ESPRIT investigator. 
2000), the dose of eptifibatide was fourfold higher than in the IMPACT II study, with two 
intravenous boluses of 180mcg/kg followed by a continuous infusion of 2 mcg/kg/min for 18- 
24 hours post-intervention. In this trial, a significant reduction in the incidence of the 
composite endpoint was seen in patients who received eptifibatide at 48 hours, 30 days, 6 
months, and was maintained at 1 year. Recent results from the EARLY ACS study (Giugliano 
et al. 2009) do not support use of Eptifibatide as upstream therapy in high risk ACS patients 
undergoing PCI. The EVA-AMI study (Zeymer et al. 2010) compared eptifibatide vs 
abciximab as an adjunctive treatment for patients undergoing primary PCI, and no significant 
difference was noted between the two agents, suggesting eptifibatide may be used as an 
alternative to abciximab in PAMI. There is however, a risk of major bleeding and 
thrombocytopenia with GP IIb/IIIa inhibitors, limiting its use in all high risk ACS patients 
undergoing PCI. 
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Prasugrel 
 
 
Prasugrel is an o r a l , irreversible P2Y12 receptor blocker, and is deemed to be 10 times 
more potent than other theinopyridine derivatives.It is a prodrug and is hydrolysed to a 
thiolactone in the intestine with the help of the Cytochorme P450 pathway. It achieves peak 
plasma concentration within 30 minutes, and has been shown to achieve greater platelet 
inhibition when compared to clopidogrel. The  Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial 
Infarction (TRITON-TIMI 38) study (Wiviott   et al. 2007) was an international, 
randomised double blind study that compared clopidogrel ( 300mg loading dose, 75 mg 
maintenance dose) with prasugrel ( 60 mg loading dose, 10 mg maintenance dose) in 13,608 
ACS patients. Patients in the  prasugrel  group  demonstrated  greater  platelet  inhibition  
when  compared  to  the clopidogrel group. Significant reduction in clinical endpoints of CV 
death, non-fatal MI or stroke was  observed in  the prasugrel  group (9.4% vs. 11.5%,  p< 
0.001) irrespective of baseline  characteristics  such  as  age  and  sex.  There was 24% 
reduction in myocardial infarction and 52% relative reduction in stent thrombosis in ACS 
patients. Patients greater than 75 years age and less than 60 kgs body weight demonstrated 
less benefit with prasugrel when compared to clopidogrel due to bleeding side 
effects.Bleeding complications were more frequent  with  prasugrel  than  clopidogrel  (2.4%  
versus  1.8%,  P=0.03),  including  fatal bleeding (0.4% versus 0.1%; P = 0.02). The Trilogy-
ACS study compared prasugrel and clopidogrel in ACS patients with NSTEMI or UA who 
were medically managed without any intervention. 9,326 patients were recruited, and no 
significant difference in primary outcome of cardiovascular death, myocardial infarction or 
stroke was noted in either the prasugrel or clopidogel group at 30 months (13.9% vs. 16%, p 
=0.21, HR 0.91) .  The maintenance dose of prasugrel was reduced to 5 mg in the > 75  
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years of age group patient, with no significant difference in primary outcome (18.7% vs.  
20.3%, p = NS) (Gurbel et al.  2012).  
The PRINCIPLE-TIMI 44 study showed that high dose clopidogrel (600 mg loading followed 
by 150mg/day) resulted in less inhibition of platelet aggregation than prasugrel (60 mg loading 
followed by 10 mg/day) in patients with stable coronary disease undergoing planned PCI 
(Wiviott   et al. 2007). The primary end point of this study was inhibition of platelet 
aggregation (IPA) with 20-µmol/L ADP measured after six hours. 201 patients were 
randomized, and IPA at 6 hours was significantly higher in subjects receiving prasugrel 
(mean+/-SD, 74.8+/-13.0%) compared with clopidogrel (31.8+/-21.1%; P<0.0001). In the 
ACAPULCO study, which was a randomised double blind cross over study, greater platelet 
inhibition was observed with prasugrel 10 mg maintenance dose compared to clopidogrel 150 
mg maintenenance dose in ACS patients. Patients who were loaded with 900 mg clopidogrel 
and switched to prasugrel 10 mg for maintenance also demonstrated further platelet inhibition 
suggesting prasugrel was a more potent platelet inhibitor (Montalescot et al. 2010). The study 
showed  that  the  10  mg  prasugrel  dose  produced  a  lower  level  of  platelet  aggregation 
compared to the 150 mg clopidogrel dose. The primary endpoint of the study was maximum 
platelet aggregation (MPA with 20 micromoles of ADP) as assessed by light transmission 
aggregometry at 14 and 28 days. MPA was 26.2% for prasugrel 10 mg and 39.1% for 
clopidogrel 150 mg (p<0.001). 
 
Ticagrelor 
Ticagrelor or AZD6140 is an oral, reversible P2Y12 receptor blocker. It is an ATP derivative 
and belongs to the cyclopentyltriazolopyrimidine group of drugs. It does not require conversion 
to an active metabolite for its action, and has a half-life of 12 hours. Being a reversible agent,  
 
 
 
38 
 
 
 
 
Ticagrelor provides greater flexibility with regards to timing of bypass surgery. In a study of 
200 patients with stable atherosclerosis (DISPERSE), ticagrelor (50mg,100mg, 200mg, 400mg) 
was compared to clopidogrel 75 mg. Although higher platelet inhibition  was  achieved  with  
higher  doses  of  ticagrelor  (100mg,  200mg  and  400mg) compared to clopidogrel, ticagrelor 
was associated with a higher incidence of bleeding and dyspnoea. In the DISPERSE-2 study 
(Cannon et al. 2007), ticagrelor was compared to clopidogrel in 990 patients with ACS. 
Although there were fewer adverse events in the ticagrelor group, the study was underpowered 
to detect a statistically significant difference. In the PLATO study (Cannon et al. 2010), 13 408 
ACS patients were randomized to receive either ticagrelor (180 mg loading dose followed by 
90 mg twice a day) or clopidogrel (600 mg loading, followed by 75 mg maintenance). The 
primary endpoint of cardiovascular death, non fatal MI, or stroke occurred was significantly 
lower in the ticagrelor group than the clopidogrel group (9% vs. 10.7%, hazard ratio 0.84, 
95% CI 0.75-0.94; p=0.0025). In this study, no significant difference was observed in bleeding 
rates in between the two groups (11.6% vs. 11.5%, p =0.88). 
 
Cangrelor 
Cangrelor is a nonthienopyridine adenosine triphosphate analogue, and a potent, short acting 
intravenous P2Y12 receptor antagonist. It is an ATP analogue with a very short half-life (3-5 
mins), with recovery of platelet function within an hour of discontinuation of the drug. The 
CHAMPION-PCI (Harrington et al. 2009) , and the CHAMPION-PLATFORM study were 
large multicentre trials comparing clopidogrel with cangrelor in ACS patients undergoing 
PCI , but the studies were prematurely terminated as no significant differences in measures of 
clinical effectiveness was seen in with cangrelor. Cangrelor did not reduce the composite 
endpoint of death, MI or ischemia-driven revascularization when compared to clopidogrel, in 
the CHAMPION PCI study. In the Champion – Phoenix study, 11 145 patients undergoing 
urgent or elective PCI were randomized in double-blind fashion to receive cangrelor in a
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bolus plus infusion or a 600-mg or 300-mg loading dose of clopidogrel. Patients in the 
cangrelor group had a significantly lower rate of the composite of all-cause death, myocardial 
infarction  (MI),  ischemia-driven  revascularization,  and  stent  thrombosis  at  48  hours 
compared with clopidogrel (4.7% versus 5.9%, p< 0.01) ( Bhatt et al. 2013). 
 
Atopaxar 
 
 
Atopaxar is a protease activated receptor antagonist and blocks the PAR 1receptor. In phase 1 
studies, it has shown inhibition of platelet aggregation, without any significant increase in 
bleeding time. It also suppresses the effects of inflammatory markers, which have been linked 
to adverse outcomes in ACS patients. The LANCELOT ACS study was a randomized, 
double blind, placebo controlled study, assessing the safety and tolerability of -Atopaxar in 
ACS patients, in addition to standard therapy. In this study, 603 patients admitted to hospital 
with ACS were randomized to placebo or to a 400-mg loading dose of atopaxar followed by a 
daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks. All patients were on aspirin and 
greater than 75% were taking aspirin in combination with clopidogrel or ticlopidine. The 
incidence of the primary enpoint of cardiovascular death, myocardial infarction, stroke, or 
recurrent ischemia was similar between the atopaxar and placebo arms (8.03% versus 7.75%; 
P=0.93). Larger trials are required to further investigate the efficacy and safety of atopaxar 
(O'Donoghue et al. 2011). 
 
Vorapaxar 
 
Vorapaxar is another novel antiplatelet agent. It is a novel thrombin receptor (PAR 1) 
antagonist.  The TRACER study (Tricoci et al.  2012)  was a multinational, randomized, 
double-blind, placebo-controlled study.12,944 patients with NSTEMI were randomised to 
either Vorapaxar or placebo, in addition to dual antiplatelet therapy. A loading dose of 40 mg 
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of vorapaxar was   given followed by 2.5 mg maintenance dose for a year. The TRACER 
study did not show a reduction in its primary endpoint which included cardiovascular death, 
myocardial infarction, stroke, recurrent ischemia with re-hospitalization and urgent coronary 
revascularization. There was a non- significant (p=0.72) 8% reduction in MACE. In the 
TRA-PCI study (The TRA-PCI Investigators et al. 2009), a phase II trial, 1031 patients 
scheduled for angiography and possible elective stenting were randomised to either vorapaxar 
or placebo. This was in additon to dual antiplatelet therapy with aspirin and clopidogrel. 
Fewer adverse events were seen in the vorapaxar group, with no significant increase in 
bleeding over a 4 month follow up period. The TRA 2P –TIMI 50 was a multinational, 
randomised, double blind trial comparing vorapaxar to placebo in patients with history of 
prior MI, stroke or PAD.  26,449  patients  who  had  a  history  of  myocardial  infarction, 
ischemic stroke, or peripheral arterial disease were randomized to receive vorapaxar (2.5 mg 
daily) or placebo and followed up for a median of 30 months. At 3 years, the primary end 
point  occurred in 9.3% in the vorapaxar group and in 10.5% in the placebo group (HR for the 
vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). There was an 
increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the 
placebo group; P<0.001) (Morrow et al. 2012). 
 
BM573 
 
 
BM573 is a combined thromboxane receptor antagonist and synthase inhibitor.It has shown 
promising results in mice and rat models, inhibiting platelet aggregation without increasing 
bleeding time. It is a torsemide derivative, but without any diuretic effect. In pig models, it 
has shown reduction in MI induced by coronary thrombosis, and has also shown reduction of 
pulmonary vascular resistance. It is yet to be tried in humans, but animal model results 
suggest this could be a promising antiplatelet and antithombotic agent. 
 
 
 
41 
 
 
 
 
Clinicians are currently able to partially improve the responsiveness to antiplatelet therapy by 
acting on extrinsic factors involved in the aetiology of resistance. This includes compliance to 
treatment, drug drug interactions and good control of blood pressure, glycaemia and lipid levels. 
Studies have shown that clopidogrel loading with 600 mg has a stronger and faster inhibitory 
effect on platelet reactivity than the 300 mg loading dose (Patti et al. 2005). Increasing the 
loading dose to 900 mg has not been shown to be of benefit, indicating a threshold to the platelet 
inhibitory effect of clopidogrel (Von Beckerath et al. 2005). The CLEAR-PLATELETS study 
showed that Clopidogrel loading combined with eptifibatide resulted in reduced myocardial 
necrosis compared to standard or high loading dose of clopidogrel alone (Gurbel et al. 2005).  
The ISAR-CHOICE-2 study demonstrated the beneficial effect on platelet inhibition of 
increasing the maintenance dose of clopidogrel to 150 mg (Von Beckerath et al. 2006). In the 
ARMYDA-4 study, reloading with 600 mg clopidogel pre PCI did not confer any additional 
benefit in patients on chronic clopidogrel therapy.The ARMYDA-5 study, which compared 
Clopidogrel loading with 600 mg in lab vs. 4–8 hours pre PCI, did not show any significant 
difference in outcome in the two groups, but this study was underpowered to detect a significant 
difference (Germano et al. 2010). Results from the recent ARMYDA-PRO study suggest high 
pre PCI platelet reactivity using the VerifyNow P2Y12 assay may predict MACE at 30 days 
(Patti et al. 2008). Use of point of care platelet function tests may help in identification of these 
high-risk patients, and assist the clinician in optimising their antiplatelet medications.Results 
from the TRITON-TIMI 38 study showed that prasugrel significantly reduced the rates of 
recurrent ischemic events, including stent thrombosis, although this was offset by an increase in 
major bleeding (Wiviott et al. 2007).  The GRAVITAS study did not demonstrate improved 
clinical outcomes with tailoring of doses of clopidogrel based on the results of the VerifyNow 
assay. Whether the newer antiplatelet agents like Prasugrel, Ticagrelor and Direct thrombin 
inhibitors will be sufficient to overcome the HPR seen in some individuals and improve clinical 
outcomes remains unknown. The relative bleeding risks with these regimens will also need to be  
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evaluated in detail to understand the risks and benefits associated with assessment of high 
platelet reactivity using platelet function tests with these novel antiplatelet agents.  
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Platelet function tests  
    
  Discussed below is the mechanism of some platelet function tests used in clinical practice. 
Bleeding time 
 
Dating back as far as 1901, this very simple test measures the time it takes for a small skin 
cut to stop bleeding. It has very poor reproducibility and no study so far has shown it to 
correlate with bleeding or thrombotic risk. It is dependent on operator technique, and 
demonstrates significant variability with age, gender and body temperature (Rodgers  et 
al.1990). 
 
 
Light transmittance aggregometry (LTA) 
 
LTA has been regarded as the “gold standard” test for measuring platelet function (Cattaneo et 
al. 2009). It is often used to validate newer platelet function tests. It measures light 
transmittance in whole blood or platelet rich plasma. Platelet rich plasma is stirred in a 
cuvette at 37°C, and this cuvette sits between a light source and a photocell. When an agonist is 
added, the platelets change shape from discoid to tiny spheres, aggregate and absorb less light 
and transmittance increases. Agonists used to activate and aggregate platelets are arachidonic 
acid, ADP, Thrombin receptor activating peptide, collagen or epinephrine. Platelets clump in 
response to these agents and an increase in light transmittance is noted. Subjects whose 
platelet aggregation is more than 20% with arachidonate are considered aspirin resistant. 
Light transmittance is inversely proportionate to platelet clumping. It is a time consuming 
test performed on citrated blood, and variability in results has been noted (Ohmori et al. 2006). 
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Urinary thromboxane 
Urinary thromboxane is a simple test to assess platelet activation through urinary metabolites. 
Activated platelets synthesize 11-dihydroxy thromboxane B2 (TxB2), an active metabolite of 
TxA2, and this is detected in urine with an ELISA assay. However, although detection of 11- 
dihydroxy thromboxane B2 in urine reflects systemic TxA2 formation, 30% is derived from 
non-platelet sources, and thus falsely high readings may be observed in inflammatory 
conditions. Increasing urinary thromboxane levels are associated with increased risk of death, 
MI, and stroke. Studies measuring TxB2 levels in aspirin treated patients have reported a 
prevalence of aspirin resistance in the range of 1-1.7% (Catell et al. 1987). 
Flow cytometry 
 
Flow cytometry uses a flow cytometer, through which red blood cells labelled with 
fluorescently conjugated monoclonal antibody are passed.  The rate at which cells pass through 
the cytometer is 1000 to 10000 cells per minute. The cells are then made to pass through an 
active laser light, which activates the fluorophore that is conjugated to the monoclonal 
antibody. The intensity of fluorescence is directly proportional to the antigen being studied. P 
Selectin (CD62) is expressed on the surface of activated platelets, and helps in formation of 
monocyte-platelet aggregates, which are considered to be the most sensitive marker of platelet 
activation (Michelson et al.2000). 
Platelet Function Analyzer (PFA -100) 
The PFA-100
TM 
system (Dade Behring, Germany) is a platelet function test that uses collagen 
and epinephrine as agonists. It is a semi-automated dual channel device and is based on a 
closure time caused by occlusion of an aperture by platelet aggregates.  Blood is inserted in a 
citrate primed tube, and left for 30 minutes to 4 hours. This blood is then passed through 
twocartridges coated with collagen, and epinephrine and ADP are used as agonists. Blood is 
drawn into a tube  
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containing 3.2% citrate and allowed to stand for between 30 min and 4h, after which 800 l of 
citrated whole blood is added to each of two pre-prepared cartridges to wet the filters.  Both 
cartridges contain a membrane coated with type I equine collagen together with an agonist to 
induce platelet aggregation. In one cartridge the membrane is coated with 10 M epinephrine and 
the other with 10 M ADP. The measurement begins by drawing the blood through a capillary 
tube and a single aperture (150 µm diameter) into a collagen coated cellulose-acetate filter. 
This results in the platelets being pre-activated by shear stress of 190 dynes/cm
2 
even before 
reaching the filters and the agonists. As platelets come into contact with the collagen, they will 
adhere, aggregate and form the primary hemostatic plug, which occludes the aperture (closure 
time, CT). Closure time is inversely proportional to platelet inhibition (Hayward et al. 2006). 
Verify Now assay 
The Verify Now system (Accumetrics, San Diego, California) is a turbidometry-based optical 
detection device that utilizes light source to detect the amount of platelet aggregation. The 
assay cartridge has fibrinogen–coated beads to which platelets adhere to, aggregate and 
eventually fall out of solution.  This results in change of light transmittance in the cartridge, and 
light transmittance is inversely proportional to amount of platelet aggregation. Results are 
obtained in 5 minutes. It is a rapid, easy to use, point of care system used to assess platelet 
reactivity. There are 3 types of Verify Now Assay – Aspirin assay utilizes arachidonic acid as an 
agonist, P2Y (12) assay utilizes ADP to assess effect of Clopiodgrel, Ticlopidine or Prasugrel, 
and IIb/IIIa assay utilizes a thrombin receptor activating peptide as an agonist to assess response 
of GPIIb/IIIa inhibitors like Abciximab, or Eptifibatide The instrument measures  the  increase  
in  light  transmittance  over  time,  thus  a  blood  sample  that  is prothrombotic produces low 
light transmittance, whereas a sample with normal platelet function produces high light 
transmittance. The system reports two results for each assay: P2Y12 reaction units (PRU) report  
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the amount of ADP-mediated aggregation, and higher PRU’s are associated with worse outcomes 
in reported studies; and % inhibition (%) is the percent change from baseline aggregation, and is 
calculated from the PRU result and the BASE result, which is based on the rate and extent of 
platelet aggregation in the TRAP channel, where % Inhibition = (I – PRU/BASE) x 100. The 
GRAVITAS (Gauging Responsiveness with A Verify Now assay—Impact on Thrombosis And 
Safety) study compared  the effect of high dose clopidogrel ( 600mg loading dose,150mg 
maintenance dose) versus standard dose clopidogrel (75 mg maintenance dose)in patients with 
high on- treatment platelet reactivity using the Verify Now assay ( Price et al. 2011). 2214 
patients undergoing PCI were included in this double blind randomized study, and no significant 
reduction in end point was noted in either of the groups. Patients who were treated with PCI, and 
achieved low platelet reactivity and were tested using the Verify now assay at discharge and  at  
30  days  post  PCI,  demonstrated  a  50%  reduction  in  CV  death,  MI  and  stent thrombosis. 
The TRIGGER-PCI (Testing platelet reactivity in patients undergoing elective stent placement 
on clopidogrel to guide alternative therapy with prasugrel) study comparing prasugrel to 
clopidogrel for patients with high on-clopidogrel platelet reactivity following PCI has been 
prematurely terminated due to relatively few occurrences of primary endpoint in the study at six 
months. High on-clopidogrel platelet reactivity (>208 PRU by VerifyNow P2Y12 test) was 
observed less frequently than expected, and prasugrel was seen to reduce platelet reactivity 
greater than clopidogrel (Trenk et al. 2012). 
Thromboelastograph Haemostasis System (TEG 5000) 
Thromboelastography (Haemoscope, USA) is a platelet function test that provides global 
information on clot development, stabilization and dissolution in vitro. The original TEG involved 
native blood, but modified versions now utilize citrated blood to assess clot formation and lysis. 
Whole blood sample is placed in a cup that oscillates at an angle of 4°45’. A  
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stationary pin attached to a torsion wire is immersed in this blood, and monitored for motion. 
The strength of fibrin-platelet bond during clot formation affects magnitude of pin motion, 
and gives a measure of haemostasis. It provides measurements of clotting time, clot strength 
and kinetics, and clot lysis. Software is required to interpret results that helps assess the risk of 
ischaemia and bleeding, and determine need for antiplatelet therapy (Donahue et al. 2005) 
 
Plateletworks 
 
Plateletworks (Helena Laboratories, Texas, US) is a point of care platelet function test that 
provides information of platelet activation and aggregation. Platelet numbers are counted before 
and after activation with an agonist using collagen, ADP or arachidonic acid. Blood can be 
drawn from any existing indwelling line or by venepuncture. The change in platelet count is 
measured using an electronic impedance-cell based counter, and results expressed as percentage 
inhibition. The test can be performed in 2-5 minutes, and tests efficacy of aspirin, clopidogrel, 
and glycoprotein IIbIIIa inhibitors. In the POPULAR trial, six platelet function tests were 
compared head to head to predict a composite of death, MI, stent thrombosis, and stroke at one 
year in 1069 stable patients on clopidogrel undergoing elective PCI. Of the six tests, only three 
tests - light transmittance aggregometry (LTA 5 µmol/L ADP (n = 1,049; P = 0.0002), LTA 20 
µmol/L ADP (n = 1,051; P = 0.0003), VerifyNow (n = 1,052; P = 0.0002), and the 
Plateletworks assay (n = 606; P= 0.054) were noted to have a modest effect on predicting 
cardiovascular outcomes. None of these tests were able to predict bleeding risk in PCI patients 
(Breet et al. 2010). 
 
Multiplate Analyser 
 
  The Multiplate analyser (Multiplate, Roche Diagnostics, Switzerland) or multiple platelet     
 aggregometry (MEA) is a platelet function analyser that utilises different reagents like ADP,   
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TRAP, Collagen and ristocetin to determine high platelet reactivity. It has multiple channels and  
 uses multiple electrodes to accurately assess platelet function. It utilizes the principle of  
 impedance aggregometry. Hirudin anticoagulated blood is stirred for a few minutes in a test  
 curvette at 37°C, and ADP in a concentration of 6.4 µmol/l (ADP test), or a combination of ADP  
 (6.4 µmol/l) and PGE1 (9.4 nmol/l) (ADP test high sensitivity – ADPtest HS) are added and   
 aggregation recorded for 5 minutes (Johnson et al. 2008). Platelets attach to the multiplate sensors    
 and increase impedance which is transformed into arbitrary aggregation units (AAU) and plotted  
 against time. In a large study by Sibbing et al, 1608 patients undergoing PCI were enrolled.    
 Clopidogrel non responders were identified using the multiplate analyser, and the composite of  
 death or stent thrombosis was higher in low responders compared to normal responders (3.1% vs.  
 0.6%; CI: 2.2-11.6; P< 0.001) and significant correlation was observed between the MEA and  
 LTA (rho= 0.71; P<0.0001) (Sibbing et al. 2008). In another study by Sibbing et al, MEA has  
 been shown to predict thrombotic and bleeding events (Sibbing et al. 2010). Based on another  
 study, MEA test value of 468 AAU has been taken as a cut off for prediction of stent thrombosis  
 (Freynhofer et al. 2011).  
 
Vasodilator-stimulated phosphoprotein assay (VASP) 
Vasodilator-stimulated phosphoprotein is an intracellular platelet protein, phosphorylation of 
which is regulated by the cAMP cascade. ADP inhibits this cascade and Prostaglandin E1 
activates it. The Platelet VASP test (Biocytex, Marseille, France) is a flow cytometry assay that can 
assess the effect of the P2Y12 antagonists. It is reproducible, uses citrated blood, and samples can be 
stored at room temperature for upto 48 hours for analysis. Like most platelet function tests, the 
first few mls of blood collected must be discarded. The optimum time to perform the P2Y12 assay is 6 
hours after a loading dose, or at least 7 days after commencing maintenance therapy with clopidogrel. The  
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assay measures the suppression of VASP phosphorylation due to the ADP–P2Y12 interaction, and 
results are expressed as platelet reactivity index (PRI, %). Normal individuals who are not on any 
P2Y12 antagonist have a PRI > 69%, and studies have demonstrated PRI< 50% to have a very 
high negative predictive value. Lower PRI is indicative of good response to clopidogrel, and 
higher PRI is indicative of a poor response to clopidogrel. Recent studies have demonstrated a 
correlation between PRI and clinical outcomes in PCI patients (Bonello et al. 2007), stent 
thrombosis (Morel et al. 2007), and recurrent ischaemic cardiac events (Frere et al. 2007).  
Global Thrombosis Test 
The Global Thrombosis Test (GTT, Montrose Diagnostics, London, UK) is a point of care test 
that is designed to assess platelet reactivity, thrombotic status and thrombolytic activity.The 
equipment comprises 4 channels, into which four plastic tubes can be inserted. The top of the 
tube consists of a detachable conical plastic tube which contains 2 metal ball bearings (Figure 
2.1). Native blood is withdrawn with a 21 gauge butterfly cannula, first 2 mls discarded and 
subsequent 3-5 mls injected into the plastic GTT tubes within 15 seconds of venepuncture.   
Blood flows at 37 degrees by gravity through the narrow gap between the large metal ball 
and the conical plastic tube, and high shear stress (175 dynes/cm
2
) in this space activates the 
platelets (Figure 2.2).  Blood then flows through the space between the two ball bearings, where 
low shear and turbulent flow favour large platelet aggregation. Thrombin i s  gen er a t ed  b y  the 
platelets, and blood coagulation initiated. Large fibrin stabilized platelet aggregates are formed 
which flow in the space below the lower ball bearing and the conical end of the plastic tube, and 
eventually results in arrest of flow displaying Occlusion   time   (OT:   seconds). Increased   or   
decreased   OT   indicates   inhibition or enhancement of platelet reactivity respectively.  The 
instrument measures the time (d) between   two consecutive blood drops. There is a sensor at the 
base of the unit, which generates a signal whenever a drop of blood interrupts the light path.  
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Blood collects in the bottom collecting tube, and the time interval increases gradually as the flow 
slows down, and when d > 15 seconds the end point of the initial measurement is displayed on 
the instrument as occlusion time (OT; seconds). This time coincides with the time it takes for the 
fibrin stabilized platelet aggregate to occlude the conical end of the tube. There is also a preset 
“thrombi stabilization time” following OT (200 sec), during which the sensors are inactive. This 
time allows stabilization of the formed thrombi, lasting occlusion and ignores small re-bleeds. 
Subsequently, blood flow restarts  due  to  spontaneous  thrombolysis  of  the  formed  thrombus,  
displaying  a  second reading  Lysis time (LT; seconds). LT is the time difference between the last 
drop before thrombus formation, and the first drop after occlusion during restart of blood flow. 
When this time (d) exceeds 200 seconds, lysis time is displayed. LT = (time of first drop with d > 
lysis – d) – (time of last drop with d< lysis –d). If lysis does not occur within 6000s, no lysis is 
recorded. Increase or decrease in LT indicates inhibition or enhancement of spontaneous 
thrombolysis, respectively.  
The unique features of this test are that it uses native non- anticoagulated blood, uses high shear 
stress to activate platelets and appears to be more physiological than other platelet function tests 
that utilize agonists in citrated blood. It measures the effect of thrombin on platelet aggregation, 
which is inhibited in citrated blood due to low calcium levels. In a normal coronary artery (Stepp 
et al. 1999), shear stress is upto 19 cm
2
 whereas in stenosed arteries (Ikeda et al. 1991) the shear 
stress can be up to 1500 dyne/cm
2
. The shear stress created in between the plastic tube and 
big ball bearing o f  t h e  G T T  t u b e  is 175 dynes/cm
2
.  The shear rate (G) for the GTT 
was initially calculated by Prof. Yamamoto and colleagues (Yamamoto et al. 2003) with the 
equation 4Q/pR
3 
where Q was the flow rate (ml/s) calculated by measuring the weight (and 
converting it to volume) and timing of the first three blood drops and R was the radius of the gap 
(cm). Shear rate was converted to shear stress by multiplying it with blood viscosity. This initial  
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shear stress (178 dynes/cm2) corresponds to and is even a bit higher than that which exists in a 
critical stenosis of 70% luminal stenosis (150 dynes/cm2) where thrombosis is likely to occur 
(Merino et al. JACC 1994). Shear stress as high as 3000 dyne/cm2 has  been reported at high 
levels of stenosis ( Strony et al. 1993).There is data to suggest that high shear stress  does not 
necessarily favour  large platelet aggregate formation, as such aggregates get fragmented at this 
high force.  At high shear, low shear is required immediately below the high shear level at the post 
stenotic level for aggregation to take place. There is also some evidence to suggest minimal 
platelet activation may be required for platelet aggregation and this shear induced process may be 
a result of mechanical cross linking of platelets (Zhang et al. 2002). 
The principle of the GTT technique has been supported by experiments performed by Prof 
Yamamoto and colleagues who concluded that there it was the initial pressure that determined the 
rate of thrombus formation and there was no need to maintain the applied pressure accurately. The 
optimal initial pressure was 50-90 mmHg. They also demonstrated large platelet aggregates in 
between the lower ball bearing and conical end of the tube, but not in the space between the two 
balls. As it was difficult to ascertain some of the morphology due to small space between some 
gaps, they carried out specific experiments using tubes with none, one ball bearing or two ball 
bearings to confirm the mechanism of occlusion. In a tube with one ball bearing, occlusion time 
was greatly prolonged. Although aggregation occurred distal to the ball, the blood flow was not 
obstructed suggesting delayed occlusion was secondary to coagulation. On the contrary, in a tube 
with two ball bearings, shear activation of platelets in the first space in between the two balls 
resulted in generation of thrombin, and eventually arrest of blood flow. If platelet aggregation 
occurred in between the two balls, the aggregates would disintegrate due to the high shear in 
between the second ball and the conical lumen of the tube, and occlusion would not occur. Once 
the thrombus is formed, there is reduction of pressure and the thrombus is allowed to stabilise for 
a period of 200 seconds known as “thrombi stabilization time” during which the sensors are  
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inactive. This time allows stabilization of the formed thrombi, lasting occlusion and ignores small 
re-bleeds.  The pressure then reverses and there is restoration of flow by dislodgement of the 
thrombus i.e. lysis occurs (Yamamoto et al. 2003).Fibrinolysis of the platelet thrombus requires 
shear stress of at least 250 dynes/cm
2 
(Brown et al. 1975), hence when blood passes through 
the space between the big metal ball and the tube, platelets get activated and start aggregating, 
whereas lysis is minimal during that stage. 
In a study by Taomoto et al, 185 stroke patients were tested using the GTT. Their OT and LT 
were compared to 195 healthy volunteers not taking any medication. Occlusion time was 
significantly shorter in stroke patients (mean age 65.5 years) compared to healthy volunteers 
(mean age 39.7 years) (OT: 210.3±140.8s vs. 284.9±92.2s, P= < 0.0001) suggesting a 
prothrombotic state existed in the patient population.  LT was significantly prolonged in 
stroke patients when compared to healthy volunteers (LT: 3159±1549s vs. 2231±1223s, 
P<0.0001) suggesting stroke patients had impaired endogenous thrombolytic activity (Taomoto et 
al. 2009).   
All patients had been admitted with an acute cerebrovascular event, and MRI and MRA were 
the initial investigations performed for establishing the diagnosis. All 185 patients received 
Aspirin or Cilostazol, a thromboxane A2 synthesis inhibitor such as Ozagrel, or anticoagulants 
agents such as Heparin or Warfarin. OT and LT were assessed again after patients had been 
stabilized on medication for atleast 14 days, and OT in stroke patients on medication was 
significantly prolonged, and LT shortened suggesting medication reduced the thrombogenic 
potential in stroke patients. 
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Figure 2.1: GTT tube demonstrating 2 metal balls and space in between the balls and wall of 
the plastic tube ( Saraf et al. 2009) - A flat segment created along the inner wall of a conical 
plastic tube forms the basis of the technique, since it prevents the round steel ball bearing from 
occluding the lumen. When blood is added, it flows through the narrow gaps by the ball and 
exits in droplets into an adjacent collecting tube. The latter is trans-illuminated and a light 
sensor generates a signal whenever a drop of blood interrupts the light path. The instrument 
detects the time interval [d] between consecutive blood drops. 
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Figure 2.2: Principle of the GTT – Shear stress activates platelets and platelet  
aggregation begins in the space between the 2 metal ball bearings (Saraf et al. 2009)- Blood 
flows at 370C under the influence of gravity through a narrow gap [1]formed between the 
larger ball bearing and the inner wall of the tube, where high shear stress (175 dynes/cm2) 
activates platelets. These activated platelets remain single, since the very short transit time and 
high shear prevent aggregation. In contrast, in the space downstream, low shear and turbulent 
flow favour large platelet aggregate formation. The activated platelets generate thrombin and 
initiate coagulation. Flow then carries these fibrin-stabilised platelet aggregates into the gap 
[2] resulting in occlusion of the gap and arrest of flow. 
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Antiplatelet Resistance: Review of the evidence and extent of the problem 
 
 
 
Platelet activation and aggregation play an important role in development of atherosclerosis 
and result in manifestation of conditions such as acute coronary syndrome, stroke and 
peripheral vascular disease. A significant percentage ( 8-60%) of atherothrombotic patients, 
despite  being  on  optimum  antiplatelet  therapy  continue  to  experience  recurrent  adverse 
cardiac events such as ACS, stroke, peripheral vascular disease and are considered to be 
resistant to antiplatelet medications (Hovensal. 2007). Patients resistant to aspirin or 
clopidogrel  continue  to  experience  thrombotic  events  and  fail  to  demonstrate  platelet 
inhibiton, as measured in the laboratory using different platelet function tests (Cattaneo et al. 
2004). Several studies have been carried out under different settings to determine the level of 
resistance and its relation with adverse events. There has been poor correlation so far amongst 
the various different platelet function tests and it is extremely difficult for clinicians to 
determine which method to use and in which cohort of patients. Therefore, new tests and 
treatments are being studied to help overcome this problem. 
 
The proposed mechanism of antiplatelet resistance is multifactorial and depends on various 
intrinsic and extrinsic factors, and is outlined in Table 1. 
 
Non compliance with aspirin accounts for 3% of aspirin resistant patients, and this resistance 
could be overcome by a monitored treatment program in hospital (Tantry et al.2005). 
Bioavailability of aspirin is increased with food, and enteric coated aspirin may affect 
absorption.  Non steroidal antiinflammatory drugs (NSAIDS) seem to interact with aspirin by 
interfering with the COX pathway and increasing thromboxane A2 production. Inflammation 
increases COX-2 activity and release of TXA 2 by platelets, resulting in prothrombotic events 
in patients on aspirin (Awtry et al. 2003). The Antithrombotic Trialists’ Collaboration 
demonstrated 33.3% reduction in occurrence of non fatal MI, a 25% reduction in stroke and 
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16%  reduction  in  vascular  mortality  in  atherosclerotic  patients  on  aspirin  (Antiplatelet 
 
Trialists’Collaboration. 2005). 
 
 
Similarly, clopidogrel resistance can be multifactorial and various mechanisms for resistance 
have been proposed in the literature. Non compliance, inadequate dosing and reduced 
gastrointestinal absorption are common causes. Various studies have demonstrated greater 
platelet inhibition with loading dose clopidogrel 600 mg, when compared to 300 mg (Muller 
et al. 2001). Clopidogrel is a prodrug that is converted to its active thiol metabolite by 
cytochrome (CYP) P enzymes CYP3A4 and CYP2C19, and CYP3A4 inhibitors such as 
erythromycin,  clarithromycin,  and  antifungals  such  as  ketoconazole,  fluconazole, 
itraconazole affect clopidogrel conversion to its active metabolite (Taubert et al. 2004). 
Omeprazole is a CYP2C19 inhibitor, and various studies have demonstrated inhibition of 
clopidogrel   with   this   proton   pump   inhibitor (   Sibbing   et   al.   2009).   Some   patients 
demonstrating clopidogrel resistance have reduced CYP2C19 metabolic activity, which can 
be genetically determined (Boulenc et al. 2012). Enzyme inducers such as rifampin, 
carbamazepine, barbiturates, and St. John’s wort increase CYP3A4 activity, and enhance the 
antiplatelet effects of clopidogrel resulting in increaed bleeding risk in some patients. 
 
Athough variably defined, resistance to antiplatelet therapy is a serious emergent clinical 
entity  for  which  an  efficient  diagnostic  test  as  well  as  a  management  plan  becomes 
imperative. The clinician is currently able to partially improve the responsiveness to 
antiplatelet therapy by acting on extrinsic factors, involved in the aetiology of resistance, 
including compliance to treatment, drug-drug interactions and good control of blood pressure, 
glycaemia and lipid levels. Antiplatelet resistance remains a major cause of concern, as 
antiplatelet agents are the most important therapeutic options in patients with coronary artery 
disease
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Prevalence of Antiplatelet resistance in different populations 
 
 
 
Stable Coronary artery disease 
 
 
A prospective study of 326 patients with stable CAD were followed up for 2 yrs. 5.5% were 
resistant to aspirin by Light Transmission Aggregometry and 9.5 % resistant to aspirin by 
Platelet Function Analyzer 100 (Gum et al. 2001).  Resistance to aspirin was defined as 
mean aggregation greater than 70% with 10 microM ADP, and   mean aggregation greater 
than 20% with 0.5 mg/ml arachidonic acid. Another study in a cohort of 98 subjects showed 
29.6% resistance in patients on Aspirin 160 mg/d. Resistance to aspirin by PFA-100 was 
defined as having   normal collagen or epinephrine closure time less than 193 seconds. 
(Macchi et al. 2003). 
 
Acute Coronary syndrome 
 
 
In a study involving 204 patients (104 with ACS and 100 with stable CAD) 40.3% were 
resistant to aspirin by PFA 100 compared to 27% with stable CAD. The Warfarin Aspirin 
Reinfarction II Study (WARIS-II) study involved 202 patients allocated to receive either 
Aspirin, Warfarin or both. Aspirin resistance was observed in 35% taking aspirin alone and in 
40% taking aspirin and warfarin.There was an increased CV event rate in aspirin non 
responders compared to responders (36% vs 24%) (Andersen et al. 2002). 
 
Primary percutaneous coronary intervention 
60 patients with acute MI undergoing primary PCI were loaded with 300 mg clopidogrel 
followed by 75 mg/d, and 300 mg aspirin followed by 200 mg /d. They were divided into 4 
quartiles based on reduction in platelet aggregation. Patients in the first quartile had platelet 
aggregation 103+/- 8%, whereas those in the 2
nd
, 3rd and 4
th 
quartile had platelet aggregation 
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of 69, 58 and 33 % of their respective baselines. After 6 months’ follow up, 7 patients in 
the first quartile and 1 patient in the 2
nd 
quartile had a CV event (Matetzky et al. 2004). 
 
  Elective percutaneous coronary intervention 
 
In a study involving 151 Asian patients undergoing elective PCI, aspirin resistance was 
assessed by the Verify Now assay. All patients had been taking 80-325 mg aspirin for at 
least a week prior to the procedure and clopidogrel for 12-24 hrs prior to the PCI. 29 
(19.2%) patients were deemed aspirin resistant (Chen et al.  2004).Another study looked 
at antiplatelet resistance to IIbIIIa inhibitors in 485 patients undergoing elective PCI using 
the Verify Now assay. Patients whose platelet function was inhibited by 90% or more 
had an event  rate  of  2%  compared  with  10%  for  patients  with  inhibition  of  less  
than  90%( Hochholzer et al. 2006). 
 
  Stent thrombosis  
 
 
The CREST trial (Clopidogrel Effect on Platelet Reactivity in patients with stent 
thrombosis) showed high platelet reactivity in patients with stent thrombosis (ST) when 
assessed by LTA and VASP methods. Another study by Gurbel et al compared 20 patients 
with ST to 100 patients with patent stents. Platelet function was assessed by LTA and the 
results suggested that high post treatment platelet reactivity and incomplete inhibition of 
P2Y12 are risk factors for stent thrombosis (Gurbel et al. 2005). Another prospective study 
by Muller et al followed up 105 patients undergoing elective PCI and found that 2 patients 
who developed ST were resistant to clopidogrel (Muller et al.2003).  A study by Azenberg 
et al compared 10 patients with ST to 22 controls using the shear induced platelet  
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aggregation method and found that resistance to antiplatelet therapy and increased shear 
induced platelet aggregation correlated well with stent thrombosis (Ajzenberg  et al. 
2005). The interval between stent thrombosis and assessment of antiplatelet resistance 
in all the above studies was variable. Also, the patient population was diverse hence 
further trials are required to assess the relation between stent thrombosis and antiplatelet 
resistance mechanisms. 
 
  Cerebrovascular disease 
 
In a study involving 180 post stroke patients, 33% patients were found to be aspirin 
resistant. All patients were followed up for 2 years and major end points were observed in 
40% of aspirin resistant patients compared with 4% of aspirin responders (p< 0.0001) 
(Grotemeyer et al. 1993). Another small study compared 35 patients with symptoms 
(ischaemic stroke or TIA) in previous 3 days to 18 patients without symptoms (no CVA 
symptom for > 24 mths).All patients had been on aspirin for at least 5 mths prior to being 
tested for aspirin resistance.34% of symptomatic patients were identified as aspirin 
resistant compared to none of the asymptomatic patients (Grundmann et al. 2003). 
 
  Peripheral vascular disease 
 
A study involving 100 patients with intermittent claudication undergoing elective 
ileofemoral percutaneous balloon angioplasty were assessed for aspirin resistance. 
Corrected whole blood aggregometry (CWBA) was assessed at baseline and at regular 
intervals for up to a year post angioplasty while they were on aspirin 100 mg/d. AA, ADP 
and collagen were used as main stimulants, and significant platelet inhibition to AA was  
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noted. Inhibition to platelet aggregation using CWBA was reduced in male patients, who 
were noted to be at significant risk of recocclusion at site of angioplasty (p= 0.009). None 
of the female patients had reocclusion, and statistical analysis demonstrated significant 
difference in risk profile in the male patient group, including levels of smoking and HDL 
levels. 65 % patients were detected to be aspirin resistant with 8 male patients having a 
repeat vascular event during a 1 year follow up (Mueller et al. 1997). 
 
Table 2.1 and 2.2 summarize prevalence of Aspirin and Clopidogrel resistance in 
different patient populations respectively. 
 
Table 2.3 and 2.4 summarize clinical implications and relevance of Aspirin and 
Clopidogrel resistance in different patient populations  
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Table 2.1: Studies demonstrating prevalence of Aspirin non-responsiveness or resistance  
 
 
 
 
 
 
 
Study Number 
of 
subjects 
Patient 
subgroup 
Aspirin 
dose 
Platelet 
function test 
Prevalence 
of 
resistance 
(%) 
Gum et al  
 
325 Stable CAD 325 mg ADP and AA 
induced optical 
aggregation 
5.2 
Mueller et al  
 
100 PVD 100 mg Corrected whole 
blood 
aggregometry 
60 
Grotemeyer 
et al 
180 CVA 1500 mg Platelet 
reactivity 
33 
Chen et al 151 Elective 
PCI 
80-325 mg RPFA 19 
Anderson et 
al 
202 Post MI 160 mg 
aspirin vs. 
75 mg 
aspirin 
plus 
warafarin 
PFA-100 35 % in 
aspirin only 
patients 
compared to 
40% in 
patients on 
aspirin plus 
warfarin 
Macchi et al 72 Stable CAD 160 MG PFA-100 29.2 
Helgason et 
al 
306 CVA 300-325 
mg 
ADP induced 
platelet 
aggregation 
25 
Alberts et al  129 CVA 81 vs. 325 PFA-100 37 % overall 
56% in 
patients on 81 
mg vs. 28% 
in patients on 
325 mg 
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Table 2.2: Studies demonstrating prevalence of Clopidogrel non-responsiveness or 
resistance 
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Table 2.3:  Studies demonstrating clinical implications of Aspirin non-responsiveness or 
resistance 
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Table 2.4: Studies demonstrating clinical implications of Clopidogrel non- responsiveness 
or resistance 
 
Study Patients and Follow up period Platelet function test Clinical implications of 
Clopidogrel resistance 
Matetzky et al .2004 60 patients with STEMI 
undergoing PCI 
 
6 months follow up 
ADP induced aggregation using 
LTA 
Higher ADP induced platelet 
aggregation in recurrent cardiac 
events group ( 91±21 vs. 
62±21%, p< 0.001 ) 
Barragan et al.2003 16 patients with stent 
thrombosis compared to 30 
patients with no stent 
thrombosis 
 
Retrospective study 
Enhanced platelet reactivity 
using VASP assay 
Stent thrombosis patients had 
higher VASP assay measured 
platelet reactivity ( 63.2±.6 vs. 
39.8±10.9%, p<0.0001) 
Ajzenberg et al.2005 49 patients ( 10 patients had 
stent thrombosis, remaining 39 
were control group) 
 
Retrospective study 
Shear induced platelet 
aggregation (SIPA) 
Patients with Stent thrombosis 
had higher SIPA (41±12 vs. 
18±8%, p=0.013 at shear rate of 
200/s) 
CREST study. Gurbel 
et al. 2005 
120 
 
Retrospective study 
High post-treatment reactivity 
assessed by LTA and 
incomplete P2Y12 receptor 
inhibition assessed by VASP 
Greater incidence of Stent 
thrombosis in patients with 
greater ADP induced 
aggregation ( 5µmol/l ADP: 
49±4 vs. 33±2%,p<0.05 , 20 
µmol/l ADP: 65±3 vs. 51±2%, 
p<0.001) 
Cuisset et al. 2006 106 patients treated with PCI 
 
1 month follow up 
LTA assessed at the time of the 
intervention 
Recurrent events in patients 
with greater ADP induced 
aggregation ( p <0.0001) 
EXCELSIOR. 
Hochholzer et al. 2006 
802 undergoing PCI pre-treated 
with 600 loading dose of 
clopidogrel 
 
1 month follow up 
ADP induced platelet 
aggregation assessed by LTA 
immediately before intervention 
MACE increased  with increase 
in ADP induced aggregation ( 
0.5% in first 2 quartiles,3.1% in 
3rd quartile, and 3.5% in 4th 
quartile, p=0.034) 
PREPARE POST- 
STENTING. Gurbel et 
al.2005 
192 patients undergoing PCI 
 
6 months follow up 
ADP induced platelet 
aggregation assessed by LTA 
Aggregation greater in patients 
with recurrent ischaemic events 
( 63±2 vs. 56±15,p=0.02) 
Lev et al.2006 150 patients (aspirin resistant 
and aspirin sensitive) 
undergoing elective PCI 
 
Assessed at discharge 
LTA Aspirin resistant patients had 
lower response to clopidogrel 
than aspirin sensitive patients ( 
20µmol/l ADP:19 vs. 73%, 
p=0.001, 5µl/l ADP:18 vs. 
79%,p=0.001) 
Geisler et al.2006 379 (206 stable angina and 173 
ACS) undergoing PCI, treated 
with 600 mg loading dose. 
 
3 months follow up 
Assessment of response to 
clopidogrel using LTA 
Significant higher risk of major 
cardiovascular events in non- 
responders compared to 
responders (22.7% vs 5.6%; 
p=0.004) 
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There are many tests to assess platelet reactivity and these have demonstrated a large variability 
in the response to antiplatelet medication, with variable prevalence of “resistance”. The 
definition of “resistance” is fraught with difficulty as the different methods report different 
prevalences, depending on the test used, the cut-off value used to define resistance, the timing 
with respect to medication and the population studied. A metanalysis by Hovens et al found 
heterogeneity in the prevalence of aspirin resistance, and this was due to the variability in results 
using different platelet function tests (Hovens et al. 2007). It is extremely difficult for clinicians 
to determine which method to use to assess platelet function and how to interpret the results. 
There has been no good correlation so far amongst the various different platelet function tests. 
Many are time consuming, and not applicable to a clinical setting. None fulfills the “ideal” 
criteria described in our introduction. Furthermore, to date, there is very little data to suggest that 
altering antiplatelet medication based on the results of laboratory tests of “resistance” improves 
clinical outcomes.  A metanalysis by Snoep et al (Snoep et al. 2007) suggests patients with 
laboratory aspirin resistance are more likely to experience adverse cardiac events, but it is 
important to point out that no prospective, well-powered clinical trial has assessed the benefit of 
tailoring antiplatelet medication specifically to populations with increased platelet reactivity. 
This is partly because we do not know which test or tests best define antiplatelet resistance and 
which medications best improve outcome in these patient populations.The approach to the 
problem of antiplatelet resistance has been to develop newer drugs to further inhibit platelet 
reactivity or increase the dose and timing of treatment with currently available antiplatelet 
agents. However, both these approaches have been targeted at “allcomers”, rather than 
specifically tailoring either of these approaches to those patients identified as being non-
responders. Importantly, the common side effect of bleeding with all antiplatelet medications 
means that the risk vs. benefit ratio needs to be carefully balanced, and it may be more important  
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to individualize such medications to subjects identified as “resistant” rather than giving stronger 
medication or higher doses to allcomers. Furthermore, the prevalence of “resistance” to these 
newly developed antiplatelet medications has not been evaluated. We believe a simple, rapid, 
near-patient test, which is affordable and useful in the clinical (not just laboratory) setting needs 
to be validated in a large scale clinical trial, to identify patients with impaired response to 
antiplatelet medication. This would allow risk stratification and individualization of antiplatelet 
medication to improve outcome in these patients, with novel treatments or optimised doses of 
currently available drugs (Saraf et al. 2009).  
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Determinants of endogenous lysis (Lysis time), mechanism of fibrinolysis 
and plasma fibrinolytic markers 
 
Fibrinolysis plays an important role in lysis of a platelet rich thrombus, and disturbances in 
the lytic system may result in thrombotic or haemorrhagic complications. Plasminogen is the 
main component of the fibrinolytic pathway, and it is converted to plasmin by tissue type 
plasminogen activator t-PA and urokinase type plasminogen activator uPA. Plasmin assists in 
degradation of fibrin and extracellular matrix proteins such as fibronectin, laminin, 
proteoglycan, and type IV collagen, and PAI-1 and α2-antiplasmin help in regulation of the 
fibrinolytic system. 
 
The most common determinants of endogenous fibrinolysis and fibrinolytic markers are: 
tissue type plasminogen activator (t-PA), urokinase type (u-PA) plasminogen activator, 
plasminogen activators inhibitors type 1 (PAI-1), alpha2-antiplasmin (alpha2-AP), plasmin-
alpha2-antiplasmin (PAP) complexes, thrombin activable fibrinolytic inhibitors (TAFI), D-
dimer and fibrin/fibrinogen degradation products (FDP). 
 
Various markers of plasma fibrinolysis as mentioned above have been studied, but no 
conclusive evidence is available to suggest use of any particular fibrinolytic marker. Studies 
have used the different biomarkers with conflicting results, and the role of different 
fibrinolytic markers in predicting outcome of coronary artery disease remains undetermined 
.This is primarily due to variability in plasma levels of these proteins between and within 
subjects, and other non fibrinolytic properties of these proteins. 
 
Tissue type plasminogen activator (t-PA) 
 
 
t-PA is a serine protease found in endothelial cells, and activates fibrinolysis by converting 
plasminogen to plasmin .High plasma levels of t-PA antigen and activity have been reported  
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during the acute phase of myocardial infarction, and high levels during the subacute phase 
have been predictive of future adverse cardiac events ( Soeki et al. 2002). An association 
between elevated t-PA concentrations and risk of subsequent cardiac events has also been 
noted in patients with stable angina (Jansson et al.1996). In the MIRACL (Myocardial 
Ischaemia Reduction with Aggressive Cholesterol Lowering) study, higher levels of t-PA 
were associated with recurrent adverse cardiac events. This may be due to an association 
between t-PA and sex, body mass index or smoking or due to formation of t-PA/PAI-1 
complex (Kinlay et al. 2009). t-PA levels in healthy individuals (Gram et al. 2000) and post 
menopausal women are also predictive of future coronary artery disease  (Pradhan et al. 
2004). 
 
 
Recombinant t-PA is used in clinical setting to treat STEMI, large pulmonary infarcts and 
ischaemic stroke. PAI-1 and PAI-2 are specific t-PA inhibitors produced by endothelial cells, 
smooth muscle cells, fibroblasts and hepatocytes. t-PA forms a complex with PAI-1 which 
has inhibitory effect on fibrinolysis and thus paradoxically reflects impaired endogenous 
fibrinolysis ( Jansson et al. 1993). 
 
Plasminogen activator inhibitor -1 (PAI-1) 
 
 
PAI-1 is a serine protease inhibitor secreted primarily by endothelial cells, and inhibits 
fibrinolysis  by  inhibition  of  t-PA  and  Urokinase  –type  plasminogen  activator  (u-PA). 
Majority of PAI-1 is secreted by vascular endothelium, but it is also present in platelets, liver 
and vascular smooth muscle cells (Hinsberg et al.1991). It has the ability to bind to fibrin 
resulting preventing fibrin degradation, and its ability to bind to t-PA results in inhibition of 
fibrinolysis promoting thrombus formation.There are studies suggesting high levels of PAI-1 
are independently associated with occurrence of first myocardial infarction in healthy young  
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individuals and subsequent increased risk of future cardiac events in patients with coronary 
artery disease (Thögersen et al.1998).  PAI-1 accumulates in vessels, and its accumulation is 
known to be associated with atherosclerosis resulting in plaque formation. Diabetic patients 
have been known to have higher PAI-1 levels, which may partly explain the increased 
incidence of coronary disease in this subgroup (Sobel et al. 1998).In the Stockholm Heart  
Epidemiology Program (SHEEP), plasma concentration of tPA/PAI-1 complex was 
significantly associated with risk of MI in both genders (Nordenhem et al. 2005). On the 
contrary, in the ADVANCE (Action in Diabetes and Vascular Disease) and a subgroup of the 
Framingham study, no significant correlation was seen between PAI-1 levels and adverse 
outcomes (Wang et al. 2007). Nevertheless, in the Caerphilly Study, elevated levels of PAI-1 
were associated with higher incidence of cardiovascular events (Smith et al.2005). 
Several factors stimulate release of PAI-1 and include the activated renin angiotensin system 
(RAS), hypertriglyceridaemia, hyperglycaemia, and hyperinsulinaemia. Oestrogen production 
in females is known to maintain PAI-1 at normal levels. 
The Renin angiotensin system is primarily concentrated in the vascular and endothelial 
cells. Angiotensin II stimulates production of PAI-1 by binding to these endothelial cells. 
Angiotensin converting enzyme (ACE) converts Angiotensin I to Angiotensin II stimulating 
production of PAI-1 (Rakugi et al.1994). Bradykinin is a vasodilator that promotes t-PA 
production and promotes fibrinolysis. ACE increases Bradykinin degradation thus inhibiting 
fibrinolysis and promoting thrombus formation (Brown et al. 1999). 
Elevated glucose and Insulin levels are known to stimulate release of PAI -1. Glucose 
stimulates PAI-1 release by stimulating transcription of PAI-1 gene in vascular smooth 
muscle cells. Good control of diabetes by antidiabetic medications thus helps in reduction of 
PAI-1 activity reducing thrombogenicity, and reduces risk of future cardiac events (Pandolfi 
et al. 1996). 
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Endogenous Insulin and its precursors promote PAI-1 activity and use of exogenous Insulin 
helps in reducing and PAI-1 mRNA expression, inhibiting PAI-1 mediated thrombosis ( Jain 
et al. 1993). 
 
Hypertriglyceridaemia is associated with coronary artery disease, and this can be explained 
by the association between triglycerides and PAI-1. VLDL and LDL triglyceride stimulates  
release of PAI-1 from endothelial cells, inhibiting fibrinolysis (Mussoni et al. 1992). 
Thrombotic events are more commonly seen in post menopausal women. This is primarily 
due  to  the  protection  provided  by  oestrogen  in  premenopausal  women  and  in  post 
menopausal women on oestrogen containing Hormone replacement therapy (HRT).Oral 
oestrogen reduces production of PAI-1 from the liver and promotes fibrinolysis. Nitric oxide 
also inhibits PAI-1 expression, and oestrogen exerts a protective effect by increasing 
production of nitric oxide (Brown et al. 2002). 
Pharmacological agents have also been shown to influence levels of PAI-1 and have a 
beneficial effect on the fibrinolytic system. Angiotensin converting enzyme inhibitors (ACE- 
i), Hormone replacement therapy agents (HRT), Biguanides like metformin, and HMG 
coenzyme-A reductase inhibitors like statin have shown to have a beneficial effect on the 
fibrinolytic system by altering levels of PAI-1. 
In both human and animal models, ACE-I have been shown to significantly attenuate PAI-1 
expression and activity. High dose quinapril demonstrated a 26% reduction in PAI-1 activity , 
p= 0.08 in normotensive patients who had no underlying cardiovascular, renal, pulmonary or 
endocrine disease ( Brown et al. 1998).A study by Vaughan et al demonstrated a 44% 
reduction of PAI-1 antigen in 120 patients who were started on ramipril within 24 hours of an 
acute myocardial infarction (Vaughan et al.1997). Captopril provided a significant reduction 
of PAI-1 antigen level when initiated after 2 days (p= 0.02) and 1 month (p< 0.001) of an 
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AMI (Mor i yama  et al. 1998).   In another study, captopril reduced PAI-1 antigen level  
 
by 46% when initiated 8 weeks after an AMI (p= 0.001) (Wright et al.1994). 
 
Hormone replacement therapies have various beneficial effects when taken in 
postmenopausal women. They improve carbohydrate metabolism by controlling 
hyperglycaemia and hyperinsulinaemia, and regulating body fat distribution. They decrease 
LDL cholesterol and increase HDL cholesterol levels, and play an important role in control of 
insulin resistance syndrome. Oral oestrogen reduces PAI-1 antigen levels and activity in 
contrast t o  t r an s d e r m a l  o e s t r o g e n .  This i s  p o s s i b l y  due t o  s u p p r e s s i o n  o f  
h ep a t oc yt e  production and enhancement of hepatic clearance of PAI-1. HRT also increase 
t-PA activity by reducing t-PA Antigen levels and hence promote fibrinolysis.They increase 
nitric oxide bioavailability which in turn inhibits expression of PAI-1. In a study of 288 post-
menopausal women, Shahar et al demonstrated a 28% reduction in PAI-1 antigen (p= 0.04) 
and 18% reduction in t-PA antigen level ( p= 0.004) in post-menopausal women on HRT 
when compared to post-menopausal women not on oestrogen replacement. Oestrogen is also 
known to elevate triglyceride levels in post- menopausal women, but PAI-1 activity 
reduction was independent  of  this  effect  as  demonstrated  in  the  Atherosclerosis  Risk  in  
Communities (ARIC) study (Shahar et al. 1996). A study by Katz et al demonstrated 45% 
reduction of PAI- 1 levels only in the early hours of the morning in postmenopausal patients 
on oestrogen replacement, suggesting circadian rhythm plays an important role in 
fibrinolysis (Katz et al. 1996). 
Biguanides like metformin are used in the treatment of Type 2 Diabetes Mellitus. These 
drugs improve insulin sensitivity; reduce glucose production by the liver and increase it’s 
utilization   in peripheral   tissues.   They reduce   cholesterol   levels   and   aid   in   weight 
reduction. They act as a fibrinolytic by reducing PAI-1 levels. Several studies have 
demonstrated significant reduction in the levels of PAI-1 antigen in diabetic patients on  
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metformin. Grant et al demonstrated significant reduction in PAI-1 antigen levels in 75 
diabetic patients on different doses of metformin. Reduction of PAI-1 was independent of the 
dose of metformin used, and a significant reduction was noted when compared to placebo 
group who were not on biguanide treatment (Grant et al. 1996). In the BIGPRO -1 study, 457 
non diabetic obese patients were randomized to metformin or placebo. There was 30-40 % 
reduction in PAI-1 antigen and activity level in both groups, but no added benefit was seen in 
the metformin group compared to placebo (Charles et al. 2000). 
Thiazolidinediones lower blood glucose levels and improve insulin sensitivity. In a small 
study by Kato et al, high doses of troglitazone were shown to reduce PAI-1 antigen and 
activity level in diabetic patients, but no reduction in PAI-1 was seen in non-diabetics or  
healthy lean patients (Kato et al.2000).Larger studies are required to determine the true effect 
of this medication on fibrinolysis. 
Insulin therapy is used in diabetic patients to lower glucose levels. Hyperinsulinaemia 
results in elevated PAI-1 levels, and insulin therapy improves insulin sensitivity and helps in 
reduction of PAI-1 and aids fibrinolysis in diabetic patients (Lormeau et al. 1997). 
Statins are HMG-Coenzyme A reductase inhibitors that help lower cholesterol levels in 
patients with hypercholesterolaemia, but also in patients with normal cholesterol levels. 
Several small studies have been carried out comparing effect of statins on PAI-1 activity. A 
study by Weisbauer et al demonstrated reduction of PAI-1 production by all statins but 
pravastatin (Weisbauer et al.2002). On the contrary,a study by Dangas et al demonstrated a 
significant 22% reduction in PAI-1 levels in 57 hyperlipidemic patients on pravastatin when 
compared to placebo. This effect was seen independent of cholesterol reduction (Dangas et 
al.2000).   A study by Isaacsohn et al showed a significant decrease in PAI-1 activity with 
lovastatin (Isaacsohn   et al.1994), whereas another small study by Zambrano et al  
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demonstrated no effect on PAI-1 with lovastatin in hyperlipemic heart transplant patients 
(Zambrano et al.1997). 
 
Urokinase type (u-PA) plasminogen activator 
 
Urokinase type plasminogen activator is a serine protease found in the blood stream plasma 
and extracellular tissue. It is a plasminogen activator, which when activated to plasmin 
facilitates fibrinolysis.   It is found in plasma concentrations of 2 to 4 ng/ml. Recombinant 
urokinase is used in treatment of pulmonary embolism, and in flushing haemodialysis 
catheters. 
 
Plasmin-alpha2-antiplasmin (PAP) complex 
 
PAP is a serine protease that inactivates plasmin. There have been several studies to 
demonstrate relationship between PAP levels and future coronary events. In the 
Cardiovascular health study, PAP levels were predictive of myocardial infarction in healthy 
individuals > 65 years age (OR: 3.1) (Cushman et al. 1999).Similarly, association was noted 
between PAP levels and death in the large Multiethnic study of Atherosclerosis (HR: 2.0) 
 
(Folsom et al.2009). By contrast, in the AtheroGene study, PAP levels had no association 
with future adverse cardiac events (Morange et al.2006). 
 
Thrombin activable fibrinolytic inhibitors (TAFI) 
 
TAFI is a carboxypeptidase B-like proenzyme identified in platelets at a concentration of 50 
ng/l x 10
9
. It is activated by thrombin, either alone or in combination with thrombomodulin to 
form TAFIa.TAFIa is the active form of TAFI, and is associated with down regulation of 
fibrinolysis by removal of C-terminal lysine’s from fibrin. It is synthesized in the liver, 
and active form has a half-life of several hours. People deficient in TAFI tend to suffer with 
bleeding diathesis. A study by Cloucci et al demonstrated increased bleeding in cirrhotic  
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patients was secondary to hyperfibrinolysis due to deficiency of TAFI. TAFI antigen is 
measured using ELISA and Clot Lysis assay (Colucci et al. 2003). There is data to suggest 
that both high and low levels of activated TAFI antigen are seen in patients with coronary 
artery disease. High TAFIa levels were seen in the Athero Gene study (Tregouet et al.2009) 
and were independently associated with a high risk of cardiovascular death (HR: 1.7). On the 
contrary, in the ATTAC (The role of thrombin activatable ﬁbrinolysis inhibitor in arterial 
thrombosis at a young age) and SMILE study (Study of Myocardial Infarctions Leiden), low 
levels of TAFIa were associated with a higher incidence of cardiovascular disease (Meltzer et 
al.2009). 
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Endogenous Thrombolysis- A neglected entity, with prognostic usefulness in 
Acute Coronary Syndrome 
 
 
Endogenous thrombolysis is considered a protective mechanism against lasting arterial 
occlusion, and acute myocardial infarction has been considered a result of failure of timely 
spontaneous thrombolysis (Swan et al. 1989). 
As discussed in the previous chapter, the vascular endothelium cells synthesize various 
thrombotic and thrombolytic agents, and these agents are activated and released during vessel 
wall injury and are regulated by nitric oxide release. The common agents that stimulate 
thrombosis are PAI-1, PAI-2, TAFI, D-dimer and Protein C and the common fibrinolytic 
agents are t-PA and u-PA. A balance between the activity of these pro and anti fibrinolytic 
factors is crucial in determining the efficacy of endogenous thrombolysis. In various clinical 
conditions like diabetes mellitus, multiple sclerosis, severe sepsis and advanced cirrhosis, 
endogenous thrombolysis is impaired resulting in a prothrombotic state. Great individual 
variation is seen in the efficacy of the fibrinolytic system in individuals, and is hugely 
dependent on activity of PAI-1 antigen, TAFI and t-PA levels. Several factors can result in 
failure of spontaneous lysis, common factors being excess circulating PAI-1 antigen, lack of 
lytic elements, increasing thrombogenicity of the plaque secondary to increase in size, 
composition or location. Marked variation in the level of plasma ﬁbrinolytic proteins levels 
both between and within subjects, and its antifibrinolytic effects may explain reduced interest 
in this important clinical entity. Below, we discuss the various studies that have demonstrated 
beneficial effects of endogenous thrombolysis in atherothrombotic patients. 
In a study by Swan et al (Swan et al. 1989), patients with occluded arteries had coronary 
angiography few weeks to months after their initial AMI, and patency of the culprit artery 
was demonstrated during angiography, suggesting endogenous thrombolysis had a key role to 
play in the dissolution of the thrombus.  In another study, greater than 90% AMI patients had  
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complete occlusion of the affected coronary artery secondary to thrombus within 4 hours of  
cardiac chest pain, and repeat angiography 12 hours later demonstrated 30-40% spontaneous 
recanalization of this artery (DeWood et al. 1980). Hackett et al demonstrated spontaneous 
intermittent coronary reperfusion in a small study of 45 AMI patients. Continuous ECG and 
serial coronary angiography was performed in these patients, and in 8 patients, the ST 
elevation on ECG returned to baseline prior to the coronary arteriogram being performed 
suggesting spontaneous reperfusion was common in early stages of an AMI (Hackett et al. 
1987).  In a study by Rentrop et al, 122 acute MI patients were randomized to intracoronary 
streptokinase, intracoronary nitroglycerin, intracoronary streptokinase and intracoronary 
nitroglycerin, or conventional therapy without initial angiography. In 67% patients, baseline 
angiography demonstrated complete occlusion of the infarct related artery (Rentrop et al. 
1984). However, at 10-14 days repeat angiography demonstrated patency of culprit vessel in 
74% patients irrespective of treatment received, demonstrating the positive effect of 
endogenous thrombolysis.   Evidence also suggests spontaneous reperfusion occurs within 40 
minutes in unstable angina, at 60-90 minutes in partial thickness myocardial infarction, and 
greater than 3 hours in full thickness myocardial infarction.  Late  spontaneous  lysis  also  
occurs  in  a  significant  proportion  of  patients, especially those developing a left 
ventricular aneurysm ( Forman et al. 1986). In a study by De Wood et al, 29 of 36 patients 
with AMI had completely occluded arteries, of which 17 demonstrated spontaneous 
recanalization on repeat angiography. Left ventricular function was measured in all 
patients, at baseline and during repeat angiography. Although no significant difference was 
observed in the completed occluded group (55±8% to 52±8%, P=NS), a significant 
improvement in ejection fraction was noted in the spontaneous recanalization group (44±15% 
to 56±10%, P= 0.05). No significant difference was observed in the ejection fraction 
difference in the 2 groups during repeat angiography (52±8% versus 56±10%, P=NS), nor  
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did all patients with spontaneous reperfusion demonstrate improvement suggesting larger 
studies are required to study the beneficial effects of recanalization (DeWood et al.1985). 
Myocardial salvage using technetium -99m sestamibi perfusion imaging was determined in 
AMI patients treated with aspirin and heparin, and patency of the infarct related artery was 
seen to increase from 16-24% during the first 24 hours to 57-64% after 3 days. Heparin is an 
anticoagulant, and prevents conversion of prothrombin to thrombin preventing further clot 
formation and propagation. It does not act as a thrombolytic, and increase in perfusion noted 
was presumed to be secondary to spontaneous reperfusion of the infarct related artery 
(Christian et al. 1991). Myocardial salvage was detected in 21 patients, and noted to be 
around 6%±11%  of  the  left  ventricle,  and  was  significantly  greater  with  patent  infarct  
related arteries, compared to arteries that were completely occluded ( P= 0.001)( 
Christian et al.1998). More data from 8 studies have suggested that patency of the infarct 
related artery ranged between 9-28% before thrombolytic therapy or angioplasty, and 
increased to 36-78% by 72 hours on heparin infusion in the absence of any other reperfusion 
therapies ( Granger et al. 1992). Significant symptomatic benefit with resolution of chest pain 
was noted in patients with patent infarct related arteries (100% vs 55%, P=0.003). 
Lee et al demonstrated that reperfusion secondary to spontaneous fibrinolysis resulted in 
faster coronary blood flow and significantly improved clinical outcomes. The study included 
199 patients with STEMI who underwent primary angioplasty. 6 weeks post angioplasty, 
patients with spontaneous reperfusion in this subset of patients  had a higher rate of TIMI 3 
flow, and mortality, reinfarction and congestive heart failure were significantly lower in this 
group of patients ( 4.5% vs 18.4%, P <0.05) suggesting spontaneous reperfusion was a 
prognostic indicator in AMI patients undergoing primary angioplasty ( Lee et al. 2001). 
There are case reports on spontaneous fibrinolysis of thrombi in internal carotid arteries  
(Calleja et al. 2004), and peripheral arteries (Weiner et al. 1984) suggesting spontaneous 
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reperfusion  secondary  to  endogenous  thrombolysis  can  occur  both  in  the  central  and 
peripheral vasculature. 
A Japanese group led by Ikarugi et al. investigated the extent of platelet reactivity and 
spontaneous thrombolysis in men and women using the GTT, and significantly reduced 
thombolytic activity were noted in men > 51 years age. 145 normal subjects without any 
significant cardiac history or risk factors were tested using the GTT. No significant difference 
was observed in the OT values in the different age groups in either men or women, but LT 
was significantly prolonged in older men > 51 yrs age when compared to middle aged men 
aged 31-50 years ( LT: 3657±461s vs 2398±236s,  P= 0.0002) ( Yamashita et al. 2005). 
Coronary artery disease is more prevalent in men, and these findings are in agreement with 
this observation. Another Japanese study in 64 subjects demonstrated significantly longer 
LT’s i n  e l d e r l y  men compared to the young men (mean age 64.5±1.1 years in the 
elderly, LT: 4555.0±187.2 vs 3134.2±249.3s, P< 0.001) using the GTT. In elderly smokers, 
LT was prolonged when compared to elderly non-smokers (LT 5407.1±83.4 vs 
2910.4±404.6S, P<0.001), and may be secondary to age related endothelial dysfunction 
and reduced nitric oxide release (Ikarugi et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
Tests to assess endogenous plasma fibrinolysis 
 
 
Global assays of fibrinolysis have been in place for a while, but none of the tests are really 
used in the clinical setting. They are time consuming, labour intensive and most importantly 
there is uncertainty with regards to which biomarker to be measured, as limited data is 
available on fibrinolytic marker levels and cardiac outcomes. Furthermore, most of the tests 
available measures clot lysis as opposed to thrombolysis. Below, I discuss the different 
available tests for assessing fibrinolysis below, with their merits and shortcomings. 
 
Fibrin plate method 
 
 
The fibrin plate assay was introduced in 1952 by Astrup and Mullertz. Plasminogen was 
added to the fibrin plates, and was incubated with urokinase or streptokinase for few hours. 
This assay has been reported to be complicated, time consuming, unreliable and has low 
reproducibility (Marsh et al. 1972). 
 
Euglobulin Clot Lysis time (ELT) 
 
 
The ELT is a test that measures overall fibrinolysis. It uses addition of acid to citrated 
platelet-poor plasma to precipitate clotting factors in the euglobulin fraction. The euglobulin 
fraction also contains fibrinolytic factors like fibrinogen, PAI-1, t-PA, Plasminogen, Factor 
VIII, and alpha 2 anitplasmin. Addition of calcium is required to activate clotting, and 
subsequently there is clot lysis. The test is sensitive to temperature and pH, and data suggests 
results are not reproducible and it is not a reliable test for measurememt of fibrinolysis (Katz 
et al. 1970).  
Fibrinolysis Parameters Assay (FIPA) 
This assay of fibrinolysis measures the amount of plasmin activity in blood. The FIPA 
reagent consists of urokinase, tranexemic acid, and albumin and is added to citrated blood. 
Further reagents are added to determine plasmin activity. At fibrinolysis reaction time (FRT)  
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of 10 mins at 37°C, maximally inducible plasmatic plasmin activity is measured. Normal 
range is 100±15% (MV ±1 SD). This assay is not sensitive to physiological concentrations of 
pro-urokinase  and  tissue  type  plasminogen  activator,  and  has  its  limitations  in  clinical 
practice (Stief et al. 2000). 
Intrinsic Oxidative Clot Lysis Assay (INOXLA) 
Granulocytes a r e  m e d i a t o r s  o f  f i b r i n o l ys i s , a n d  r e l e a s e  p r o u r o k i n a s e , 
c h l o r a m i n e  and NADPH - oxidase, which in turn release superoxide anion and play a 
role in fibrinolysis. Chloramine g e n e r a t e s  0 2  w h i c h  e n h a n c e s  u r o k i n a s e  
m e d i a t e d  f i b r i n o l y s i s .  Plasma  is incubated  with  various  agonists  like  calcium  
chloride  to  which  chloramine  is  added. Urokinase is then added to this microtitre plate, and 
fibrinolysis occurs. Normal range for INOXLA has been reported as 100% ±25% (mean 
±SD).  If the urokinase activity is quenched by PAI -1 no clot lysis occurs. Based on this 
principle, the INOXLA has been developed where clot turbidity helps in determination of 
clot mass or clot lysis (Steif et al.2007). 
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Limitations of current platelet function tests, Rationale behind assessment of 
platelet reactivity and need for newer testing modalities  
 
Current European Society of Cardiology Guidelines do not recommend routine use of platelet 
function testing as dose adjustments of clopidogrel have not demonstrated any clinical benefit 
(Price et al. 2011). A IIb indication has been issued for testing of high platelet reactivity in 
selected NSTEMI patients who are on clopidogrel. They also recommend use of novel 
antiplatelet agents Prasugrel or Ticagrelor in PCI treated NSTEMI patients, provided there is no 
contraindication (Hamm et al. 2011). The AHA/SCAI Guidelines 2011 recommend use of 
platelet function testing in patients who are at high risk of clinical events after PCI and switching 
them to novel antiplatelet agents if their results are suggestive of high on treatment platelet 
reactivity (Levine et al. 2011). 
The platelet function tests that have shown to predict clinical outcomes are the Verify now assay, 
Multiplate assay, VASP and the LTA (Freynhofer MK et al. 2011, Stone et al. 2013).. However, 
due to the lack of standardization with the LTA, use of LTA is only recommended if other assays 
are not available (Bonello et al. 2010).  
In a study of 297 patients with ACS (Pannicia et al. 2009), residual platelet reactivity was 
assessed using the MEA, LTA and the PFA-100 and significant correlation was noted between 
the MEA and the LTA (P< 0.0001) and between MEA and the PFA-100 (P< 0.0001). On the 
other hand, in another study by Gaglia et al (Gaglia et al. 2011), 200 patients undergoing PCI and 
on clopidogrel were assessed for HPR using the VASP, LTA and the Verify now assay. The 
percentage of patients with high HPR using the VASP was 39.3%, 27.3% with Verify Now, and 
23.1 %( ADP 5 µM and 16.2 %( ADP 20 µM) with the LTA. No significant correlation was 
noted between the three tests (Bonello et al. 2010). Another study of 201 stable coronary artery 
disease patients did not demonstrate any significant correlation using different platelet function 
tests. The prevalence of aspirin was 10.3–51.7% using the LTA, 6.7% for Verify now assay,  
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18.0% for whole blood aggregometry, 59.5% for PFA-100, and 22.9% by measuring urinary 11-
dehydro-thromboxane B2 concentrations (Lordkipanidzé et al. 2007). 
The ADAPT-DES registry was a large multicenter registry that demonstrated early (HR: 3.00, 
95% CI: 1.39–6.49, P = 0.005) and late stent thrombosis (HR: 2.49, 95% CI: 1.43–4.31, P = 
0.001) in patients with HPR using the Verify now assay (Stone et al. 2013). In the TRILOGY-
ACS study, medically managed NSTEMI patients on prasugrel demonstrated greater platelet 
inhibition compared to clopidogrel, but this did not translate into improved clinical outcomes 
(Gurbel et al. 2012). In the GRAVITAS study, despite higher platelet inhibition using the Verify 
now assay no significant difference in MACE was noted between high dose and standard dose 
clopidogrel groups (HR: 1.01, 95% CI: 0.58–1.76, P = 0.98) (Price et al. 2011). Similarly, in the 
RECLOSE-2 ACS study, although patients with HPR had an increased risk of cardiac death and 
stent thrombosis, increasing the dose of clopidogrel did not reduce their risk of an adverse event 
(Parodi et al. 2011). Although higher doses of clopidogrel did not improve outcomes in these 
studies, it remains to be seen if switching these HPR patients to newer antiplatelet agents will 
result in improved outcomes.  
The major limitation of the above mentioned available platelet function tests are that they are all 
performed on citrated blood. Citrate reduces the plasma Ca2+ concentration from 0.94–1.33 mM 
to 40–50 μM. Platelet aggregation is optimum at levels of 100 μM Ca2+, and at levels below 10 
μM, platelet aggregation does not occur.  In citrated blood, thrombin is not generated, and Ca2+ 
levels are significantly reduced to 40–50 μM, resulting in suboptimum platelet aggregation 
(Ataullakhanov. 1994, Moore et al. 1970,).  
In most platelet function tests, the citrated sample is tested between 30 mins to 48 hours of 
collection. During this duration, the platelet behavior and response to aggregating stimuli change 
resulting in minimal response to aggregation, as maximum aggregation is demonstrated upto an 
hour after collection of blood (Rossi et al. 1975). 
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Above mentioned platelet function tests in clinical use measure response of platelets to only one 
particular agonist, either ADP, epinephrine, arachidonic acid or collagen. The effect of shear 
stress and thrombin is not measured due to reasons mentioned above. Also, overall fibrinolytic 
status is difficult to ascertain using these platelet function tests as most of these tests measure 
response to only one or few, but not all fibrinolytic markers. Hence, it is difficult to ascertain the 
individual’s true thrombotic and thrombolytic status using currently available platelet function 
tests, and hence the need for a more global test of thrombosis and thrombolysis. 
The GTT is performed on native blood immediately after collection; is shear induced, and is able 
to assess the effect of thrombin on thrombosis. It is also able to assess endogenous thrombolytic 
activity and hence seems to be a more physiological test than currently available platelet function 
tests in clinical use.  
In the last few years there has been a significant reduction in the rate of recurrent events after an 
ACS due to routine use of antiplatelet therapy and interventional procedures.  However, the risk of 
a recurrent event remains high. Recent studies suggest most of these events occur after discharge 
in the first year after the initial event (Fox et al. 2010), with a recurrence rate of approximately 
10% per annum (Wallentin et al. 2009, Wiviott SD et al. 2007).  
Dual antiplatelet therapy is currently recommended for upto 1 year after an ACS (Wright et al. 
2011). Although tailoring clopidogrel therapy based on platelet function assay results is currently 
not recommended, Expert groups recommend platelet function testing in patients at high risk of 
events post PCI or at risk of stent thrombosis (Aradi et al. 2013). It remains to be seen if newer 
and novel antiplatelet agents such as prasugrel, ticagrelor, and direct thrombin inhibitors in due 
course can improve clinical outcomes in patients with HPR.  
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Chapter 2: Methodology 
 
Platelet function was assessed in healthy volunteers and in patients with coronary artery disease 
using the Global Thrombosis Test. A detailed description of this test has been described in 
Chapter 1. Testing was performed in healthy volunteers to develop a normal range, and then 
assessed and compared to various different patient populations. It was our aim to assess whether 
impaired thrombotic and thrombolytic status in patients with coronary artery disease had any 
relationship to adverse outcomes. 
 
Sampling procedure 
 
 
Blood samples were taken from an antecubital vein using an 18 –G butterfly cannula using a 
 
2- Syringe technique. The first 3 mls of blood was either discarded or used for routine blood 
tests and the next 2 ml blood samples were used to assess thrombotic and thrombolytic status. 
This blood sample was injected with force into the GTT tube, and the shear force between the 
small aperture between tube and ball bearings resulted in platelet activation and subsequent 
aggregation. Measurement was started within 15 seconds, and the instrument indicator changed 
colour once the analysis was complete. Each instrument had a memory card, which could be 
connected to a computer to download and view the measurement graphs. 
 
Healthy Volunteers 
 
A normal range was established using the GTT in 100 healthy volunteers. The study was 
approved by the local Research Ethics Committee, and all volunteers gave written informed 
consent. Advertising for healthy volunteers was done via the Hospital trust bulletin, and posters 
were put up in hospital wards and outpatient units. A brief summary of the study and need for 
control group was included in the poster. Recruited volunteers were nonsmokers, not on any 
regular medication, and were advised not to take any medication with known platelet effect in the 
preceding 7 days (aspirin or the oral contraceptive pill). None of the volunteers recruited were  
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heavy alcohol consumers and all were asked to abstain from alcohol the night before sampling. 
Blood pressure and ECG were not performed prior to recruitment, but none of the volunteers had 
any known underlying illness, history of hypertension or cardiac disease. All healthy volunteers 
were tested in the morning, between the hours of 0900 and midday. 
ACS patients 
 
Patients admitted to hospital with ACS were included in the study. ACS was defined by the 
presence of at least two of the following: ischaemic chest pain, elevation of cardiac enzymes 
(troponin or creatine kinase isoenzyme at least twice the upper limit normal limits), or dynamic 
electrocardiographic changes (ST elevation, ST depression or T wave inversion). All 
patients received dual antiplatelet therapy for a year since index admission.Exclusion criteria 
are listed in Table 6.1.  All patients were loaded with Aspirin 300 mg and Clopidogrel 
300 mg on admission, and were taking 75 mg each of Aspirin and Clopidogrel thereafter as 
maintenance dose. 300 patients admitted with ACS were included in the study and sampled 
during their index admission.  Most ACS patients receive unfractionated low molecular weight 
heparin (LMWH) on admission, and all these patients were sampled a minimum of 48 hours, (5 
± 3 days after admission, Mean ± SD) after discontinuation of LMWH to avoid any effect of the 
anticoagulant on OT and LT. Fasting was not required. All patients received dual antiplatelet 
medication for a whole year for follow-up as per normal clinical care. Informed written consent 
was obtained from all subjects, and the study was approved by the local REC. 
Stable angina patients pre and post Aspirin 
 
We measured OT and LT using the GTT in 10 stable angina patients. All patients were 
reviewed and recruited in the outpatient clinic, and none of these patients had been on Aspirin 
prior to being tested. None of these patients were on any other antiplatelet medications. 
Baseline samples were taken prior to starting Aspirin. Post aspirin samples were taken at  
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least a week after each patient had been taking 75mg aspirin. None of these patients had 
been loaded with higher doses of aspirin. 
Healthy volunteers pre and post Clopidogrel 
 
Thirteen normal healthy volunteers were tested before and 8 hours after a loading dose of 300 
mg clopidogrel. Volunteers were non-smokers, not taking any regular medications and in 
particular, did not take any medication with known platelet effect (such as aspirin or the oral 
contraceptive pill) in the preceding 7 days. Testing was performed at the same time of the day 
by the same operator, under similar conditions. 
 
Effect of Clopidogrel on OT and LT in Stable angina patients on Aspirin 
 
We examined the effect of clopidogrel in Stable angina patients. Ten patients with stable angina 
were tested on 75mg Aspirin ( pre clopidogrel), and retested atleast a week later on aspirin 
75mg and clopidogrel 75 mg. Testing was performed by the same operator, under similar 
conditions. 
 
Western and Japanese volunteers 
 
We collaborated with Professor Yamamoto and his colleagues in Kobe Gakuin University, 
Kobe, Japan. Our aim was to compare thrombotic and thrombolytic activity in the native 
Japanese  and  native  Western  population,  to  determine  if  ethnicity  had  any  effect  on 
thrombotic and thrombolytic status. 100 volunteers in each group were tested. Advertising for 
healthy volunteers was done via the Hospital trust bulletin, and posters were put up in hospital 
wards and outpatient units. A brief summary of the study and need for control group was 
included in the poster. Recruited volunteers were nonsmokers, not on any regular medication, 
and were advised not to take any medication with known platelet effect in the preceding 7 days 
(aspirin or the oral contraceptive pill). None of the volunteers recruited were heavy alcohol  
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consumers and all were asked to abstain from alcohol the night before sampling. Blood pressure 
and ECG were not performed prior to recruitment, but none of the volunteers had any known 
underlying illness, history of hypertension or cardiac disease. All healthy volunteers were 
tested in the morning, between the hours of 0900 and midday. 
The Accelerated Global thrombosis test (a GTT) 
The aim of this modification was to induce ADP release from RBC, and assess the effect of this   
on   shear-induced   thrombosis.   Due   to   the   osmotic   gradient,   contact   between 
RBC/platelets and water would result in haemolysis causing localised release of ADP from 
RBC and platelets, which we postulated would accelerate the thrombotic process and reduce 
OT. Prior to injection of blood in the GTT tube, 0.5 ml distilled water was added to the 
tube. Water was added 5-10 minutes before injection of blood to the tube, and filled the space 
between the two balls (100 µl) and the upper water level was constantly 1-2 mm above the 
upper ball (Fig 5.1). Due to the osmotic gradient, on contact of water with blood there was 
cell destruction, haemolysis and release of ADP from RBC and platelets which we postulated 
would accelerate the thrombotic process and result in shortening of OT. This method was 
used to assess the effect of endogenous ADP release on OT and LT. To assess the effect of 
exogenous ADP, we preloaded a GTT tube with ADP solution (5µM ADP in saline; 0.5 ml) 
prior to injecting native blood from normal volunteers. 
Clopidogrel in aGTT 
Thirteen healthy volunteers were tested using the aGTT before and 8 hours after a loading dose of 
clopidogrel. Before introducing the blood sample into the GTT, a small volume of distilled water was 
placed into the tube, which remained at the site where platelet activation occurred. Normally, when the 
inflowing native blood would come in contact with distilled water, haemolysis would occur with release 
of ADP resulting in shortening of OT. Clopidogrel is an ADP antagonist, and would prevent this 
shortening of OT, demonstrating sensitivity of the individual to this thienopyridine derivative.  
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In clopidogrel resistant individuals, the shortening of OT would not be neutralised by the 
administration of clopidogrel. 
Saline priming of GTT tubes 
The aim of saline priming of the GTT tube was to avoid RBC haemolysis and ADP release that 
may be caused due to contact of blood with the plastic surface of GTT tube, or due to contact 
of air with blood. Saline 0.5 ml was added to the GTT tube 5-10 minutes before addition of 
blood. The upper level of saline was maintained 1-2 mm above the upper metal ball. 
Verify Now assay 
In a subgroup of 71 patients, thrombotic status was assessed using the Verify Now assay 
(Accumetrics, San Diego, California) and compared with thrombotic status measured using 
the GTT. Venous blood samples were taken and anticoagulated with sodium citrate 0.109 mol/l 
(ratio 9:1). The VerifyNow system is a turbidometry-based optical detection device that 
measures platelet-induced aggregation in a system containing fibrinogen-coated beads (9). 
The instrument measures changes in light transmission and thus the rate of aggregation in 
whole blood. In the cartridge of the VerifyNow P2Y12 assay, there is a channel in which 
inhibition of the adenosine diphosphate (ADP) P2Y12 receptor is measured. This channel 
contains ADP as platelet agonist and prosta- glandin E1 as a suppressor of intracellular free 
calcium levels, to reduce the nonspecific contribution of ADP binding to P2Y1 receptors. 
Results are expressed as P2Y12 reaction units (PRU). Recently, in patients with ACS, a 
cutoff level of PRU 240 was shown to be predictive of major cardiovascular events. The 
VerifyNow system does not assess thrombolytic status. 
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Chapter 3: Platelet function in Healthy Volunteers and comparison with 
Japanese volunteers  
 
 
Background: The Global Thrombosis Test is a point of care platelet function test, that assesses 
the time to form a thrombus (OT: seconds), and subsequently determines the time to lyse the 
formed thrombus (LT: seconds). Our aim in this study was to develop a normal range in healthy 
Caucasian volunteers, and to determine if OT or LT was normally distributed in healthy 
individuals, who were not on any medication.  
We also collaborated with Professor Yamamoto and his colleagues in Kobe Gakuin University, 
Kobe, Japan. Our aim here was to compare thrombotic and thrombolytic activity in the native 
Japanese and native Western population, to determine if genetic; lifestyle and environment 
factors influenced platelet activation and predisposed certain ethnic groups to higher risk of 
thrombotic diseases. 
The   incidence   of   and   mortality   from   acute   myocardial   infarction   is significantly 
lower in the Japanese population in Japan, has been on the decline over the last 40 years and 
is four times lower than the risk of coronary disease in USA (Kitamura et al. 2008). This 
does not hold true for Japanese living in the Western countries, as their risk of an AMI is much 
higher, and is comparable to the Western population. A study by Takeya et al demonstrated 
significantly higher risk of coronary disease in Japanese men living in Hawaii and California 
(Takeya et al 1984). Classical risk factors such as genetic background, smoking, dietary habits 
and lifestyle measures do not explain these inter racial differences in risk, and it is possible 
thrombotic and fibrinolytic markers play an important role in determination of this risk. 
The most important thrombotic factors that are associated with an increased risk of 
cardiovascular disease are fibrinogen, vWF levels, plasma viscosity, and fibrin D–dimer in 
women. In a study by Yano et al, plasma fibrinogen levels were higher in elderly Japanese men 
living in Hawaii compared to elderly Japanese men in Japan. The MONICA Optimal 
Haemostasis study (Yarnell et al. 2005) demonstrated a strong association between thrombotic  
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factors and coronary disease. Levels of fibrinogen (clottable and nephelometric), vWf, tissue 
plasminogen activator antigen, PAI inhibitor activity, fibrin D-dimer, plasma viscosity,  C-
reactive  protein,  and  total  cholesterol  were  measured  in  3996  subjects. Significant 
correlations were noted between adverse cardiac events and these thrombotic factors when 
adjusted for age, smoking habits and body mass index , most significant being vWF antigen in 
both sexes, nephelometric fibrinogen in men, and D-dimer in women. The PRIME study 
(Scarabin et al. 2003) was a prospective cohort study in which 10,600 men aged between 
50-59 years were recruited from Northern Ireland and France. The risk of future coronary 
events was 1.9 times higher in the Irish than in the French population (95% confidence interval: 
1.5–2.4). Fibrinogen levels accounted for 30 % of the increased risk of coronary  heart  disease  
in  the  Irish  population,  and  conventional  risk  factors  together accounted for 25 % 
increased risk in the Irish population. 
Hypothesis: 
We postulated that healthy Western volunteers would have shorter OT and LT when compared 
to healthy Japanese volunteers as the incidence of coronary artery disease is lower in the 
Japanese population. 
 
Methods: Thrombotic and thrombolytic status of 100 healthy Western and Japanese volunteers 
was tested using the GTT.  All  volunteers  gave  informed  consent  and  the  study  was  
approved  by  the  local Research   Ethics   Committee.   Volunteers   were   non-smokers,   not   
taking   any   regular medications and in particular, did not take any medication with known 
platelet effect (such as aspirin or the oral contraceptive pill) in the preceding 7 days. All 
patients were tested in the morning, between the hours of 0900 and midday. 
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Advertising for healthy volunteers was done via the Hospital trust bulletin, and posters were 
put up in hospital wards and outpatient units. A brief summary of the study and need for 
control group was included in the poster. Recruited volunteers were nonsmokers, not on any 
regular medication, and were advised not to take any medication with known platelet effect in 
the preceding 7 days (aspirin or the oral contraceptive pill). None of the volunteers recruited 
were heavy alcohol consumers and all were asked to abstain from alcohol the night before 
sampling. Blood pressure and ECG were not performed prior to recruitment, but none of the 
volunteers had any known underlying illness, history of hypertension or cardiac disease. All 
healthy volunteers were tested in the morning, between the hours of 0900 and midday. 
100 volunteers in each group were tested and all volunteers gave written informed consent.  
Results:  
Results were analysed using SPSSv16 (SPSS Inc., Chicago, Illinois).Continuous variables were 
not normally distributed, hence median and interquartile range (IQR) statistics were evaluated 
using non parametric methods (Spearmans rho, Mann-Whitney), and dichotomous variables 
evaluated using cross tabulation. Effect size of non-parametric comparison was evaluated using 
Somer’s d. 
Repeatability of GTT test 
 
Repeatability was assessed by testing 8 healthy Western subjects with two separate blood draws. 
The coefficients of variation (CV) for OT was 12%, and for LT 20%. One healthy female 
subject was tested twice a week for 4 weeks by the same person (Table 3.1), under similar 
conditions, and at the same time of the day. The CV for OT was 6.2%, and for LT 20.9%. 
 
 
 
 
 
91 
 
 
 
 
  Table 3.1: OT and LT results (in seconds) as measured in the healthy female volunteer 
 
Week Occlusion Time (sec) Lysis Time (sec) 
1.1 318 1741 
1.2 343 1058 
2.1 361 1094 
2.2 383 1166 
3.1 342 1732 
3.2 368 1244 
4.1 348 1519 
4.2 383 1176 
Coefficient of 
variation (%) 
6.2 20.9 
 
  Distribution of OT in Western volunteers  
 
The W e s t e r n  group consisted of 55 males and 45 females. The age of the volunteers was 
38±11 years (range 22-76, IQR 11).  
  OT was normally distributed in the healthy volunteer population (Fig 3.1). Mean OT was 
 
377.80s, and using mean ± 2SD, we derived a normal range of 185-569s (200-550s).  There 
was no relationship between OT and gender, even after excluding post-menopausal women 
from the analysis. There was no relationship between OT and age in the population. 
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Figure 3.1:Distribution of OT in healthy Western volunteers (X axis: OT in seconds; Y axis:  
Number of subjects) 
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Distribution of LT in healthy Western volunteers 
 
 
Median LT was 1052s (range 457-2934, IQR 405), and was not normally distributed in the 
healthy volunteers (Fig 3.2). The distribution was skewed, with values ranging between 457 
– 2934s. Using log transformation, a reference range of 600-2000s was developed. 
There was no relationship between LT and gender even after excluding post- 
menopausal women from the analysis. There was no relationship between LT and age. 
 
Figure 3.2:Distribution of LT in healthy Western volunteers. (X axis: LT in seconds. Y axis: 
Number of subjects) 
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 The Japanese population consisted of 28 men and 72 women and median age was 50±9 years 
(range 22-76, IQR 11). Western volunteers were younger compared to the Japanese volunteers 
(z= 7.25, P< 0.001), and there were more men in the Western population (X
2
=16.2, P<0.001). 
There was no correlation between age and OT or LT (rho < 0.1 in all cases). No difference was 
noted between men or women in either population (P> 0.05 in all cases). Median OT in the 
Western cohort was 365 (range 109-674, IQR102) and median OT in the Japanese cohort was 
545 (range 189-713, IQR 149) (Fig 4.1). OT in the Japanese cohort was significantly longer than 
OT in the Western cohort (OT: 545 vs. 365s, P< 0.0001, z =8.83, d = 3.76). Median LT in the 
Western cohort was 1052 (range 457-2934, IQR 405) and median LT in the Japanese cohort 
was 1753 (range 205-5555, IQR 1036) (Fig 4.2). LT was significantly longer in the 
Japanese population than LT in the Western cohort (LT: 1753 vs 1052s, P< 0.0001, z = 8.94, d 
= 3.99) (Fig 4.3). Markedly impaired lytic status was noted in 18% Japanese subjects, with LT > 
3000s compared to none of the Westerners (P< 0.0001) (Fig 4.4). 
There was no relationship between OT and LT, in either the Japanese or the Western cohorts. As 
outlined above, neither age nor sex had a significant impact on the differences observed between 
Western and Japanese participants. Although age and sex are potential confounders in this sample, 
there was no obvious bias introduced in the observed differences in OT and LT between the 
Western and Japanese samples, but this was further interrogated as follows. 
Subgroup analyses to investigate effects of age and sex. 
To eliminate the effects of age and sex, we also compared 56 Western subjects (28 M, 28 F) with 
56 Japanese subjects (28 M, 28 F) matched for age. Since it is accepted that pre-menopausal 
women have a low incidence of cardiovascular events and post-menopausal women are at higher 
risk, only premenopausal women were included in these groups. 
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The mean age in the Western cohort was 31±6 yrs and in J was 31±8yrs. OT was significantly 
prolonged in Japanese compared to Western subjects (537 vs. 363, P<0.0001). LT was also 
prolonged in Japanese compared to Western subjects (1660 vs. 1115, P<0.0001) (Table 3.2). This 
subgroup analysis confirms that the observed differences were not attributable to differences  
between the groups in terms of age or sex. This subgroup analysis in age-matched Western and 
Japanese men and women showed consistently longer OT in both Japanese men and women, 
compared to Western, with no difference between men and women, only between the two racial 
groups. Lysis time was prolonged in Japanese compared to Western subjects. This again was not 
confined to men or women, but interestingly, premenopausal Japanese women exhibited even 
longer LT than Japanese men.  
 
Figure 4.1: Distribution of OT in Western (W) and Japanese (J) volunteers. (X axis: OT in 
seconds. Y axis: Percentage of total number of subjects) 
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Figure 4.2: Box and Whiskers plot demonstrating minimum, maximum and  
median difference in OT between Japanese and Western volunteers. 
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Figure 4.3: Distribution of LT in W and J volunteers (X axis:  LT in seconds. Y axis: 
Percentage of total number of subjects). 
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Figure 4.4: Box and Whiskers plot demonstrating minimum, maximum and median difference 
in LT.  
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Table 3.2. Subgroup analysis to eliminate the effects of age and sex. Distribution of occlusion 
time (OT, sec) and lysis time (LT, sec) in Japanese (J) and Western (W) volunteers. 
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Discussion, Limitations and Conclusions  
We developed our own reference range in the healthy Western population. The idea was to 
characterize the distribution of OT and LT measurements in healthy individuals who had no 
underlying disease condition, and then test it in patients with coronary artery disease. 
Reference limits were generated, and using the GTT, we developed a normal range for OT: 
200-550s, and for LT: 600-2000s.  OT was normally distributed, whereas LT showed a 
skewed distribution with a tail at either end.  This may be partially explained by the small 
sample size, there also remains a possibility that some outliers had underlying clinical 
conditions which they were unaware of which could potentially result in impaired lysis. As 
there is limited data on endogenous thrombolysis and factors that affect it, it was beyond the 
scope of this study to accurately determine and investigate the factors contributing to this. This 
remains a limitation of our study. Data from larger studies will help in determination of factors 
resulting in impaired endogenous thrombolysis.   
Reliability was assessed by assessing repeatability and measuring coefficient of variation. CV 
for OT ranged between 6-12%, and for LT- 20%. Although our small sample size remains a 
limitation, similar variations have been reported using the GTT in other studies. In one study 
CV for OT was 9.3% and LT was 19.9% (Yamamoto et al. 2003), and in another CV for OT 
was 10% and LT was 11.1% (Yamashita et al. 2005).  We think the reason of the relatively high 
variation of lysis times can be explained by the technique. The GTT measures the first drop of 
blood after the complete arrest of flow and a thrombus stabilization period of 200 sec. At the 
beginning of thrombolysis the re-established flow is extremely slow and it takes >100 sec for 
the first blood drop to detach and to be detected by the sensor. In addition to the low 
atmospheric pressure, several other factors affect the speed of the detachment of the first blood 
drop and this may account for the relatively high variation. Thus despite the excessive variation,  
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this technique is able to differentiate between rapid, existing thrombolysis and lack of 
thrombolysis.  
It is important to note that even using well established techniques, the coefficient of variation in 
patients can be as high, or even higher, than that which we measured for lysis times. Measuring 
aspirin resistance in patients with ischemic heart disease, a recent study found the CV for the 
PFA-100 technique to be 31.2% for arachidonic acid induced platelet activation, which is 
considered to be the gold standard for detecting aspirin resistance (Muir et al.2009). 
Furthermore, the CV for measurement of PAI-1 activity, considered to be the most reliable 
marker of fibrinolysis, is reported to be 21.4% (Sakkinen et al. 1999). 
The results  in the Japanese population suggest  Japanese  population  are less  prothrombotic 
with  longer OT’s, and have less favourable endogenous thrombolytic activity with longer LT’s. 
The prolonged OT in this group indicates that thrombosis is less likely to occur, and therefore 
the clinical significance of the impaired lysis may be lessened in case of cardiac events. On the 
contrary,  the  incidence  of  haemorrhagic  stroke  is  much  higher  in  Japan  compared  to 
incidence in Western countries (Kitamura et al.2008). In Japan, haemorrhagic stroke 
(intracerebral haemorrhage or subarachnoid haemorrhage) accounted for approximately 33% of 
all strokes, whereas in USA it accounts for 10-13% of all strokes (Robertson et al. 1977).  
Stroke is one of the major causes of mortality in Japan (Turin et al. 2010). A large registry in 
Kyoto, Japan analysed 13788 stroke patients over 10 years. The majority of strokes were due to 
cerebral infarction (65.4%), but a significant proportion suffered with intracerebral haemorrhage 
(25.7%) and subarachnoid haemorrhage (8.7%). On analysis of risk factors, hypertension 
seemed to be the most important risk factor as greater than 60% stroke patients were deemed to 
be hypertensive (Shigematsu et al.2013). Despite the high prevalence of hypertension in Japan, 
the mortality from ischaemic heart disease is quite low and Japanese population has the longest  
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life expectancy in the world. Although blood pressure levels have decreased over recent years 
and other lifestyle changes may explain the reduced incidence of coronary disease in Japan 
(Ueshima et al. 1987), it does not explain the continued high incidence of haemorrhagic stroke. 
This suggests there are other factors which are involved; this remains a subject for further 
research. 
Our results of prolonged OT in the Japanese volunteers may support this finding, and may 
explain why Japanese have a reduced incidence of coronary artery disease, but increased 
incidence of haemorrhagic stroke. LT was prolonged in the Japanese population, suggesting if a 
thrombus does occur, it would take more time to lyse and final outcome may be less favourable 
in case of myocardial or cerebral infarction. The Japanese stroke data bank results 
demonstrate an increase in incidence of cerebrovascular infarction in Japan, and cerebral 
infarcts account for 78% of all acute stroke. 
In a study by Taomoto et al, 185 stroke patients in Japan were tested using the GTT. Their 
OT and LT were compared to 195 healthy volunteers not taking any medication. Occlusion 
time was significantly shorter in stroke patients (mean age 65.5 years) compared to healthy 
volunteers ( mean age  39.7 years) (OT: 210±140s v s . 284±92s, P < 0.0001) suggesting a 
prothrombotic state existed in the patient population. LT was significantly prolonged in stroke 
patients when compared to healthy volunteers (LT: 3159±1549s vs.2231±1223s, P<0.0001) 
suggesting stroke patients had impaired endogenous thrombolytic activity. 
These observed racial differences in the Japanese and Western population could not be attributed 
to the effects of age or sex. Further large population studies are required to directly assess the 
relationship between thrombotic and thrombolytic profile and the occurrence of cardiovascular 
and cerebrovascular events, in different ethnic groups. . Furthermore, the modern Japanese diet  
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is identical to a Western diet, thus the effects of diet are likely to be insignificant, if any. 
Cholesterol levels were not compared in our two groups, but the population cholesterol levels 
are reported to be similar by the WHO. Impaired fibrinolysis is a known risk factor for 
cardiovascular events. The impaired fibrinolytic activity observed in the Japanese cohort in our 
study is in contrast to the findings of Iso and co-workers, who reported higher tPA and PAI-
1 levels in Caucasians than in Japanese (Iso et al. 1990, Iso et al. 1993). However, our results 
are supported by Takayima and co-workers who observed significantly lower PAI-1 levels in 
American than in Japanese men (Takamiya et al. 2006). 
However, approximately 90% of the total amount of PAI-1 present in blood is stored in the 
alpha granules of platelets and released only from the platelet aggregates in the thrombus mass. 
For this reason, measurement of plasma PAI-1 content in these earlier studies ( Iso et al. 
1990) does not reflect true potential thrombolytic status. In contrast, the GTT employed in our 
study measures the lysis of an autologous thrombus, a process in which PAI-1 released from 
platelets plays a decisive role and therefore this test provides a far more accurate reflection   of   
the   global   thrombolytic   status.   Furthermore,   our   finding   of   impaired thrombolytic 
status in Japanese, who are an ethnic group with an unusually high incidence of hemorrhagic 
stroke, is in keeping with the finding that in a well conducted, prospective study, tPA/PAI-1 
complex, a marker of impaired fibrinolysis, was independently associated with the development 
of a first-ever stroke, especially hemorrhagic stroke (Johansson et al. 2000). 
In conclusion, Westerns were more prothrombotic than Japanese. The thrombolytic profile of 
Westerns however, was more favourable than that of Japanese. Although OT and LT status 
probably both contribute to thrombotic risk, since thrombotic events are more frequent in the 
Western population, we postulate that OT is likely to be more predictive of thrombotic events  
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than LT. Although LT is less favorable in Japanese, the prolonged OT in this group indicates 
that thrombosis is less likely to occur, and therefore the clinical significance of the impaired 
lysis is lessened. However, if thrombosis does occur, its outcome may be less favorable in 
Japanese persons. Further large population studies are required to directly assess the relationship 
between thrombotic/thrombolytic profile and the occurrence of cardiovascular events, in 
different ethnic groups. 
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Chapter 4: Role of ADP, Aspirin and Clopidogrel on thrombus formation 
 
Background: ADP is an important component of the thrombotic pathway and promotes 
platelet activation and aggregation. Minute concentrations of ADP can result in platelet 
aggregation, and most platelet function tests utilize ADP as an agonist to determine the 
efficacy of an antiplatelet agent. Most tests use supra high doses of ADP which make the test 
results physiologically difficult to interpret. The GTT is a shear induced platelet function test, 
in which  the shear force causes haemolysis and releases minute concentrations of ADP (up 
to 0.5 µM) which are not only adequate to cause platelet aggregation, but also increase the 
sensitivity of the test and help in monitoring of aspirin mediated platelet inhibition. 
There are 2 main ADP receptors on the platelet surface: P2Y1 and P2Y12. The two 
P2Y1 and P2Y12 receptors are G-protein coupled receptors which utilize ADP as agonist. The 
P2Y1 receptor binds to Gq/11 activates phospholipase C and mobilizes intracellular calcium 
while P2Y12 receptor binds to Gi, inhibits adenylate cyclase, activates PI3-kinase and reduces 
cAMP intracellular levels. These receptors also inhibit the N-type voltage-gated calcium 
channels, and activate the G protein gated inward rectifier potassium channels in neurons and 
endocrine cell lines, and activate the chloride channels in airway epithelium ( Ralevic et al. 
1998, Burnstock et al. 2004). ADP mediated activation of the P2Y12 receptor  leads  to  a  
series  of  intracellular  signals  that  activate  the  GP  IIb/IIIa  receptor, resulting in granule 
release and platelet activation and aggregation. Clopidogrel selectively and irreversibly 
inhibits the P2Y12-receptor by forming a disulphide bridge between the two cysteine residues 
of the P2Y12 receptor.  
Using various platelet tests at high shear (Haemostatometry, GTT, Cone-and-plate analyzer,  
PFA-100, whole blood impedance aggregometry), significant correlation was found between  
occlusion times and haematocrit. Further, the presence of red blood cells (RBC) was shown to  
be critical, as from platelet rich plasma (PRP) occlusion could not be achieved. Recent  
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studies on the mechanism by which shear promotes platelet aggregation in vivo has revealed 
a two-stage process. The first stage is the formation of an unstable aggregate of platelets 
attached by membrane tethers. Conversion of these initial aggregates into stable thrombus 
requires the release of ADP. The ADP receptors P2Y (1) and P2Y (12) were shown to have 
distinct and determinant roles in von-Willebrand factor (vWF)-mediated initial platelet 
adhesion and aggregation P2Y (1), in the formation of larger aggregates, in activation of 
intrinsic coagulation and thrombus stabilization P2Y (12) under high shear stress. Platelet 
aggregation at high shear was impaired in a patient with congenital defect of platelet response 
to ADP. It is known that even minute concentrations   of   ADP   can   induce   rigid   platelet   
aggregate   formation.   Such   low concentrations of ADP can exist in shear-induced in vitro 
tests as a result of the unavoidable haemolysis during blood sampling, release from platelets 
and RBC at the blood-air interface and through interaction of these cells with the dry plastic 
surface of the test-tube or cartridge. The functional importance of such low ADP 
concentrations is further supported by the observation that only low ADP concentrations (up 
to 0.5 muM), much lower concentrations than those commonly employed as agonists to 
induce platelet aggregation, can be considered a useful platelet agonist for monitoring aspirin-
mediated platelet inhibition, since higher concentrations reduce the sensitivity of the test (Saraf 
et al. 2009). Using the experiments we performed using the GTT, it was not possible to 
determine the exact source and amount of ADP release from RBC and platelets. Alkhamis et al 
using the cone-and-plate viscometer have previously demonstrated the amount of ADP release 
from RBCs and percent decrease of platelets in their study during laminar shear flow at a low 
shear stress of 200 dyne/cm2. ADP release from RBCs was about twice that of platelets in their 
study (Alkhamis et al. 1990). Further experiments need to be performed using the GTT to 
determine the exact source and amount of ADP release. 
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GTT is a platelet activation test, in which high shear stress induces platelet activation and 
aggregation. Recent studies have revealed that platelet aggregation is a two stage process  
 (Maxwell et al. 2007) - initial stage involves formation of an unstable aggregate of platelets 
which then subsequently form a stable thrombus on release of ADP. The ADP receptor P2Y (1) 
plays an important role in von-Willebrand factor (Vwf) mediated initial platelet adhesion and 
aggregation, and P2Y (12) receptor plays an important role in the formation of larger 
aggregates, in the activation of intrinsic coagulation system and stabilization of the thrombus  
(Mazzucato et al.2004). Data suggests that in patients with congenital defect of platelet 
response to ADP, platelet aggregation at high shear is impaired (Cattaneo et al. 1994). 
 
It is known that contact of blood with air at the blood-air interface promotes damage to blood 
cells and furthermore, contact of blood with foreign surfaces results in release of ADP from 
RBC and platelets. We aimed to exclude these factors by priming the GTT tube with saline, 
to avoid the contact of blood with the plastic surface of the GTT cartridge and avoid air in the 
system, thus avoiding the effect of haemolysis at the blood-air interface. 
 
The aim of addition of water to the GTT tube was to induce ADP release from RBC and 
platelets, and assess the effect of this on shear-induced thrombosis. Due to the osmotic 
gradient, contact between RBC/platelets and water would result in haemolysis causing 
localised release of ADP from RBC and platelets, which we postulated would accelerate the 
thrombotic process and reduce OT. Using the GTT, it is not possible to determine the exact 
source and amount of ADP release from RBC and platelets, but the main determinant of the 
observed changes in our experiments is likely to be platelet-derived ADP.  
Aspirin is an antiplatelet agent, and acts by irreversibly acetylating COX1 enzyme, and inhibits 
platelet aggregation by inhibiting prostaglandin and TxA2 production. It is the most common  
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antiplatelet agent, and has been in use for greater than 100 years. A metanalysis by Eideleman 
(Eidelman et al. 2003), which included 5 major studies and 55,580 patients, a significant 32 % 
reduction in risk of first MI was observed in people who were on aspirin and had underlying 
risk factors for coronary artery disease. Aspirin reduces this risk by inhibiting platelet 
activation and aggregation. Our aim in the Aspirin study was to demonstrate the antiplatelet  
effect of aspirin. We hypothesized that inhibition of platelet aggregation would prolong time to 
thrombus formation, and hence result in prolongation of OT. There is limited evidence on the 
fibrinolytic properties of aspirin, and it was our aim to determine if there was any effect of 
aspirin on LT. 
Clopidogrel is an antiplatelet medication, and acts by binding to the P2Y (12) receptor. It is a 
prodrug, oxidized by the hepatic cytochrome P450system to its active metabolite and 
irreversibly binds to the ADP P2Y12 receptor. P2Y12 inhibition thus inhibits ADP-induced 
platelet activation and resultant aggregation. Inhibition of platelet activation and aggregation 
prolongs time to thrombus formation. Our aim in this study was to examine the effect of 
clopidogrel on OT and LT. We will demonstrate in this chapter that addition of distilled water 
to the GTT tube prior to injection of native blood resulted in acceleration of the thrombotic 
reaction and shortening of OT (a GTT). It was also our aim to observe the effect of clopidogrel 
on aGTT, to observe its effect on ADP mediated accelerated thrombotic reaction to determine 
if the GTT was capable of monitoring the efficacy of ADP-inhibitor antiplatelet medications. 
This would allow us to individualise antithrombotic therapy to achieve optimal thrombotic 
status, as well as allow us to monitor individual response to antiplatelet therapy. 
To summarize, our aim in this study was to observe the effect of endogenous and exogenous 
ADP on OT, the effect of Aspirin and Clopidogrel and to investigate the effect of these in 
monitoring the efficacy of ADP- antagonist medication.  
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Hypothesis: 
We postulated that ADP would shorten OT by promoting platelet activation and aggregation, 
with no significant effect on LT. We also postulated that aspirin and clopidogrel would prolong 
OT due to its antiplatelet effect, with no significant effect on LT.  
Methods: 
Endogenous ADP using the Accelerated Global thrombosis test (a GTT) 
Prior to injection of blood in the GTT tube, 0.5 ml distilled water was added to the tube. 
Water was added 5-10 minutes before injection of blood to the tube, and filled the space 
between the two balls (100 µl) and the upper water level was constantly 1-2 mm above the 
upper ball (Fig 5.1). Due to the osmotic gradient, on contact of water with blood there was 
cell destruction, haemolysis and release of ADP from RBC and platelets which we postulated  
would accelerate the thrombotic process and result in shortening of OT. 
As the water was limited to the small part of the tube where platelet reaction took place, the 
bulk of the sample was not diluted by the water and exited the system in less than 20 seconds. 
Thus, the dilution affected only the very start of the measured thrombotic reaction maintaining 
physiological conditions. Due to this short contact between blood and water, minute amounts of 
ADP are released which can be inhibited more sensitively than higher concentrations of ADP 
which are generally employed as agonists in various platelet function tests (Dobaczewski et al. 
2008). Neither water nor clopidogrel had any effect on lysis times. 
Saline priming of GTT tubes 
Saline 0.5 ml was added to the GTT tube 5-10 minutes before addition of blood. The upper 
level of saline was maintained 1-2 mm above the upper metal ball .The aim of saline priming of 
GTT tube was to avoid RBC haemolysis and ADP release that may be caused due to 
contact of blood with the plastic surface of GTT tube, or due to contact of air with blood. 
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Exogenous ADP 
We preloaded a GTT tube with ADP solution (5µM ADP in saline; 0.5 ml) prior to injecting 
native blood from normal volunteers. Our aim was to examine the effect of exogenous ADP 
on OT and LT in normal healthy volunteers, using the GTT. 
Statistical analysis was done using SPSS version 16. As OT is an interval variable, paired 
comparisons such as a paired t-test were used. In situations where results were skewed, non 
parametric test such as Wilcoxon signed rank’s test was used. Data are presented as mean 
±2SD and p < 0.05 is considered significant. 
Stable angina patient’s pre and post Aspirin 
We measured OT and LT using the GTT in 10 stable angina patients. All patients were 
reviewed and recruited in the outpatient clinic, and none of these patients had been on Aspirin 
prior to being tested. None of these patients were on any other antiplatelet medications. 
Baseline samples were taken prior to starting Aspirin. Post aspirin samples were taken at 
least a week after each patient had been taking 75mg aspirin. None of these patients had 
been loaded with higher doses of aspirin. 
Healthy volunteers pre and post Clopidogrel 
Thirteen normal healthy volunteers were tested before and 8 hours after a loading dose of 300 
mg clopidogrel. Volunteers were non-smokers, not taking any regular medications and in 
particular, did not take any medication with known platelet effect (such as aspirin or the oral 
contraceptive pill) in the preceding 7 days. Testing was performed at the same time of the day 
by the same operator, under similar conditions. 
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Effect of Clopidogrel on OT and LT in Stable angina patients on Aspirin 
We examined the effect of clopidogrel in Stable angina patients. Ten patients with stable angina 
were tested on 75mg Aspirin ( pre clopidogrel), and retested atleast a week later on aspirin 
75mg and clopidogrel 75 mg. Testing was performed by the same operator, under similar 
conditions. 
The Accelerated Global thrombosis test (a GTT) 
The aim of this modification was to induce ADP release from RBC, and assess the effect of this   
on   shear-induced   thrombosis.   Due   to   the   osmotic   gradient,   contact   between 
RBC/platelets and water would result in haemolysis causing localised release of ADP from 
RBC and platelets, which we postulated would accelerate the thrombotic process and reduce 
OT. 
Prior to injection of blood in the GTT tube, 0.5 ml distilled water was added to the tube. 
Water was added 5-10 minutes before injection of blood to the tube, and filled the space 
between the two balls (100 µl) and the upper water level was constantly 1-2 mm above the 
upper ball (Fig 5.1). Due to the osmotic gradient, on contact of water with blood there was 
cell destruction, haemolysis and release of ADP from RBC and platelets which we postulated 
would accelerate the thrombotic process and result in shortening of OT. This method was 
used to assess the effect of endogenous ADP release on OT and LT. To assess the effect of 
exogenous ADP, we preloaded a GTT tube with ADP solution (5µM ADP in saline; 0.5 ml) 
prior to injecting native blood from normal volunteers. 
Clopidogrel in aGTT 
Thirteen healthy volunteers were tested using the aGTT before and 8 hours after a loading dose 
of clopidogrel. Before introducing the blood sample into the GTT, a small volume of distilled 
water was placed into the tube, which remained at the site where platelet activation occurred.  
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Normally, when the inflowing native blood would come in contact distilled water, haemolysis 
would occur with release of ADP resulting in shortening of OT. Clopidogrel is an ADP 
antagonist, and would prevent this shortening of OT, demonstrating sensitivity of the 
individual to this thienopyridine derivative. In clopidogrel resistant individuals, the shortening 
of OT would not be neutralised by the administration of clopidogrel. 
Results:  
Accelerated GTT: Reduction of OT was observed with addition of distilled water (OT.W) 
in all 13 volunteers (OT vs. OT.W = 379±30 vs. 177±26, n=13, Wilcoxon signed rank’s test 
z= -3.1, p<0.01) (Fig 5.2, 5.3). There was no effect on LT (LT vs. LT.W = 1390±206 vs. 
1420±153, n=13, Wilcoxon signed rank’s test z= -0.105, p= NS) (Fig 5.4). 
Figure 5.1: Accelerated GTT - 0.5 ml distilled water was added to the tube, some 5- 
10 min before the start of the test. The added water fills up the space between the two 
balls and the upper water level is constantly 1-2 mm above the upper ball. Due to the 
osmotic gradient, contact between RBC/platelets and water would result in haemolysis 
causing localised release of ADP from RBC and platelets, which we postulated would 
accelerate the thrombotic process and reduce the occlusion time (Saraf et al 2009). 
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Figure 5.2: OT before and after water priming (aGTT) - OT (sec) - time is shown in seconds, 
OT= occlusion time. Reduction of OT was observed with addition of distilled water (OT.W) in 
all volunteers 
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Figure 5.3: Box plot demonstrating minimum, maximum and median OT pre and post 
distilled water. OT (sec) - time is shown in seconds, OT= occlusion time. Reduction of OT was 
observed with addition of distilled water (OT.W) in all volunteers 
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Figure 5.4: LT before and after water priming (aGTT) - LT (sec) - time is shown in seconds, 
LT= Lysis time. Addition of distilled water had no effect on LT.  
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Saline priming of GTT tubes 
 
 
13 healthy volunteers were tested using the GTT and addition of saline was noted to increase 
the OT (OT.S) (Fig 5.5) in all volunteers (OT vs. OT.S =391± 40 vs. 489±37, n =13, paired t- 
test, df =12, t= -4.428, p< 0.001). Saline had no effect on LT (LT.S) (Fig 5.6) (LT vs LT.S 
= 1400±99 vs. 1320±94, n=13, Wilcoxon signed rank’s test z= 0.561, p= NS). 
 
 
 
 
Table 4: GTT results before and after priming the GTT tube with saline (OT= occlusion time, 
LT= lysis time, OT.S = OT after saline priming and LT.S = LT after saline priming, sec= time in 
seconds, SEM= standard error of mean, IQR= Interquartile range) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 OT(sec) OT.S(sec) LT(sec) LT.S(sec) 
Mean ± SEM 391.80 ± 40.2 489.20  ± 36.8 1400.9 ± 99.0 1320.7 ± 93.8 
Median (IQR) 334 (204) 483 (182) 1312 (490) 1374 (503) 
 
P value 
                   
                    P<0.001 
                  
                       P=NS 
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Figure 5.5: OT before and after saline priming. OT (sec) - time is shown in seconds, 
OT=occlusion time. Addition of saline was noted to increase the OT (OT.S) in all volunteers. 
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Figure 5.6: LT before and after saline priming. LT (sec) - time is shown in seconds, LT= lysis 
time. Addition of saline did not have any effect on LT (LT.S). 
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Exogenous ADP 
 
 
ADP resulted in acceleration of thrombotic reaction and a reduction of 53% was noted in OT 
(Fig 5.7, 5.8) (OT vs. OT.ADP = 441±32 vs. 254±38, n=5, Wilcoxon signed rank’s test z= - 
2.0, p < 0.05). There was no effect on LT (Fig 5.9). (LT vs. LT.ADP = 2955±1036 vs. 
 
1989±990, n=5, Wilcoxon signed rank’s test z = -0.67, p= NS).  
 
 
The effect noted with exogenous ADP was similar to the effect noted with addition of 
distilled water, suggesting ADP played an important role in the thrombotic process. Mean Hct 
was 0.41, and no significant correlation was noted between Hct levels and OT.ADP or 
LT.ADP. The small sample size remains a limitation of this substudy. 
 
  Figure 5.7: OT before and after ADP priming. OT (sec) - time is shown in seconds, OT=   
  occlusion time. Reduction of OT was observed with addition of ADP (OT.ADP) in all  
  volunteers 
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Figure 5.8: OT percentage inhibition before and after ADP priming (Percent inhibition defined as 
percent decrease of measurable response as a consequence of compound treatement) 
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Figure 5.9: LT before and after ADP priming. LT (sec) - time is shown in seconds, LT= lysis 
time. Addition of ADP had no effect on LT (LT.ADP). 
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Pre and post Aspirin  
In this small study, there were 7 men and 3 women, and mean age was 57.5 years (range 47-
83 years). None of these s t ab l e  an g in a  patients were diabetic, 50 % had underlying 
history of hypertension, 20% were current smokers, 30% were on ACE inhibitors and 20 % 
were taking statin. None of these patients were on any other antiplatelet medications.  
Aspirin significantly prolonged OT (365±37s vs.527±31s, p = 0.001) (Fig 6.1, 6.2), OT mean 
difference (Fig 6.3):  -162.1 (95% CI -234.6 to -89.6).  Effect size 162.1/101.3 = 
1.60 (large effect) suggesting patients on aspirin were less prothrombotic. There was 
significant variability in LT values pre and post aspirin (Fig 6.4), (1034±141s vs. 1443±223s, 
p = NS), LT mean difference (Fig 6.5):  -408.4 (95% CI -1113.6 to +296.8). However, a 
moderate effect was noted post aspirin with an effect size 408.4/985.7 = 0.41 suggesting 
Aspirin could potentially have some role in endogenous thrombolysis. 
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Figure 6.1: Ladder plot demonstrating OT pre and post aspirin. OT (sec) - time is shown in 
seconds, OT= occlusion time. An increase in OT was observed in all volunteers post aspirin 
(OT.A). 
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Figure 6.2: Box plot demonstrating minimum, maximum and median OT pre and post 
aspirin 
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Figure 6.3: Box plot: Paired analysis demonsrating difference in OT pre and post aspirin 
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Figure 6.4: Box plot demonstrating minimum, maximum and median LT pre and post 
Aspirin 
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Figure 6.5: Box plot: Paired analysis demonsrating difference in LT pre and post aspirin 
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Clopidogrel effect on OT and LT 
Mean age of the 13 healthy volunteers was 36±14 years, and there were 6 males and 7  
females included in the study. Results below are presented as mean ± SEM. 
Clopidogrel significantly prolonged OT (Fig 7.1, 7.2): OT vs. OTC = 379 ±30 vs. 477±29, n= 
13, Wilcoxon signed rank’s test z= -3.1, p<0.01, with no measurable effect on LT (Fig 7.3): LT  
vs. LTC = 1390 ± 206 vs. 1345 ± 170, n=13, Wilcoxon signed rank’s test z= -0.8, p=NS. 
Eight volunteers (Group 1) seemed to have a shorter OT (OT< 490s) compared to the remaining  
five volunteers (Group 2), (OT > 490s). Figure 7.1 suggests there is a characteristic difference in  
the 2 groups and they responded differently to Clopidogrel. Group 1 volunteers showed a greater  
rise in OT post Clopidogrel compared to Group 2 (Table 5.1, 5.2). The effect on LT was less  
variable. These changes were not age or sex related, and comparison between OT’s was done  
using independent group’s t-test. All volunteers were healthy non smokers, and not on any  
medication. The Effect ratio of Clopidogrel in Group 1 was 0.64, suggesting people with shorter  
OT showed a greater beneficial response to the drug, potentially achieving, and would achieve  
greater benefit from its use.  
Due to the small sample size in this pilot study, it is difficult to clearly interpret the results, and  
further larger studies are required to demonstrate a greater effect size which may help in  
identification of high risk patients who will benefit most with use of this drug.However, the  
statistical power of the difference in OT in this small study is relatively strong. For alpha =0.05,  
the power of this study using 13 subjects was 0.8 (80% power), P < 0.0001. 
 
Clopidogrel and aGTT 
We have shown clopidogrel significantly prolonged OT in healthy volunteers, and we also 
demonstrated that water priming of the GTT tube significantly shortened OT, reflecting 
release of ADP secondary to haemolysis. In all 13 volunteers, aGTT was measured 
simultaneously alongside the GTT. Clopidogrel was seen to prevent the water-priming induced  
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acceleration of the thrombotic occlusion (Fig 7.4, 7.5, 7.6, 7.7) (OT.W vs. OT.W.C = 177±26 
vs. 362±25, n=13, Wilcoxon signed rank’s test z = - 3.1, p <0.01), with no observable effect on 
LT (LT.W vs. LT.W.C = 1420±153 vs. 1377±322, n=13, Wilcoxon signed rank’s test z = -
1.0, p=NS). 
Effect of Clopidogrel on OT and LT in patients with Stable angina 
10 patients with stable angina were tested using the GTT. Baseline demographics of these   
patients are listed in Table 5.3. Mean age in these patients was 72±15 years and 50% were 
males, 50% females. All patients were known to suffer with coronary artery disease, and 30% 
had coexistent type 2 diabetes and 80% were known to be hypertensive. All patients were non-
smokers. All patients were taking ACE inhibitors, 90% were on a form of statin therapy and 
50% were on a beta blocker. Clopidogrel significantly prolonged OT (Fig 7.8), (OT vs. OTC 
= 404±27 vs. 544±35, p=0.002), with mean change in OT being an increase of 140 sec 
(95% CI 67.9-221.1).   The standard deviation of the difference was 100.1. Median was 
109.5 and reflected positive skew.  Paired t test was quite robust, and the equivalent non-
parametric test (Mann Whitney) gave a p value of 0.005. 
There  was  no  measurable  effect  of  clopidogrel  on  LT  (LT  vs.  LTC = 1572±252 vs. 
1939±476, p= NS). The LT data was quite skewed mean±SD 367 ±1787.9. A T test was not 
feasible and Mann Whitney gave a p value of 0.721. There was high level of variability in the 
paired differences. Larger studies are required to determine if clopidogrel significantly affects 
endogenous thrombolysis. 
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Figure 7.1: OT pre and post clopidogrel. OT (sec) - time is shown in seconds, OT= occlusion  
time.  Clopidogrel significantly prolonged OT (OT.C) in all volunteers. Group 1 volunteers  
showed a greater rise in OT post-clopidogrel compared to Group 2. 
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Figure 7.2: Box plot demonstrating minimum, maximum, and median OT pre and post 
clopidogrel 
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Figure 7.3: LT pre and post clopidogrel . LT (sec) - time is shown in seconds, LT= lysis time. 
Clopidogrel had no significant effect on LT (LT.C) 
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Figure 7.4: Comparison of normal OT (pre-clopidogrel) and the accelerated OT after water- 
priming following clopidogrel, shows that clopidogrel completely inhibits the effect of water- 
priming. 
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Figure 7.5: Box plot demonstrating minimum, maximum and median OT of normal OT ( pre 
clopidogrel) and accelerated OT after water priming following clopidogrel 
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Figure  7.6:  Effect  of  clopidogrel  on  aGTT  (accelerated  GTT  with  water-priming). 
OT.W=OT after waterpriming and OT.W.C=OT after water-priming, and after clopidogrel 
ingestion. Clopidogrel prevented the acceleration OT produced by water-priming. 
  
 
 
 
 
 
 
 
P <0.01 
 
 
700 
 
 
600 
 
 
500 
 
 
400 
 
 
300 
 
 
200 
 
 
100 
 
 
0 
OT.W  OT.W.C 
134 
 
 
 
O
T
 (
s
e
c
) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Box plot demonstrating minimum, maximum and median OT in a GTT pre and 
post clopidogrel 
 
 
 
 
 
 
 
 
 
 
 
 
 
500 
 
 
 
400 
 
 
 
300 
 
 
 
200 
 
 
 
100 
 
 
P <0.01 
 
 
 
0 
 
OTW 
 
 
 
OT.W.C 
135 
 
 
 
L
T
 
(s
e
c
) 
 
 
Figure 7.8: GTT and aGTT results before after clopidogrel loading. A. Effect on Occlusion 
Time (OT). B. Effect on Lysis Time (LT). Times are shown in seconds. (OT.W and LT.W denote 
the results after water-priming with aGTT= accelerated Global Thrombosis Test. [C] 
denotes measurements post-clopidogrel). Comparisons between treatment conditions were  
evaluated using Wilcoxon sign-ranked test. Columns represent the mean value and the error  
bar is the standard error of the mean. 
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Figure 7.9: OT pre and post clopidogrel in stable angina patients. OT (sec) - time is shown in 
seconds, OT= occlusion time.  Clopidogrel significantly prolonged OT (OT.C) in all stable 
angina patients 
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Table 5.1: GTT results in Group 1 before and after priming the GTT tube with water, and post 
administration of clopidogrel (OT= occlusion time, LT= lysis time, OTW = OT after water 
priming and LTW= LT after water priming, OTC= OT post administration of clopidogrel, 
LTC= LT post administration of clopidogrel, OTCW = OT post clopiogrel in aGTT, LTCW= 
LT post clopidogrel in aGTT, SEM= standard error of mean, IQR= Interquartile range) 
 
 
 
 
 
Group 1: Shorter OT, Effect ratio of clopidogrel =0.64 
 
 
 
 
 
 
 
 OT OTW LT LTW OTC OTCW LTC LTCW 
Mean 
 
 
± 
SEM 
300 
 
 
± 
 
 
9.95 
112.3 
 
 
± 
 
 
11.38 
1600.3 
 
 
± 
 
 
314.2 
1711.3 
 
 
± 
 
 
163.5 
410.2 
 
 
± 
 
 
21.74 
330.1 
 
 
± 
 
 
31.8 
1526.6 
 
 
± 
 
 
252.6 
1502.25 
 
 
± 
 
 
367.4 
Median 
 
 
(IQR) 
301 
 
 
(42.75) 
100 
 
 
(55) 
1188 
 
 
(1312.25) 
1760.5 
 
 
(755.2) 
409.5 
 
 
(119.25) 
316.5 
 
 
(128.25) 
1157.5 
 
 
(1454) 
1078.5 
 
 
(1170) 
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Table 5.2: GTT results in Group 2 before and after priming the GTT tube with water, and post 
administration of clopidogrel (OT= occlusion time, LT= lysis time, OTW = OT after water 
priming and LTW= LT after water priming, OTC= OT post administration of clopidogrel, 
LTC= LT post administration of clopidogrel, OTCW = OT post clopiogrel in aGTT, LTCW= 
LT post clopidogrel in aGTT, SEM= standard error of mean, IQR= Interquartile range) 
 
 
Group 2: Longer OT, less response to clopidogrel 
 
 
 
 OT OTW LT LTW OTC OTCW LTC LTCW 
Mean 
 
 
± 
SEM 
506 
 
 
± 
 
 
6.54 
281 
 
 
± 
 
 
26.4 
1054.6 
 
 
± 
 
 
93.1 
954.4 
 
 
± 
 
 
142.8 
584.6 
 
 
± 
 
 
21 
414 
 
 
± 
 
 
31.1 
1056.4 
 
 
± 
 
 
113.29 
1177.8 
 
 
± 
 
 
644.3 
Median 
 
 
(IQR) 
505 
 
 
(27.50) 
278 
 
 
(110.5) 
933 
 
 
(379) 
910 
 
 
(517) 
570 
 
 
(88.5) 
428 
 
 
(135) 
1130 
 
 
(427) 
649 
 
 
(1804) 
 
 
Table 5.3: Baseline demographics of stable angina patients - Values are mean (range) or n 
(%). 
 Overall group (n=10 ) 
Age, yrs 72  (57-87) 
Male 5 (5%) 
Diabetes mellitus 3 (30%) 
Smoking 0 (0%)  
Hypertension 8 (80%) 
Prior CAD 10 (10%) 
Renal insufficiency 0 (0%) 
PVD 0 (0%) 
Prior CVA 0 (0%) 
Beta blocker 5 (50%) 
ACE inhibitor 10 (100%) 
Statin 9 (90%) 
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Discussion, Limitations and Conclusions  
Our results provide evidence that ADP may play a role in the GTT, a test of shear-induced 
thrombosis. It is known that air interface promotes damage to blood and contact of blood 
with foreign surfaces results in release of ADP from RBC and platelets (Alkhamis et al. 
1990). Exclusion of these these factors with saline priming significantly prolonged OT. It 
should be emphasized that the bulk of the blood sample was not diluted by the applied saline, 
since saline was restricted to the small part of the tube where platelet reaction took place. In 
less than 30 sec the saline-diluted blood exits the tube thus influencing only the very start of 
the thrombotic reaction. Although our experiments cannot distinguish between the effects of 
these two factors, i.e. contact with a plastic surface and blood-air interface, we regard the 
former to be more important. At shear stresses similar to that created in the GTT, different 
plastic materials were ranked according to their haemolytic effects (Offeman et al. 
1979, Lafayette et al. 2007). This concords with information obtained from the GTT 
manufacturer that using GTT test tubes with identical gap-sizes and thus identical shear- 
forces, but made from different plastic material showed great variation in blood flow rates 
and OT in parallel measurements of identical blood. We therefore think that the initial contact 
of inflowing blood with the plastic surface results in variable ADP release from platelets 
(Moritz et al. 1983), RBC or both. Given the observed effects of clopidogrel on OT and 
OT.W, the main determinant of these changes is likely to be platelet-derived ADP. The 
significant prolongation of OT with saline-priming demonstrates the importance of preventing 
the initial generation of thrombin from RBC attached to plastic surfaces (Keuren et al. 2003). 
Aspirin significantly prolonged OT in all 10 stable angina patients. A large Effect size of 
1.60 was noted with OT measurements suggesting aspirin prolonged OT and reduced 
propensity to thrombus formation. Aspirin has long been used in atherothrombosis, due to its 
recognised antiplatelet effects which were clearly demonstrated using the GTT. LT results 
were variable, but a moderate effect size of 0.41 was noted. This study was a pilot study,  
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and there were only 10 subjects as a result of which it was underpowered to detect a 
statistically significant effect. 
Aspirin acetylates the lysine residues in the fibrinogen molecule and alters the fibrin network 
structure, resulting in enhanced permeability of the fibrin network structure initiating 
fibrinolysis (Antovic et al. 2005). Williams et al investigated the effects of low and 
intermediate dose aspirin on fibrin gel porosity and fibrinolysis in 19 subjects, with 75 and 
325 mg aspirin.  Increased fibrin gel porosity was observed with low dose aspirin only 
 
(Williams et al. 1998). 
 
 
A study by Bjornsson et al used the clot lysis assay to determine the fibrinolytic potential of 
aspirin. Five healthy subjects received 650 mg of aspirin twice daily for 5 days. Although the 
sample size was small, the results suggested shorter clot lysis times after aspirin when 
compared to control group (9.1 min vs. 12.4 min, p = 0.04) (Bjornsson et al. 1989).Reports 
also suggest fibrinolytic activity of aspirin through the stimulation of NO synthesis in human 
volunteers (Karmohapatra et al. 2007). Further larger studies are required to help us study the 
effect size of aspirin on endogenous thrombolysis, which if significant could prove beneficial 
in modulation of impaired endogenous thrombolysis, and improve outcomes. 
 
The  GTT  sensitively  detected  the  effect  of  haemolysis  and  endogenous  ADP  release. 
Turbulent flow of blood just below the upper ball may initiate haemolysis (Kamaneva et al. 
2004).The importance of cell destruction, haemolysis and ADP release in the thrombotic 
 
occlusion were shown by the effect of water priming, which greatly enhanced the thrombotic 
reaction. The great individual variation in the shortening of OT with water-priming may be 
attributable to variable response of platelets to ADP or variable osmotic damage to RBC. 
Clopidogrel significantly prolonged OT in the GTT, and furthermore, greatly reduced or 
rather prevented the accelerated OT (aGTT) indicating that haemolysis and ADP release are  
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responsible for the acceleration of the thrombotic reaction. We have to emphasize that GTT 
OT measurements reflect not only platelet reactivity to aggregate but also the coagulant  
activity of platelets i.e. thrombin generation. 
In all 13 healthy volunteers, clopidogrel resulted in a significant prolongation of OT with no 
observable effect on LT (Fig 6.8). Clopidogrel is an ADP antagonist and exerts this effect by 
inhibiting ADP release, providing us evidence that haemolysis and ADP release are essential 
in the shear induced thrombotic reaction. We have demonstrated shortening of OT due to 
haemolysis induced by distilled water in the aGTT. We postulated that  due  to  the  osmotic  
gradient  between  water  and  blood,  there  is  cell  destruction, haemolysis and release of 
ADP from RBC and platelets which in turn activates platelet adhesion and aggregation 
resulting in the accelerated thrombotic reaction. Clopidogrel was able to inhibit this 
accelerated thrombotic reaction, providing evidence that ADP released during haemolysis is 
responsible for the enhanced thrombotic reaction. Clopidogrel prevented shortening of OT in 
most individuals in the aGTT, allowing the GTT to sensitively determine the  efficacy  of  
ADP  antagonist  therapy  which  can  prove  to  be  an  invaluable  tool  in optimizing dose or 
determining resistance to antiplatelet agents. Parallel measurements of GTT and aGTT can 
allow assessment of global thrombotic status and monitor response and efficacy of ADP 
antagonists in cardiac patients, and help optimize antiplatelet therapy to improve outcomes. 
Neither water nor clopidogrel had any effect on lysis times. This concords with earlier 
findings that clopidogrel does not induce fibrinolysis in healthy subjects (Taher et al. 2004). 
In relation to our findings, we have to discuss the pathological significance of RBC damage 
in arterial thrombus formation. The contribution of RBC to arterial thrombogenesis is 
supported by clinical and experimental evidence. Thrombotic complications occur in 
conditions such as haemolytic anaemias, and RBC haemolysis is reported around valve  
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replacements. Formation of thrombi on cardiovascular devices is partly attributed to the 
significantly higher osmotic sensitivity of RBC exposed to turbulent shear forces (Michelson 
et al. 2007) and the haemolytic effect of turbulent flow (Aziz et al. 2007). Thrombin is a key 
factor  in  arterial  thrombogenesis  and  RBC  lysates  are  strong  promoters  of  thrombin 
generation (Quinlan et al. 2007). The extent of RBC damage by very high turbulent shear  
forces around prosthetic valves or around deep vessel wall injury (such as plaque rupture) 
should not be underestimated. The accelerated thrombosis test used here simulates conditions 
where ADP is released mainly from RBC by high shear forces and turbulent flow in an artery 
of severely reduced lumen, or at the site of plaque rupture. The test can be criticized for not 
using a well defined concentration of ADP, however in individuals the extent of haemolysis 
and hence the released ADP concentration is variable. We regard this as an advantage of this 
test over using fixed ADP concentrations, as it reflects the in vivo situation of variable RBC 
damage during an arterial thrombotic event. In addition, the minute amount of ADP released 
during the very short contact between blood and water can be inhibited more sensitively, than 
the  much  higher  concentrations  of  ADP  commonly employed  as  the  agonist  in  various 
platelet function tests. 
As a "global test", GTT has the obvious limitation that it is not specific for any particular 
agonist.  It  reflects  true  thrombotic  status  but  cannot  reveal  the  causes  of  enhanced  or 
inhibited thrombotic activity. Contribution from potential plasma thrombotic/inflammatory 
factors to the results obtained with the GTT should also be considered. Among all such 
factors,  only  vWF,  which  reflects  endothelial  damage/dysfunction  is  regarded  to  be 
significant. Although the importance of vWF in the pathogenesis of myocardial infarction is 
undeniable, the association between high plasma vWF levels and arterial thrombosis has been 
controversial (S p en ce r  et al. 2007, May et al. 2007). An earlier report of increased vWF  
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levels and platelet reactivity after coronary angioplasty only in blood samples taken from the 
coronary sinus but not in peripheral venous samples may explain the above controversy 
(Gorog et al. 2003). Nevertheless, a good correlation was found between GTT OT 
measurements and plasma vWF levels (Nishida et al. 2006). 
Although the normal GTT detected a significant antiplatelet effect of clopidogrel, the test in 
this form is not sensitive enough to monitor individuals for clopidogrel effect or resistance. 
The accelerated thrombosis test presented here allows a more physiological assessment of 
thrombotic risk; since it employs native blood, high shear akin to that in a significantly 
stenosed  vessel  and  detects  the  contribution  of  endogenous  ADP  release  to  occlusive 
thrombus  formation.  Furthermore, it sensitively detects the effect of ADP-antagonist 
medication on shear-induced thrombus formation and may allow individualised tailoring of 
such therapy. Ongoing  studies  in  patients  with  coronary  disease  will  reveal  the  clinical 
usefulness of using the normal and accelerated GTT in detecting antiplatelet resistance . 
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Chapter 5: Platelet function in Acute Coronary Syndrome, stable angina and 
Healthy volunteers  
 
 
OT and LT in Acute Coronary Syndrome Patients 
 
 
Background: Spontaneous thrombolysis is a determinant of the outcome of arterial 
thrombosis. The risk of future events after an acute myocardial infarction depends not only on 
occlusive thrombus formation, but also on the physiological process of spontaneous 
thrombolysis, preventing lasting occlusion and prolonged ischaemia of the myocardium. 
Thrombotic events continue to occur despite treatment of high risk patients with dual 
antiplatelet medication. Nonresponsiveness to antiplatelet drugs remains a major limitation in 
the prevention of future thrombotic episodes in patients who experience acute coronary 
syndrome (ACS). Previous studies estimated that 5.5-56.8% of the population are aspirin 
resistant (Kim et al. 2008), while the prevalence of clopidogrel nonresponsiveness was 21% 
(Snoep et al. 2007). Although much fewer published data are available for dual (aspirin and 
clopidogrel) nonresponsiveness, the incidence in a recent study in 746 patients was only 6% 
(Gori et al. 2008). 
In a study using Verify now assay and five other platelet function tests (Lordkipanidze et al. 
2007), poor correlation was observed between the tests suggesting there is low agreement 
between assays. In the ARMYDA-PRO (Antiplatelet therapy for Reduct ion of Myocardial 
Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study, PRU was tested in 
160 patients undergoing PCI and high platelet reactivity was a significant predictor of MACE 
(Marcucci et al. 2009).  Using ROC curve analysis, the optimal cut-off for the primary end 
point was PRU ≥ 240 (area under the curve: 0.69; 95% CI: 0.56 to 0.81, p=0.016).Similarly, 
in a study by Price et al, 380 patients undergoing PCI with DES were tested using the 
Verify now assay, and the optimal cut-off for MACE was a PRU ≥235 (area under the curve  
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0.711; 95% CI: 0.529–0.893, P = 0.03) (Price et al.2008). Based on the results of these 
studies, PRU ≥ 240 was considered a significant determinant of high platelet reactivity.  
Our aim in this study was to determine OT and LT in patients admitted to hospital with a 
diagnosis of Acute Coronary Syndrome (ACS), and to determine if either of these variables 
were a significant predictor of future adverse cardiac events. 
It was also our aim to compare OT and LT in healthy volunteers, stable angina and ACS 
patients to determine if the GTT was able to identify individuals at high risk of thrombus 
formation, due to prothrombotic status or impaired endogenous fibrinolysis .This would allow 
us to monitor the high risk stable angina patients, and modify risk factors to prevent 
development of subsequent thrombus that could result in acute myocardial infarction. 
 We also compared platelet reactivity using the GTT and Verify Now Assay, to determine if   
 there was any correlation between these two tests.  
 
 Hypothesis: 
We postulated that OT would be prolonged in coronary artery disease patients due to the 
antithrombotic effect of antiplatelet medications. We also postulated that ACS patients with 
prolonged LT would be at increased risk of future major adverse cardiac events due to 
impaired endogenous thrombolysis. 
 
Methods: 
Study Population of ACS patients  
Patients admitted to hospital with ACS were included in the study. ACS was defined by the 
presence of at least two of the following: ischaemic chest pain, elevation of cardiac enzymes 
(troponin or creatine kinase i s o e n z y m e  at least twice the upper limit normal limits), or  
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dynamic electrocardiographic changes (ST elevation, ST depression or T wave inversion). 
All patients received dual antiplatelet therapy for a year since index admission.Exclusion  
criteria are listed in Table 6.1.  All patients were loaded with Aspirin 300 mg and Clopidogrel 
300 mg on admission, and were taking 75 mg each of Aspirin and Clopidogrel thereafter as 
maintenance dose. 300 patients admitted with ACS were included in the study and sampled 
during their index admission.Most ACS patients receive unfractionated low molecular weight 
heparin (LMWH) on admission, and all these patients were sampled a minimum of 48 hours, (5 
± 3 days after admission, Mean ± SD) after discontinuation of LMWH to avoid any effect of the 
anticoagulant on OT and LT. 
The coefficient of variation was assessed in ten patients with ACS twice, at 24 h intervals. The   
CV for OT was 7% and for LT was 19%, similar to the CV obtained in normal volunteers. 
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Table 6.1: Exclusion criteria  
 
 
 
Inability to consent  
Current participation in another study  
More than 90 years of age or <18 years of age 
 Cardiogenic shock 
 Sepsis 
 Malignancy 
 Bleeding diasthesis 
 Thrombolysis, warfarin, or glycoprotein IIb/IIIa inhibitor before sampling 
 Concomitant medication with erythromycin, dipyridamole 
 Blood dyscrasia (platelets <100, hemoglobin <8 g/dl, international normalized ratio >1.4, 
activated partial thromboplastin time more than twice the upper limit of normal, leukocyte 
count <3.5 X 109/l, neutrophil count <1 X 109/l) 
 Intolerance to or contraindication to aspirin or clopidogrel 
 Complete follow-up over 1-year period not likely 
 Other disease shortening life expectancy to <12 months  
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Sampling procedure 
Blood samples were taken from an antecubital vein using an 18 –G butterfly cannula using a 
2- Syringe technique. The first 2 mls of blood was either discarded or used for routine blood 
tests and the next 3-5 ml blood samples were used to assess thrombotic and thrombolytic status. 
This blood sample was injected with force into the GTT tube, and the shear force between the 
small aperture between tube and ball bearings resulted in platelet activation and subsequent 
aggregation. Measurement was started within 15 seconds, and the instrument indicator changed 
colour once the analysis was complete. Each instrument had a memory card, which could 
be connected to a computer to download and view the measurement graphs. 
Data collection and Follow up 
All ACS patients were recruited into the study during their index admission, and baseline 
demographics recorded on the case report forms (CRF). GTT measurements of OT and LT were 
taken pre PCI, and results documented for all 300 patients. Clinical or telephonic follow up was 
done at 3 monthly intervals, and source documentation of all major adverse cardiovascular 
events (MACE) obtained. After ascertainment of the time of event, blood results including 
cardiac biomarkers were obtained from the electronic pathology database, and inpatient 
admission notes screened to determine the sequence and details of the adverse events. 
Admission ECGs, echocardiogram, angiogram and other radiology reports were accessed, and 
medication history determined. Compliance to antiplatelet and other medications was 
determined by direct communication with the patient where possible. After accumulation of all 
data required for determination of MACE, analysis was performed with the use of statistical 
package SPSS v16. 
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Primary and Secondary Outcome 
The primary endpoint of the study was a composite occurrence of cardiovascular death, non- 
fatal myocardial infarction or stroke (MACE) at 1 year. The endpoints of the study were: 1) 
cardiovascular death, defined as death in the presence of ACS, significant cardiac arrhythmia, 
refractory congestive heart failure, or death attributed to cardiovascular cause at post mortem; 2) 
nonfatal MI ( a rise in troponin I or an increase in creatinine kinase – myocardial band 
isoenzyme at least twice the upper limit normal limits with atleast 1 of the following : acute 
onset of prolonged ( ≥ 20 minutes) ischaemic sounding chest pain; ST- segment elevation of 
atleast 1 mm in 2 or  more contiguous electrocardiographic leads, or ST- segment depression 
≥0.5 mm in ≥2 contiguous leads; or T- wave inversion> 1 mm in leads with predominant R 
waves; or 3) stroke, defined as the presence of new neurological deficit though to be vascular in 
origin, with signs or symptoms lasting more than 24 hours and supported by an imaging 
procedure such as a computed tomography (CT scan) or magnetic resonance imaging (MRI).The 
secondary endpoints of the study included MACE at 30 days, bleeding complications and the 
need for repeat revascularization at 1 year.Bleeding complication was defined as intracranial or 
intraocular bleeding, access site haematoma > 5 cm diameter, significant bleeding resulting in 
haemodynamic compromise, or a drop in Hb ≥ 3 g/dl. 
Statistical Analysis 
SPSS version 16 (SPSS Inc., Chicago, Illinois) was used for all analyses.   Normally distributed  
variables  were  analysed  using  unpaired  t  test  and  non-normally  distributed variable  were  
analysed  using  Mann  -  Whitney  U  Test.    Dichotomous variables  were compared using 
Chi – Square or Fisher’s Exact tests. Correlations were analysed using Spearman’s coefficient 
of rank correlation and Log transformation was used, where appropriate. Receiver operating  
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curve (ROC) was used to discriminate between patients with and without MACE. A cut-off 
value was determined by identifying an LT value providing greatest sum of sensitivity and 
specificity. Cox regression was used to investigate relationship between LT and MACE, and LT 
was divided into bands of 1000’s, and Kaplan - Meier curve with log-rank test was used to 
compare survival curves. 
Univariate and Multivariate hazard regression model of Cox were used to determine risk factors 
for clinical end points, and to adjust for potential confounders that were associated with clinical 
endpoints in Univariate analysis. A significance level was defined as p<0.05. 
OT and LT were found to be separately related to MACE. To establish whether OT or LT 
outside the normal range may be predictive of MACE, a normal range was established from 
Mean ± 2SD s of normal volunteers. 
Comparison of platelet function in ACS, Stable angina and Healthy volunteers 
We evaluated OT and LT using the GTT in seventy five stable angina patients. Stable  
angina  patients  were  reviewed  and  recruited  in  cardiac  outpatient  clinic,  and  all patients 
with underlying evidence of coronary artery disease were recruited in the study. All patients 
were on aspirin and clopidogrel at the time of recruitment. OT and LT of normal volunteers, SA 
and ACS patients were then compared to demonstrate if there was any significant difference in 
the three groups. 
SPSSv16 was used for statistical analysis. Comparison between groups was done using 
ANOVA, and non-parametric Mann –Whitney test was used to demonstrate any statistically 
significant difference (p<0.05). 
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Comparison between GTT and Verify now assay in ACS patients  
In a cohort of 71 ACS patients, we assessed thrombotic status using the GTT and the Verify 
now assay. Venous blood samples were taken from the antecubital vein and anticoagulated with 
sodium citrate 0.109 mol/l (ratio 9:1). We used the Verify Now P2Y (12) cartridge which 
measures ADP (P2Y12) inhibition.   
Results from the Verify Now P2Y (12) assay are measured in P2Y (12) reaction units (PRU), 
higher the PRU worse the outcome in reported studies. Based on normal range of OT in 
healthy volunteers (200-550s, we compared OT < 200s to Verify now PRU ≥ 240 units as an 
indicator of prothrombotic status in ACS patients. 
Results 
Demographics of ACS patients are listed in Table 6.2.    
Completed follow-up was available in 297 patients. It has been mentioned in previous chapters 
that OT was normally distributed in healthy volunteers (Fig 8.1), and LT distribution was 
skewed (Fig 8.2). In ACS patients, OT was significantly prolonged compared to that of normal 
volunteers (428±155s vs. 378± 96s, p<0.001) (Fig 8.3, 8.4). The ROC curve analysis for OT and 
LT demonstrated that LT level significantly discriminated between patients with and without 
MACE with an area under the curve of 0.63 (95% CI: 0.51 to 0.69; p<0.05). LT ≥3000 was 
identified as the optimal cut point to predict MACE outcome, with sensitivity of 60% and 
specificity of 80%. (Fig 8.5).  
Survival analysis did not demonstrate any relationship between OT and MACE (Fig 8.6, 8.7).   
Different variables were interrogated for effects on OT, including patient demographics,  
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echocardiographic and angiographic characteristics, medications and a significant effect was  
observed only with the use of statin. Patients on statin therapy were noted to have a longer  
OT (less prothrombotic) compared to those not on statin therapy (439±157s vs. 359±120s, p=  
0.02). Patients on recent LMWH (< 48 hrs earlier) and recent thrombolysis (< 5 days earlier)  
were excluded from this analysis to avoid any confounding results. 
LT was positively skewed in both healthy volunteers and ACS patients. LT was significantly 
prolonged in ACS patients compared to healthy volunteers [median 1053 (978 to 1125) s vs. 
1362 (1240 to 1514) s, p < 0.001]. 23 % ACS patients had LT > 3000S, compared to none of 
the healthy volunteers, with 15.3% patients demonstrating markedly impaired thrombolytic 
status with LT≥5000s. 
LT was noted to be significantly predictive of MACE at 180 days and at 1 year.  
At LT ≥3000s, the HR 2.48 (CI = 1.2 -4.8, p= 0.007) at 6 months (Fig 8.8), and HR 1.85 
(CI= 1.01- 3.4,  P=0.04) at 1 year (Fig 8.9). Above this LT level, the HR increased as the LT 
increased. With LT≥ 5000s HR was 2.57 (CI = 1.2-5.2, P=0.009) at 6 months (Fig 9.0), and  
HR: 2.08 (CI=1.07-4.01, p=0.02) at 1 year (Fig 9.1). 
Using Univariate Cox regression analysis, LT ≥3000s was associated with a significantly higher 
risk of cardiovascular death at 6 months (Fig 9.2) (HR:   4.04, CI = 1.3-12.0, P=0.012), 
and at 1 year (HR: 3.9, CI= 1.3-11.9, P= 0.013) (Fig 9.3). The risk of CV death did not increase 
significantly with increase in LT (LT ≥ 5000s; CV Death HR: 3.6, CI = 1.18-11.1, P= 0.024) 
but LT ≥ 5000s was a significant predictor of recurrent ACS (HR: 2.2, CI=1.08-4.6, P= 0.02) 
both at 6 months and at 1 year (Fig 9.4, 9.5). 
Variables were interrogated for effects on LT: patient demographics, echocardiographic and 
angiographic features, and medications. In patient demographics, only age was related to LT, 
and LT increased with age (p=0.008). A trend was noted between troponin and LT (p= 0.05). A 
weak association was also noted between OT and LT (r = -0.2, p=0.07). 
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Univariate analysis suggested some variables were related to MACE: age, diabetes mellitus, 
metformin, l o w  h aem o gl o b i n , l o w  h aem a t o c r i t , C -reactive p r o t e in , p e r i p h e r a l  
v a s cu l a r  disease, angiotensin-converting enzyme inhibitor, and oral nitrate therapy. Very few 
patients were known to suffer with peripheral vascular disease in the study. 
Variables were then inserted into the final model of multivariate logistic regression analysis; 
age, sex, diabetes mellitus, angiotension-converting enzyme inhibitor, and nitrates. Multivariate 
analysis demonstrated  LT to be an important  independent predictor of MACE , after 
adjustment for all these risk factors at 6 months and at 1 year (LT ≥3000s at 6 months: HR 2.4, 
95% CI: 1.2-4.8, p =0.008,  LT ≥3000s at 1 year: HR 1.9, 95% CI: 1.04-3.5, p=00.03, LT 
≥5000s at 6 months: HR 2.69, 95% CI: 1.3-5.5, p =0.007, LT ≥5000s at 1 year: HR 2.1, 95% 
CI: 1.12-4.2, p =0.002). Hazard ratio was noted to increase slightly as LT increased. 
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Table 6.2: Baseline demographics of ACS patients 
 
 Overall group (n=300) LT<3000 s (n= 231) LT≥3000s (n=69) P value 
Age, yrs 65 (40-90) 64.2 66.7 NS 
Male 216(72.3) 170(73.6) 47(68.1) NS 
Diabetes mellitus 50(16.7) 35(15.2) 15(21.7) NS 
Smoking 68(22.7) 54(23.4) 14(20.3) NS 
Hypertension 142(47.5) 111(48.1) 31(44.9) NS 
Prior CAD 129(43.0) 105(45.5) 24(34.8) NS 
Renal insufficiency 24(8.1) 17(7.4) 7(10.1) NS 
PVD 8(2.7) 6(2.6) 2(2.9) NS 
Prior CVA 16(5.4) 13(5.6) 3(4.3) NS 
STEMI 73(24.5) 55(23.8) 19(27.5) NS 
Troponin positive 226(79.0) 171(74.0) 55(79.7) NS 
Dynamic ECG changes 203 (68.0) 135(58.4) 39(56.5) NS 
Beta blocker 234(78.3) 181(78.4) 53(76.8) NS 
ACE inhibitor 216(72.2) 168(72.7) 48(69.6) NS 
Statin 273(91.3) 212(91.8) 61(88.4) NS 
Nitrate 73(24.4) 59(25.5) 14(20.3) NS 
Insulin 15(5.0) 10(4.3) 5(7.2) NS 
Metformin 15(5.0) 12(5.2) 3(4.3) 1.0 
 
 
 
 
Values are mean (range) or n (%). Renal insufficiency was defined by creatinine levels >2.0 
mg/dl. ACE= angiotensin-converting enzyme; CAD =coronary artery disease; CVA = 
cerebrovascular accident; LT=Lysis time; NS= not significant; PVD= peripheral vascular 
disease; STEMI= ST-segment myocardial infarction 
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Table 6.3 - Angiographic, Interventional and Echocardiographic characteristics of ACS 
patients 
 
 
 
 Overall group 
 
(n=300) 
LT<3000 s 
 
(n=231) 
LT≥3000 s 
 
(n=69) 
P value 
Angiogram performed 263(87.6) 202/231 (87.4) 61/69(88.4) NS 
1-vessel disease 107 (36) 87/202 (43) 20/61(32.7) NS 
2-vessel disease 57 (19) 41/202 (20.2) 16/61(26.2) NS 
3-vessel disease 39 (13) 30/202 (14.8) 9/61(14.7) NS 
PCI performed 103 (34) 80/202 (39.6) 23/61 (36) NS 
DES only 46 (15) 31/80 (38.7) 15/23(65) NS 
BMS only 47 (16) 40/80(50) 7/23 (30.4) NS 
DES and BMS 93 (31) 71/80 (88.75) 22/23 (95.6) NS 
GPIIb/IIIa antagonist 0 (0) 0 (0) 0 (0) NS 
Echo performed 197 (66) 152 (65.8) 45 (65.2) NS 
LVEF >50% 136 (45) 109/152 (71.7) 27 /45(60) NS 
LVEF 40-50% 23 (7.7) 15/152 (9.86) 8 /45(17.7) NS 
LVEF 30-40% 22 (7.3) 17/152 (11.18) 5 /45(11.1) NS 
LVEF <30% 16 (5.3) 11/152(7.2) 5 /45(11.1) NS 
Referred for CABG 34 (11) 26/202 (12.8) 8 /61(13.11) NS 
 
 
 
 
Values are n (%). PCI=percutaneous coronary intervention; DES= drug-eluting stent (s); 
BMS=bare metal stent(s); GP=glycoprotein; LVEF=left ventricular ejection fraction; 
CABG=coronary artery bypass grafting. 
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Figure 8.1: OT in healthy volunteers demonstrating normal distribution 
 
 
 
Figure 8.2: OT in ACS patients - In ACS patients taking dual-antiplatelet medication, OT was 
significantly prolonged (showing reduced platelet reactivity) compared with that of normal 
volunteers. 
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Figure 8.3: LT in healthy volunteers 
 
 
 
Figure 8.4: LT in ACS patients- In ACS patients, LT was significantly prolonged (impaired 
endogenous thrombolysis) compared with that of healthy volunteers. 
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Figure 8.5: ROC Curves for OT and LT   (Receiver-operating characteristic (ROC) curves for 
(A) occlusion time (OT) and (B) lysis time (LT). The LT level significantly discriminated 
between patients with and without major adverse cardiovascular events (MACE) with an area 
under the curve of 0.63 (95% confidence interval: 0.51 to 0.69; p < 0.05). An LT >3,000 s was 
identified as the optimal cut point to predict MACE outcome, with sensitivity of 60% and 
specificity of 80%).  
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Figure  8.6:  KM  curve  demonstrating  probability  of  event  free  survival  using  OT  as  a 
predictor of adverse events at 180 days. Survival analysis did not demonstrate any relationship  
between OT and MACE. 
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Figure  8.7:  KM  curve  demonstrating  probability  of  event  free  survival  using  OT  as  a 
predictor of adverse events at 1 year. Survival analysis did not demonstrate any relationship  
between OT and MACE. 
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Figure 8.8: KM curve demonstrating probability of event free survival at 180 days using LT 
≥3000s as cut-off. LT was noted to be significantly predictive of MACE at 180 days with HR  
2.48 (CI = 1.2 -4.8, p= 0.007) at 6 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    HR 2.48, P =0.007 
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Figure 8.9: KM curve demonstrating probability of event free survival at 1 year using LT 
≥3000s as cut-off. LT was noted to be significantly predictive of MACE at 1 yr with  
HR 1.85 (CI= 1.01- 3.4, P=0.04). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HR 1.85, P =0.04 
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Figure 9.0: KM curve demonstrating probability of event free survival at 180 days using LT 
≥5000s as cut-off. LT was noted to be significantly predictive of MACE at 180 days with  
HR 2.57 (CI = 1.2-5.2, P=0.009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HR 2.57, P=0.009 
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Figure 9.1: KM curve demonstrating probability of event f r e e  survival at 1 year using LT 
≥5000s as cut-off. LT was noted to be significantly predictive of MACE at 1 yr with  
HR 2.08 (CI=1.07-4.01, p=0.02). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HR 2.08, P = 0.02 
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Figure 9.2: MACE at 6 months using LT≥3000s as cut off (*P<0.05) - prolonged LT was 
highly predictive of recurrent cardiovascular events, attributable to both CV death and ACS. 
LT <3000 s is indicated by open bars; LT≥ 3000s is indicated by solid bars. 
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Figure 9.3: MACE at 1 year using LT≥3000s as cut off (*P<0.05) -  prolonged LT was highly 
predictive of recurrent cardiovascular events, attributable to both CV death and ACS. LT 
<3000 s is indicated by open bars; LT≥ 3000s is indicated by solid bars. 
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Figure 9.4: MACE at 6 months using LT≥5000s as cut off (*P<0.05)  - prolonged LT was 
highly predictive of recurrent cardiovascular events, attributable to both CV death and ACS. 
LT <5000 s is indicated by open bars; LT≥ 5000s is indicated by solid bars. 
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Figure 9.5: MACE at 1 year using LT≥5000s as cut off (*P<0.05)  - prolonged LT was highly 
predictive of recurrent cardiovascular events, attributable to both CV death and ACS. LT 
<5000 s is indicated by open bars; LT≥ 5000s is indicated by solid bars. 
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Table 6.4: Multivariate analysis using Cox regression to demonstrate HR 
for LT ≥3000s at 6 months (B= regression coefficient; SE = standard error 
of the mean; Wald= Wald statistic;Df = degrees of freedom; Sig.= 
significance; Exp (B) = Hazard ratio; CI = confidence interval) 
 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
LTV3000 .904 .342 7.008 1 .008 2.471 1.265 4.826 
AGE .030 .017 3.196 1 .074 1.030 .997 1.064 
SEX -.067 .371 .033 1 .857 .935 .452 1.934 
NITR .727 .359 4.099 1 .043 2.069 1.024 4.183 
ACE -.864 .342 6.399 1 .011 .421 .216 .823 
DM .999 .364 7.538 1 .006 2.715 1.331 5.538 
 
 
Table 6.5: Multivariate analysis using Cox regression to demonstrate HR 
for LT ≥3000s at 1 year (B= regression coefficient; SE = standard error of 
the mean; Wald= Wald statistic;Df = degrees of freedom; Sig.= 
significance; Exp (B) = Hazard ratio; CI = confidence interval) 
 
 
 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
LTV3000 .654 .312 4.401 1 .036 1.924 1.044 3.546 
AGE .017 .014 1.375 1 .241 1.017 .989 1.045 
SEX -.122 .333 .134 1 .714 .885 .461 1.699 
NITR .742 .319 5.408 1 .020 2.100 1.124 3.924 
ACE -1.063 .301 12.481 1 .000 .346 .192 .623 
DM .967 .332 8.489 1 .004 2.630 1.372 5.041 
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Table 6.6: Multivariate analysis using Cox regression to demonstrate HR 
for LT ≥5000s at 6 months (B= regression coefficient; SE = standard error 
of the mean; Wald= Wald statistic;Df = degrees of freedom; Sig.= 
significance; Exp (B) = Hazard ratio; CI = confidence interval) 
 
 
 
B SE Wald Df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
AGE .033 .017 3.791 1 .052 1.033 1.000 1.068 
SEX -.112 .369 .092 1 .762 .894 .434 1.843 
NITR .693 .359 3.727 1 .054 1.999 .989 4.039 
ACE -.785 .339 5.351 1 .021 .456 .235 .887 
DM 1.054 .362 8.487 1 .004 2.868 1.412 5.827 
LT5000 .991 .367 7.292 1 .007 2.693 1.312 5.528 
 
 
 
 
 
Table 6.7: Multivariate analysis using Cox regression to demonstrate HR 
for LT ≥5000s at 1 year (B= regression coefficient; SE = standard error 
of the mean; Wald= Wald statistic;Df = degrees of freedom; Sig.= 
significance; Exp (B) = Hazard ratio; CI = confidence interval) 
 
 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
AGE .018 .014 1.576 1 .209 1.018 .990 1.047 
SEX -.156 .332 .220 1 .639 .856 .446 1.641 
NITR .727 .319 5.185 1 .023 2.069 1.107 3.867 
ACE 1.005 .299 11.279 1 .001 .366 .204 .658 
DM 1.010 .331 9.327 1 .002 2.747 1.436 5.253 
LT5000 .783 .340 5.295 1 .021 2.188 1.123 4.264 
171 
 
 
 
 
 
Table 6.8: Total number of MACE in ACS patients, at 6 months and at 1 year 
 
 
PRIMARY 
 
ENDPOINTS 
6 months 
 
 
N (%) 
12 months 
 
 
N (%) 
CV DEATH 10 (3.3%) 12 (4%) 
ACS 26 (8.6%) 32 (10.6%) 
STROKE 0 2 (0.6%) 
MACE 36 (11.9%) 46 (15.3%) 
 
 
 
12 patients experienced an adverse cardiac event at 30 days, which included CV death in 5 
patients and non- fatal MI in 7 patients. Mean OT in these 12 patients was 431 s. None of 
these patients had OT < 200s, 10 had OT in the range 200- 550 s, and 2 patients had OT > 
550s. Mean LT in these 12 patients was 2682s, and LT ≥5000s was observed in 3 (25%) 
patients of which 1 patient did not survive and 2 patients had recurrent ACS within 30 days. 
There was no correlation between events and OT or LT in this small group. 
 
None of the 300 ACS patients had any bleeding complication while admitted as an inpatient, 
and did not report any episodes of significant bleeding at 1 year follow up. 
 
Need for repeat revascularization at 1 year was demonstrated in 2 patients. They were both 
males < 55 yrs age with LT< 3000s. Both these patients continued to experience symptoms of 
stable angina, and repeat angiography demonstrated in stent restenosis which required further 
percutaneous intervention. 
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OT Cut off Values 
 
 
Normal range for OT in our study was determined by sampling 100 healthy volunteers, who 
were non smokers, and not any medication. OT was normally distributed with mean OT 
377.80s. Normal range was determined using Mean ± 2SD, and OT values ranged between 
 
185- 569.80 (200-550s). 
 
 
In the ACS population, no correlation was observed between OT and outcome. We divided 
OT into bands of 100 s, and determined hazard ratios at 6 months and 1 year, and there was 
no significant increase in events at any cut off.  Using survival analysis, no significant 
increase in events was observed using OT < 200s; 200-550s or > 550 s as cut off. ACS 
patients were measured   using the GTT after they had been on a loading dose of Aspirin 
300mg and Clopidogrel 300mg, and maintenance dose of 75 mg of each drug. There is 
evidence that antiplatelet effects of these medications are dose dependant, and it is possible 
that when the patients were tested using the GTT, steady state concentration of the drug had 
not been achieved on the maintenance dose of 75 mg. 
 
All ACS  patients  were  tested  using  the GTT  48  hours after  LMWH  was  discontinued. 
LMWH is an anticoagulant, and its half- life is 5-6 hours. Heparin enhances agonist-induced 
activation and aggregation of platelets mainly in citrated blood, but significantly impairs 
platelet reactivity in native blood. Von Willebrand factor (vWF) is essential for platelet 
thrombus formation at high shear-rates and it is recognised that in addition to its effect on 
coagulation, heparin i n t e r f e r e s  w i t h  t h i s  p l a t e l e t /vWF-mediated h a e m o s t a s i s , 
a n d  i t  i s  possible that combination of these effects of heparin interfered with the OT result. 
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Table 6.9: Hazard ratio at 6 months and 1 year according to OT (seconds) 
 
 
 
 
 
OT values 
 
 
( seconds) 
Hazard ratio (Confidence 
 
interval and  P values ) at 6 
months 
Hazard ratio (Confidence 
 
interval and  P values ) at 12 
months 
≥200 21.1(CI:0.006-75790, 
 
P=0.465) 
1.4 ( CI: 0.95-10.25, P=0.73) 
≥300 1.5(CI: 0.53-4.3, P=0.42) 1.05 (CI: 0.47-2.34,P= 0.905) 
≥ 400 0.99 ( CI: 0.51-1.9, P= 0.98) 0.88 (CI: 0.49-1.57,P= 0.67) 
≥ 500 1.31( CI:0.64-2.6, P=0.44) 0.93 (CI: 0.47-1.84, P= 0.84) 
≥ 600 0.67 (CI: 0.20-2.2, P=0.57) 0.53 (CI: 016-1.70, P=0.28) 
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LT Cut off Values 
 
The results of our study suggest LT is an important novel predictor of MACE. The frequency 
of adverse events was greatest in the initial 6 months, following which there was relatively 
little additional risk noted. 
 
We divided LT into bands of 1000s, and optimal cut off was determined using Cox regression 
and a cut off LT value of 3000s was considered significant for determination of MACE both 
at 6 months and at 1 year. HR showed a small increase with increase in LT, and was 2.57 at 
LT≥5000s at 6 months and 2.08 at 1 year follow up (Fig 9.6, 9.7). 
 
We  also  calculated  individual  hazard  ratios  for  CV  death  and  ACS,  and  the  results 
 
demonstrated LT ≥ 3000s to be a significant predictor of CV death at 6 months ( HR 4.04, CI 
 
: 1.3-12.0, P= 0.012), and at 1 year (HR 3.9, CI: 1.34-11.9, P= 0.013). As LT increased, there 
was no significant increase in HR. Our primary endpoint also included ACS, and LT ≥ 3000s 
was not a significant predictor or recurrent ACS at either 6 months or 1 year. LT ≥ 5000s was 
a significant predictor of ACS at 6 months and at 1 year (HR – 2.2, CI: 1.09-4.6, P=0.028). 
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Table 6.10: Hazard ratio at 6 months and 1 year according to LT (seconds) 
 
 
 
 
 
 
 
 
LT values 
 
 
(seconds) 
Hazard ratio (Confidence 
 
interval and  P values ) at 6 
months 
Hazard ratio (Confidence 
 
interval and  P values ) at 
 
12 months 
≥ 1000 1.6 (CI:0.5-2.5, P=0.7) 1.17 ( CI: 0.58-2.3, P=0.7) 
≥ 2000 1.8(CI: 0.96-3.5, P=0.06) 1.55 (CI: 0.87-2.7,P= 0.13) 
≥ 3000 2.48 ( CI: 1.28-4.8, P= 0.007) 1.85 (CI: 1.01- 3.4,P= 
 
0.046) 
≥ 4000 2.50 ( CI: 1.26-5.04, 
 
P=0.009) 
1.98 (CI: 1.04- 3.76, P= 
 
0.037) 
≥ 5000 2.57 (CI: 1.26-5.2, P=0.009) 2.08 (CI: 1.07-4.01, 
 
P=0.02) 
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Figure 9.6: HR at 6 months for CV death, Non-fatal MI, and Stroke by LT (CI shown in 
brackets, *p <0.05) - An LT of ≥3000 s was identified as the optimal cut point to predict 
recurrent events. Above this LT level, the HR increased as the LT increased. The 95% 
confidence interval is shown in brackets. 
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Figure 9.7: HR at 1 year for CV death, Non-fatal MI, and Stroke by LT(CI shown in brackets, 
*p <0.05) - An LT of ≥3000 s was identified as the optimal cut point to predict recurrent events. 
Above this LT level, the HR increased as the LT increased. The 95% confidence interval is 
shown in brackets. 
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Effect of other variables on survival 
 
Using Cox regression, we determined the effect of other variables on survival. Variables that 
showed significant effect on survival at 6 months were Age, Diabetes mellitus, PVD, prior 
CAD, nitrates, ACE-I, metformin ,Hb, Hct, and CRP. Known prognostic indicators like dynamic 
ECG changes, troponin biomarker, ejection fraction or severity of disease on coronary 
angiography did not show any relationship to MACE (P=NS) in this study. 
 
Table 6.11: Variable and Hazard ratio at 6 months and 1 year. The 95% confidence  
interval is shown in brackets 
 
 
Variable HR ( Confidence interval , P value) HR ( Confidence interval , P 
Age HR 1.04 (CI: 1.0-1.08, P=0.004) HR 1.03 ( CI: 1.0-1.05, P=0.02) 
Diabetes HR 2.7 (CI: 1.3-5.5, P=0.004) HR 2.4 ( CI: 1.31-4.6, P= 0.005) 
PVD HR 4.09 ( CI:1.2-13.3, P=0.02) HR 4.5 (CI: 1.6-12.6, P= 0.004) 
Nitrates HR 2.3 (CI: 1.2-4.5, P= 0.012) HR 2.14 (CI:1.18-3.8, P=0.012) 
ACE – I HR 0.45 (CI: 0.23-0.87,P= 0.018) HR 0.38 (CI:0.21-0.69, P=0.001) 
Metformin HR 4.2 (CI: 1.7-10.3,P=0.001) HR 3.1(CI :1.34-7.5, P=0.008) 
Hb HR 0.78 (CI:0.66-09.1, P= 0.003) HR 0.83 (CI: 0.72-0.97, P= 0.02) 
Hct HR 0.001 (CI: 0.0-0.19, P=0.012) HR 0.002(CI: 0.0-0.51, P=0.02) 
CRP HR 1.006 (CI: 1.0-1.012, P=0.035) HR 1.006 (CI: 0.9-1.01, P=0.077) 
 
 
All patient demographics, characteristics, comorbidities, biomarkers, echocardiography and 
angiography results were interrogated for effects on OT and LT. Only statin was found to have a 
direct effect on OT, with patients on statin therapy exhibiting a longer (less thrombotic) OT than 
those not taking a statin (439±157 vs. 359±120 s, P=0.02).  
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 Of all variables, only age was related to LT, with increasing age relating to increased LT 
(P=0.008), although there was a trend toward a relationship between LT and troponin (P=0.055). 
There was a weak negative association between OT and LT (r = -0.2, P=0.07). 
Age is a non modifiable risk factor for cardiac disease, and was seen to be associated with 
MACE at both 6 months and 1 year.  HR was 1.04 and 1.03 suggesting age was linearly related 
to outcomes, and older people were at a higher risk of adverse cardiac events. 
Hypercholesterolemia is known to be associated with inflammation and prothrombotic state. 
Hypercholesterolaemic subjects are known to generate greater amounts of thrombin, and hence 
demonstrate increased platelet activation. Statins reduce cholesterol levels, and hence have the 
ability to reduce the prothrombotic state by reducing the amount of thrombin generated and 
hence reduce platelet activation (Davi et al. 1995, Notarbartolo et al. 1995). 
 Statins stimulate fibrinolysis by inhibition PAI-1 and increasing levels of tPA. It also helps in 
release of NO, and thus improves endothelial function. Statins also act as an antithrombotic by 
inhibiting platelet CD40 ligand and CD40L mediated thrombin generation. CRP stimulates PAI-
1 secretion, and statins reduce CRP levels resulting in inhibition of PAI-1 secretion.  
Diabetes mellitus is a known poor prognostic indicator of cardiac outcomes, but is a modifiable 
risk factor for coronary disease. HR at 6 months was 2.7 and 2.4 at 12 months, suggesting ACS 
patients with underlying diabetes were at a higher risk of recurrent cardiac events. Diabetic 
patients are known to have impaired fibrinolysis due to increased expression of PAI-1(McGill et 
al. 1994). We did not find any correlation between LT and Diabetes. This may be due to the 
effect of Insulin or Metformin on diabetic patients, as both these drugs are known to inhibit PAI-
1 activity and promote fibrinolysis (Cefalu et al. 2002). Metformin is a biguanide used in  
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patients with Type 2 diabetes mellitus. Patients on metformin had HR 4.2 and 3.1 at 6 months 
and 1 year respectively, suggesting poorly controlled diabetes had a significant impact on 
outcomes, and these diabetic patients were at a higher risk of an adverse event. Studies have 
demonstrated that diabetic patients have impaired fibrinolysis due to increased expression of 
PAI-1 (McGill et al. 1994).Metformin inhibits PAI-1 and thus promotes fibrinolysis. Studies 
have also demonstrated that better glycaemic and metabolic control in diabetes inhibits PAI-1  
activity, suggesting other antidiabetic medications like sulfonylureas alone or in combination 
with metformin have a role to play in promoting fibrinolysis, thus reducing the incidence of 
cardiac events in the diabetic population (Cefalu et al. 2002). ACE –I have been shown to have 
a beneficial prognostic effect in patients suffering an AMI as per results of the HOPE study. The 
HR at 6 months in patients on an ACE –I was 0.45, and at 12 months HR was 0.38 suggesting 
patients on this medication were significantly protected from MACE. It is known that 
Angiotensin –II increases expression of PAI-1, which inhibits fibrinolysis. ACE-I inhibit 
conversion of Angiotensin -1 to Angiotensin-II and thus promote fibrinolysis. Inhibition of 
fibrinolysis results in reduced nitric oxide production, causing endothelial dysfunction with 
predisposition to atherosclerosis. This effect of ACE-I may explain use of ACE-I in coronary 
heart disease patients, reducing risk of adverse cardiovascular events (Vaughan et al. 1998). 
Nitrates are generally used in cardiac patients with ongoing angina type pain with residual 
coronary artery disease. Following an episode of MI, it is used not only to control angina 
symptoms, but also for its effect as a vasodilator. At 6 months, patients on nitrates had a HR 2.3 
and 2.14 at 12 months, suggesting they were at a higher risk of an event probably due to 
underlying residual coronary artery disease. Intravenous isosorbide dinitrate preparations have 
shown to have an effect on reducing platelet aggregates at low doses, using Filtragometry  
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testing. Filtragometry uses blood drawn from an antecubital vein and measures amount of 
platelet aggregation. No significant effect was observed with oral preparation of the medication. 
Slight increase in t-PA and inhibition of PAI-1 was also observed, but no significant effect was 
seen when compared to the control group. Nitrates also release nitric oxide promoting 
endothelial function, and this may well play a role in fibrinolysis and exert a positive effect on 
reducing thrombogenic potential in coronary disease (Wallen et al. 1993).   
Patients with underlying PVD showed a significant relationship to outcome. HR was 4.09 at 6 
months and 4.5 at 12 months, suggesting atherosclerosis in more than 1 territory was a 
significant predictor of adverse outcomes. 
Several studies have demonstrated anaemia to be an important independent predictor of 
morbidity and mortality following an AMI (Anker et al. 2009). Patients with higher 
haemoglobin levels were noted to have a protective effect against MACE, and HR was 0.78 and 
0.83 at 6 months and 1 year respectively. Similarly, high haematocrit values demonstrated a 
beneficial effect at HR 0.001 and 0.002 at 6 months and 1 year respectively. 
C reactive protein is an acute inflammatory marker and high levels are noted with worse 
outcomes in AMI.A HR of 1.006 was noted to be of significance at 6 months , suggesting high 
CRP levels were associated with increase in MACE. 
Cigarette smoking causes endothelial dysfunction by inhibiting substance P-induced t-PA 
release and increasing PAI-1 activity in humans. This results in impaired fibrinolytic activity and 
increases risk of thrombosis (Simpson et al. 1997). Data from another small study (Ikarugi et al. 
2003) compared 11 elderly smokers to 21 elderly non-smokers (53-80yrs), and demonstrated 
impaired endogenous lysis in elderly smokers (LT: 5407 vs. 4147, p<0.001). This may partly be  
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explained by endothelial dysfunction due to smoking in elderly people, but the small sample size 
makes it extremely difficult to interpret these findings. Endothelial dysfunction may be 
accelerated in elderly smokers because of the long term exposure to smoke product. However, 
such a mechanism cannot be demonstrated in the presently used GTT or other platelet function 
test in vitro systems, where endothelium is not present.  In our study, we did not find an 
association between impaired fibrinolysis with smoking. This may be partly due to the fact that 
patients labelled as smokers, were sampled on average 5 days after admission, during which 
time they had almost universally abstained from smoking in hospital. Thus the effect of smoking 
on LT may be underestimated due to the late sampling after admission. 
All patients admitted to hospital with ACS were sampled at a mean duration of 5±3 days after 
admission. As smoking was not allowed in the hospital premises, all these patients had to abstain 
from smoking in hospital. Thus the effect of smoking on LT may be blunted due to the late 
sampling post admission.       
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Comparison of platelet function in ACS, SA and Healthy Volunteers 
 
There were 75 stable angina patients, of which 72% were males and 28 % females, and mean 
age was 66 (range 40-85 years). 20% had underlying history of diet controlled diabetes, 64% 
were hypertensive, 10.7% had chronic kidney disease, 10.7% had peripheral vascular disease 
and 5.3% had history of cerebrovascular accident. 16% of stable angina patients were 
current smokers. 93.3% of these patients were on a statin, 82.7 % on ACE inhibitors, 70.7% 
were on a beta blocker, 37.8% were on nitrate therapy and 76% patients had PCI in the previous 
year. 
Mean OT in stable angina patients (n=75) was 458.39s (range 100-752s) (Fig 10.1).  We have 
previously determined mean OT in the normal population (n=100) was 377.80s (range 109- 
674s), and OT was a normally distributed variable. In the ACS patients (n=300), mean OT 
was 428.03s (range 29-998s). Comparison of OT was done between the three populations, 
and a significant difference was noted among SA and ACS patients compared with healthy 
volunteers (Fig 10.2). Using Anova, mean OT for healthy volunteers was significantly lower 
than either the SA or ACS group (p=0.001).  Using post hoc bonferroni correction for multiple 
testing we noted that the mean OT for healthy volunteers differed significantly from both SA (p 
= 0.001) and ACS (p =0.007) means. No significant difference was observed between OT in the 
SA group compared with ACS group (p=0.292). 
We have previously a l so  determined that LT was skewed in the healthy volunteers, and in 
the ACS population. As such, median LT was compared between healthy volunteers, SA 
and ACS patients. For healthy volunteers the median LT was 1052s (95% CI: 978-1125), for 
SA 1243s (95% CI: 1076-1425) (Fig 10.3), and for ACS 1353s (1228-1504). Using Mann- 
Whitney  test,  a  significant  difference  in  LT  measurements  was  noted  between  healthy 
volunteers and SA patients (p<0.001), and between healthy volunteers and ACS patients  
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(p<0.001). There was no significant difference in LT between SA and ACS patients 
(p=0.173) (Fig 10.4). 9.3% SA patients had LT≥3000s compared to 23% ACS patients, and in 
5.3% SA patients LT was significantly prolonged at LT 6000s. 
All patient demographics, characteristics, comorbidities, biomarkers, and medications were       
interrogated for effects on OT and LT in the SA group. None of the variables had any   
significant effect on OT or LT. This may be due to the small sample size of this group; larger 
studies will help determine the effect of these variables in SA patients.  
    
Figure 10.1: OT in Stable Angina patients 
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Figure 10.2: Box plot comparing minimum, maximum and median OT in Healthy Volunteers, 
Stable Angina and ACS patients. Mean OT for healthy volunteers differed significantly from 
both SA (p = 0.001) and ACS (p =0.007) means No significant difference was observed between 
OT in the SA group compared with ACS group (p=0.292). 
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Figure 10.3: LT in Stable Angina patients 
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Figure 10.4: Box plot comparing minimum, maximum, and median LT in Healthy Volunteers, 
Stable Angina and ACS patients.Significant difference in LT measurements noted between 
healthy volunteers and SA patients (p<0.001), and between healthy volunteers and ACS 
patients (p<0.001).  No significant difference in LT between SA and ACS patients (p =0.173) 
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  Platelet function using the GTT and Verify now assay in ACS patients 
 
In a cohort of 71 ACS patients, we assessed thrombotic status using the GTT and the Verify 
now assay. Using an OT cut off < 200s to signify prothrombotic state, no patients were 
deemed prothrombotic in this small subgroup of 71 patients. We have previously mentioned 
OT was not a predictor of MACE, and antiplatelet agents prolonged OT. Using PRU 
cutoff ≥ 240, 14% ACS patients were deemed prothrombotic. No significant correlation was 
noted between OT or LT and PRU (OT and PRU: rho = -.08, p=0.49) (Fig 11.1). Using Cox 
regression, PRU ≥ 240 was a significant predictor of MACE at 6 months (HR: 4.7, 95% 
CI: 1.12-19.7, p =0.034)(Fig 11.2) and showed a trend at 1 year (HR: 3.8, 95% CI: 0.96-
15.4, p=0.057)( Fig 11.3). Of the 71 patients, 10 (14%) had an adverse cardiac event, which 
included 4 (5.6%) deaths and 6 (8.4%) ACS. Mean time to event was 120 ± 65 days. 
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Figure 11.1: Scatter plot demonstrating no correlation between GTT OT and PRU 
 
 
 
 
 
 
 
 
 
 
r = -.08, p=0.49 
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Figure 11.2: Kaplan –Meier Curve demonstating probability of event free survival using 
Verify Now Assay at 6 months. Using Cox regression, PRU ≥ 240 was a significant predictor  
of MACE at 6 months (HR: 4.7, 95% CI: 1.12-19.7, p =0.034). 
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HR: 4.7, P = 0.034 
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Figure 11.3: Kaplan –Meier Curve demonstating probability of event free survival using 
Verify Now assay at 1 year. Using Cox regression, PRU ≥ 240 showed a trend at 1 year  
(HR: 3.8, 95% CI: 0.96-15.4, p=0.057). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRU < 240 
 
 
 
 
 
PRU ≥ 240 
 
 
 
 
 
 
 
 
 
HR: 3.8, P=0.057 
 
 
 
 
 
 
192 
 
 
 
 
Discussion, Limitations and Conclusions  
This study demonstrates that ACS patients continue to experience recurrent thrombotic events 
despite being on dual antiplatelet therapy. This could be secondary to non- responsiveness or 
resistance to antiplatelet medications, or due to impaired endogenous thrombolysis. OT in ACS 
patients was significantly prolonged when compared to healthy volunteers,  suggesting  Aspirin  
and  Clopidogrel  had  an  effect  on  prolongation  of  OT. However, we were unable to 
demonstrate any significant association between OT and MACE in the ACS population. As 
patients were sampled 5 ±3 days after admission, it is possible that steady state concentration of 
antiplatelet agents was not achieved, and hence the lack of association between OT and MACE. 
It is also possible that platelet bound heparin interfered with the GTT results, even though all 
patients were sampled atleast 48 hours after the last dose of LMWH, by which time heparin 
should have completely cleared from the circulation (Collignon et al. 1995). 
 
A significant association was noted between LT and MACE. LT≥3000s was considered a 
significant predictor of MACE at both 6 months and 1 year. It was also a significant predictor 
of CV death, and LT≥5000s was demonstrated to predict recurrence of nonfatal MI at both 6 
months and at 1 year. There were only 2 strokes in the study; hence we were unable to 
demonstrate any significant association between LT and stroke in our population.In a study of 
585 patients with ST-segment elevation MI, electrocardiographic or angiographic 
spontaneous reperfusion was observed in 14.9% and 14.7%, respectively. Those with 
spontaneous reperfusion had lower mortality, lower composite of death/shock/congestive 
heart failure, and significant reduction in death or reinfarction (Bainey et al. 2008). In 
another study of 710 patients with ST-segment elevation MI undergoing percutaneous coronary 
revascularization, spontaneous reperfusion was observed in 22% of patients, and at 
 30 days, was associated with significantly lower incidence of death, congestive heart failure, 
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and recurrent ACS ( Fefer et al. 2009).It has also been suggested that impaired fibrinolysis   
 determines the outcome of coronary angioplasty ( Fornitz et al. 2001). Large prospective studies  
provided evidence for a statistically significant association between inhibited fibrinolysis as  
indicated by increased levels of fibrinolysis inhibition markers such as tissue- type plasminogen 
activator, plasminogen activator inhibitor, thrombin activatable fibrinolysis inhibitor, plasmin-
antiplasmin complex, lipoprotein (a), and an increased risk of recurrent MI or sudden cardiac 
death ( Christ et al. 2005, Katsaros et al. 2008, Morange et al. 2007, Soeki et al. 2002, Tregouet 
et al. 2009). However, multivariate analysis of the measured plasma concentrations by these 
fibrinolysis markers showed weak or no prognostic value of these tests. 
 
From the several global clot lysis assays described in the past few years, we have chosen the 
GTT technique, which has the advantage of measuring thrombolysis as opposed to clot lysis. 
Although worthy of further prospective confirmation, our results suggest a strong association 
between impaired spontaneous thrombolysis and MACE. A very recent study involving 335 
young survivors of a first arterial thrombosis reported that low plasma fibrinolytic potential, 
measured by clot LT, and found in 10% of the population, was associated with a 2-fold increase 
in relative risk of arterial thrombosis (Guimaraes et al. 2009). Our findings show that in patients 
with ACS, the increase in risk associated with impaired lysis can even be higher. 
The main limitation of our study is the fact that patients were only sampled once during their     
 index admission, generally once they had stabilized on medical therapy. There is evidence that 
the antiplatelet effects of aspirin (Undas et al. 2007) and clopidogrel ( Dangas et  al. 2009) are 
dose-dependent. When we measured platelet reactivity in patients under the effect  
 of the loading dose of 300 mg aspirin and 300 mg clopidogrel, such measurements do not  
 necessarily reflect steady state platelet function during the maintenance doses of 75 mg/day.  
 Secondly, heparin administered immediately after admission may have interfered with the GTT  
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measurement. GTT OT is determined not just by the rate of platelet aggregation but also by the  
 formation and the effect of thrombin, generated by activated platelets. Based on published data  
 regarding the plasma half-life of heparin, at the time of sampling, we anticipated no interference   
from heparin with the test. However, there is some evidence that heparin binds to platelets (Horne  
et al. 1989) and such membrane bound heparin may affect platelet behaviour for much longer 
periods. With its strong antithrombin effect (De Candia et al. 1999) such plateletbound heparin 
may have interfered with our GTT measurements. Had sampling been performed about 10 days 
after admission, when patients were established on maintenance doses of antiplatelet drugs and 
also interference by heparin could have been excluded, it is possible that the platelet reactivity 
may have been predictive of MACE and impaired thrombolysis may have been even more 
predictive of future events. Furthermore, it remains unknown whether the impaired thrombolysis 
was part of an acute phase response or whether it reflects a chronic impairment of thrombolysis 
that influences late outcome. Possible diurnal variation in LT was not investigated. Further studies 
are required to investigate the effect of medication on thrombolytic state, both in the acute and the 
chronic state.  
Comparison of OT and LT results in healthy volunteers, SA and ACS patients demonstrated 
significantly prolonged OT in SA and ACS patients compared to normal volunteers. This 
suggests that dual antiplatelet medication normalizes platelet reactivity in patients with coronary 
disease, and has a beneficial effect on the patient’s thrombotic status by prolonging time to 
thrombus formation. In previous chapters, both Aspirin and Clopidogrel have demonstrated a 
significant prolongation in OT in healthy volunteers. No significant  difference  was  observed  in  
the  prothrombotic  status  between  SA  and  ACS patients, despite the latter being considered 
more prothrombotic. 
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As previously mentioned, ACS patients were sampled at least 48 hours after discontinuation of 
heparin, but the use of heparin during the acute phase of admission may be considered as a 
limitation, and hence may not have demonstrated any significant difference in prothrombotic 
status in the two groups. 
LT was significantly prolonged in SA and ACS patients compared to healthy volunteers, 
suggesting patients with underlying coronary artery disease had impaired endogenous 
thrombolytic activity. Although no significant prolongation in LT was noted in ACS patients 
compared  to  SA  patients,  23%  ACS  patients  had  an  LT≥3000s  compared  to  9.3%  SA 
patients. 
No significant difference was noted in LT between SA and ACS patients. This may be due to 
small sample size, or difference in characteristics of the different populations. The healthy 
volunteers had no underlying medical history and were not on any medication, whereas SA and 
ACS patients had underlying risk factors and were on a multitude of medications. However, as a 
pilot study some significant observations and differences were noted in these patients thrombotic 
and thrombolytic status; larger studies in homogenous cohorts will help understand these 
differences better. 
Data suggest that the extent and severity of coronary atheroma does not predict subsequent 
development of an unstable coronary plaque. Elevated levels of proinflammatory cytokines and 
vWF have been demonstrated in ACS, and predispose to thrombus formation. Studies suggest 
increased circulating plasma levels of proinflammatory cytokines in SA and ACS patients. 
Results from a small study by Simon et al (Simon et al. 2000) suggest that both Interleukin-
1beta and Interleukin-6 are elevated in ACS, and contribute to increased prothombogenecity in 
these patients. vWF is a glycoprotein, and plays a major role in platelet aggregation and 
thrombus formation, and elevated levels are    an important predictor of adverse cardiac  
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events. Another small study by Figueras et al (Figueras et al.2000) investigated differences in 
thrombin generation and fibrinolytic potential in UA and AMI patients, and demonstrated high 
levels of thrombin-antithrombin complex, D-dimer and fibrinogen during the acute phase of the 
disease. These and other biomarkers were not investigated in our study, and hence remain a 
limitation to further analysis. 
In the subgroup of 71 ACS patients, no significant correlation w a s  n o t e d  between the GTT 
and Verify Now assay. Verify now was a significant predictor of MACE at 6 months, which 
has been demonstrated in the ARMYDA-Pro trial, and in several other studies.  
The ARCTIC study randomised 2440 patients undergoing PCI to either conventional antiplatelet 
therapy and dose adjustment, or a strategy of platelet-function monitoring using the Verify Now 
assay. The dose of antiplatelet agents was increased in patients who demonstrated a poor 
response to the drug. Platelet inhibition was measured in the cardiac catheterization laboratory 
before stent deployment and in outpatient clinic 2 to 4 weeks later. The primary end point of the 
study was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent 
revascularization 1 year after stent implantation. 34.5 % patients on clopidogrel and 7.6% 
patients on aspirin demonstrated poor platelet inhibition, and had further boluses of the drug or 
were given alternative medications like prasugrel or GpIIb/IIIa inhibitors during the intervention. 
There was no significant difference in the primary endpoint in the monitoring or conventional 
group (34.6% vs.  31.1%, HR 1.13, CI 0.98 to 1.29; P=0.10), suggesting there was no 
improvement in clinical outcomes using this point of care test (Collet et al. 2012). The Trilogy 
ACS substudy used the Verify now assay to compare platelet reactivity between clopidogrel 
and prasugrel, in 2564 NSTEMI patients managed medically without any intervention. 
Although patients on prasugrel demonstrated lower platelet reactivity, this did not translate into 
improved clinical outcomes (17.2% vs. 18.9%, p= 0.29) (Gurbel et al. 2012).  
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GTT OT was not a predictor of MACE in this study. We have previously mentioned all ACS 
patients were on dual antiplatelet medication which may have normalized platelet reactivity, and 
it is possible there was formation of heparin-platelet complex even though patients were sampled 
48 hours after discontinuation of heparin. 
We have previously mentioned the limitations of currently available platelet function tests    
including the Verify now assay in Chapter 1. The Verify now assay is a turbidometry-based 
optical detection device that measures platelet-induced aggregation in a system containing 
fibrinogen-coated beads. The instrument measures changes in light transmission and thus 
measures the rate of aggregation in whole blood. In the cartridge of the VerifyNow P2Y12 assay, 
there is a channel in which inhibition of the P2Y12 receptor is measured. This channel contains 
ADP as platelet agonist and prosta-glandin E1 as a suppressor of intracellular free calcium levels, 
thereby reducing the nonspecific contribution of ADP. Using the Verify now assay, the blood 
sample collected is tested between 10 minutes to 4 hours of collection, and during this duration 
there are changes in platelet behavior. The effect of shear  stress and thrombin is not measured in 
the Verify now assay as it uses citrated blood and low  levels of calcium result in suboptimal 
platelet aggregation. On the contrary, the GTT is performed on native blood immediately after 
collection; is shear induced, and as it does not use citrated blood is able to assess the effect of 
thrombin on thrombosis. Although both OT and PRU are platelet driven processes, the 
mechanism of action of these two tests vary significantly, and no significant correlation was 
observed between OT and Verify now PRU levels in our study. These results may be attributable 
to the small sample size, or variability of the test. 
 
 
198 
 
 
 
Chapter 6: Discussion, Future Research and Study Limitations 
 
General Discussion 
 
This is the first set of studies to demonstrate a significant relationship between impaired 
endogenous thrombolysis and adverse cardiac outcomes in ACS patients. The results of this 
study suggest impaired endogenous thrombolysis is an independent predictor of cardiac 
events, and future research with emphasis on modulation of endogenous thrombolysis, either 
through control of relevant risk factors or pharmacological measures could prove to be of 
significant benefit. Currently, there is no reliable biomarker for determining the efficacy of 
the endogenous thrombolytic system, and not enough evidence is available to determine the 
role of drugs on the endogenous fibrinolytic system. Another limitation has been the absence 
of any platelet function test that could measure endogenous thrombolysis, but the use of GTT 
in this study provides valuable insight into use of a novel point of care test that could aid in 
determination of the efficacy of endogenous thrombolytic system. 
In the above studies, we have demonstrated that novel platelet function tests are able to 
determine the thrombotic and thrombolytic status in various populations. These and newer 
tests can help us determine the effect of medications, and understand the magnitude of 
resistance in the healthy and disease populations. 
Both OT and LT were significantly increased in healthy Japanese volunteers compared to 
healthy Western volunteers, suggesting ethnicity and other genetic and environmental factors 
play an important role in thombus formation. Japanese individuals are at a lower risk of 
coronary artery disease, but at higher risk of haemorrhagic strokes, and prolonged OT and LT 
in the Japanese population would support these findings. 
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In 300 ACS patients, thrombotic and thrombolytic status was assessed. All patients were on 
dual antiplatelet therapy, and the mean OT in these patients was significantly greater than in 
the normal population. A significant proportion of these patients had recurrent cardiac events 
following their index admission suggesting they may be resistant to the effects of aspirin, 
clopidogrel or both. Using certain modifications, we have demonstrated that ADP and 
thrombin  are  important  mediators  of  thrombosis,  and  it  may  be  possible  to  identify 
clopidogrel non responders, allowing us to either increase dose or switch these patients to 
alternative antiplatelet agents. Further large studies are required to help us understand and 
determine the extent of clopidogrel resistance in different disease populations to improve 
clinical outcomes. 
LT provides us with a measure of endogenous thrombolysis. LT was significantly longer in 
the ACS population compared with healthy volunteers, suggesting they were at a higher risk 
of adverse cardiac events. Healthy volunteers had significantly shorter LT’s suggesting they 
had a functioning endogenous lytic system. Clopidogrel demonstrated no significant effect on 
LT in healthy volunteers or stable angina patients, suggesting it did not affect the fibrinolytic 
pathway. On the other hand, aspirin demonstrated a moderate effect on LT in SA patients 
suggesting it could have a beneficial effect on the endogenous fibrinolytic system. Larger 
studies using aspirin at different doses and in different subgroup of patients are necessary to 
study the fibrinolytic properties of aspirin. 
Data from various studies suggest endogenous thrombolysis could be an important predictor 
of adverse cardiac events. In the ASSENT-4 PCI study (Bainey et al. 2008), in a cohort of 
585 patients admitted with STEMI, spontaneous reperfusion was assessed pre PCI using ECG 
or angiographic result. 14.9% demonstrated ST segment resolution, and 14.7% demonstration 
TIMI 3 flow of the culprit artery suggesting spontaneous reperfusion. Significant reduction in 
CV death or reinfarction was noted in the ECG resolution group.    In the Acute Coronary 
Syndrome Israeli Survey (ACSIS) study, 710 patients admitted with a STEMI were assessed  
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for SR during their admission (Fefer et al. 2009). SR was defined as greater than 70% 
reduction in ST elevation and chest pain. 22% patients demonstrated evidence of SR, and 
were conservatively treated in the initial acute stage, with some patients requiring PCI. 78% 
patients who did not demonstrate any significant ST segment resolution underwent primary 
PCI. Adverse outcome at 30 days was significantly lower in the SR group, and was a 
composite of C V  death, congestive heart failure and recurrent ACS. Fornitz et al 
demonstrated the importance of fibrinolytic marker such as PAI-1, tPA and platelet-derived 
growth factor (PDGF) levels coronary artery disease patients pre and post PCI. 19 patients 
were included in this study and followed up for 6 months. Seven patients had instent 
restenosis, and demonstrated higher PAI-1 and lower t-PA values (Fornitz et al.2001). In a 
study of 106 patients ( Soeki et al.2002), AMI patients who had recurrent MI or CV death 
over 4 years had higher t-PA levels compared to controls in the subacute phase of MI, 
suggesting elevated t-PA levels were a significant predictor of cardiac events (P<0.01). 
Another study by Christ et al demonstrated significant elevation of PAI-1 and t-PA levels 
in patients who underwent PCI (Christ et al. 2005). In patients on Ticlopidine, attenuated 
increase of PAI-1 in the first 24 hours was significantly predictive of ISR. In another study of 
75 patients undergoing PCI (Katsaros et al. 2008), PAI-1 levels were measured pre and post 
PCI with a drug eluting stent. 16% patients had ISR at 6-8 months post PCI, and their pre 
PCI PAI-1 levels were significantly lower than the non ISR group of patients. In a case- 
control study in the Cardiovascular Health Study cohort ( Cushman et al. 1999), 5201 
individuals ≥ 65 years age were enrolled and fibrinolytic markers such as PAI-1, D-dimer and 
PAP studied. All 146 cases were not known to suffer from underlying coronary disease and 
developed subsequent MI, angina or CV death over the follow up period. D-dimer and PAP 
levels were independently associated with increased risk of myocardial infarction or coronary 
death.  There w a s  n o  significant correlation between PAI-1 and cardiac e v e n t s .  The  
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Atherogene study demonstrated a significant correlation between activated TAFI levels and 
future risk of cardiac events in 1668 patients with angiographically proven coronary artery  
disease (Tregouet et al.2009). 
Finally,  we  compared  GTT  OT  with  the  Verify  Now  assay  PRU,  and  no  significant 
correlation was observed between the two test results. Studies comparing high platelet 
reactivity using the Verify Now assay with the LTA which is considered the gold standard 
test have shown modest to poor correlation. In a study by Gaglia et al, 200 patients on 
Clopidogrel undergoing PCI were tested using Verify Now assay, LTA and VASP ( Gaglia 
et al . 2011). Incidence of high on treatment platelet reactivity was 27.3% with Verify Now, 
39.3% with VASP, and 23.1% and 16.2% with LTA ADP 5 μM and 20 μM respectively 
(rho= 0.60-0.86, p<0.001). In another study of 222 patients undergoing PCI (Ko et al. 2011), 
Verify Now assay was compared with Multiple Electrode Platelet Aggregometry (MEA). 
Weak correlations were noted between the two tests in both the arachidonic acid-induced 
(Spearman r = 0.189, p = .006) and ADP-induced platelet reactivity (rho = 0.390, p < .001). 
On the contrary, in a study of 801 high risk cardiac patients (Paniccia et al. 2010), MEA 
showed a significant correlation with the Verify Now assay (rho=0.62, p<0.0001). 
To summarize, endogenous thrombolysis has been a neglected entity, possibly as there is no 
reliable marker of fibrinolysis and until recently, there had been no test available to measure a 
patient’s endogenous thrombolytic potential. This thesis has clearly demonstrated that 
endogenous thrombolysis is an important, independent novel predictor of adverse cardiac 
events. Resources need to be directed to study this entity further, to allow us to enable to 
control  and  improve  the  endogenous  fibrinolytic  activity  and  outcomes  in  patients  with 
coronary artery disease ( Saraf et al.2010). 
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Future Research: Fibrinolytic markers and therapeutic modulation of 
fibrinolysis 
 
 
PAI-1 and plasminogen activation play an important role in fibrinolysis. Spontaneous 
thrombolysis has been a neglected entity, and there is not much data available on therapeutic 
modulation of fibrinolysis. Blocking PAI-1 activity seems to be the most feasible approach at 
enhancing  lysis,  and  use  of  PAI-1  antibodies  and  peptides  that  either  inhibits  PAI-1 
production or activity could prove beneficial in controlling thrombus formation. In animal 
models, use of PAI-1 monoclonal antibodies has shown to inhibit thrombus formation 
(Biemond et al. 1995). t-PA activates fibrinolysis, and enhancing release of t-PA from the 
endothelial cells would improve endogenous thrombolytic activity. Endothelial cells release 
nitric oxide with the help of nitric oxide synthase, and improve fibrinolysis. Several factors 
have been shown to improve NO synthase expression, and increase t-PA activity. They 
include Kruppel like Factor 2 (KLF2) (Lin et al. 2005), Dipyridamole (Kim et al. 2005) and 
All –Trans retinoic acid (ATRA) (Marchetti et al. 2003). KLF2 inhibits PAI-1 expression and 
ATRA and Dipyridamole inhibit PAI activity without altering expression. 
Endothelial progenitor cells (EPCs) restore vascular endothelium increasing nitric oxide 
release, and have been shown to improve fibrinolysis and reduce thrombotic activity 
(Ozuyaman et al. 2005). Pitavastatin is a statin in development, that reduces PAI-1 antigen 
and activity and reduces thrombotic activity (Markle et al. 2003). 
Procarboxypeptidase B (CPB) is found in plasma, and is converted by thrombin to its active 
form that inhibits fibrinolysis. CPB inhibitors are being developed, and may be used as a 
target to enhance fibrinolysis in the long term (Suzuki et al. 2004). 
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Study Limitations 
 
 
 
Sampling during index admission following Aspirin 300 mg and Clopiodgrel 300 mg 
 
All patients were sampled during their index admission at a mean of 5±3 days (Mean ±SD). 
All patients had received a loading dose of aspirin 300 mg and clopidogrel 300 mg, and were 
on maintenance dose of aspirin 75 mg and clopidogrel 75 mg. As platelet reactivity is dose 
dependent, it is difficult to anticipate effect on thrombotic status with varying doses of aspirin 
and clopidogrel. It is also possible that steady state concentration of the drug was not fully 
reached during the time of sampling. In our study, none of these patients were sampled 
during subsequent cardiac related admissions. Resampling after the time of the index event 
may have given a better idea of impaired thrombotic and thrombolytic status, helping us 
understand in more detail the effects of impaired occlusion and lysis times. 
As mentioned, all patients were sampled during their index admission in the acute phase of an 
inflammatory response. It is possible that impaired fibrinolysis was part of the acute phase 
response, alternatively it is possible it reflects chronic impairment of fibrinolysis that 
influences late outcome. 
 
Effect of Heparin on thrombotic and thrombolytic status 
 
Low  molecular  weight  heparin  is  a  depolymerized  derivative  of  unfractionated  heparin 
(UFH). It has the ability to inactivate coagulation Factor Xa, and has a higher anti-Factor Xa: 
IIa ratio compared to UFH (2:1 to 4:1). It has greater bioavailability, and a longer half life 
compared to UFH, hence is used commonly in ACS patients. The half life of the drug is 
5-6  hours,  and  twice  a  day  doses  are  used  in  ACS  patients.  Heparin w o r k s  a s  a n  
antiocoagulant by binding to antithrombin III and inhibiting the coagulation cascade. Heparin 
does not work as a thrombolytic, but prevents further clot formation. vWF is essential for  
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platelet thrombus formation at high shear-rates and it is recognised that in addition to its 
effect on coagulation, heparin interferes with this platelet/vWF-mediated haemostasis, and 
forms a heparin-platelet complex that can affect platelet behaviour for longer than 48 hours,  
extending upto 10 days. All patients in our study were sampled atleast 48 hours after 
discontinuation of heparin, but there is a possibility the membrane complex could have 
interfered with the GTT measurements. As most ACS patients undergo coronary angiography 
within 10 days of admission, and are discharged in a timely manner, it was difficult to sample 
these patients at a later date. This might in part explain why OT was not a predictor of 
adverse cardiac events in this study. 
 
Possible diurnal variation in thrombotic and thrombolytic status not investigated 
 
There is data to suggest fibrinolytic activity in blood shows a diurnal variation, peaking in the 
evening with reduced trough levels early morning (Andreotti et al. 1991). PAI-1 and t-PA are 
also known to show this diurnal variation, which may explain the difference in trough levels. 
We did not sample patients at different times of the day, and LT results may hence not be 
reflective of this change in circadian rhythm. 
 
Pharmacological modulation of endogenous thrombolytic status not assessed 
 
PAI-1 and TAFI are released from activated platelets, and inhibit fibrinolysis. As thrombin is 
required for release of both these markers at physiological calcium concentration, thrombin 
inhibition would achieve the goal of adequate fibrinolysis. Direct thrombin inhibitors are 
being developed, and use of these drugs with measurement of PAI-1 and TAFI concentration 
will in due course allow us to come to a meaningful conclusion regarding effective 
fibrinolysis. 
 
 
 
205 
 
 
 
 
Other drugs shown to have some beneficial effect on fibrinolysis are aspirin at high doses, 
antidiabetic medications like metformin and sulfonylurea, ACE-I and nitrates. There is data 
to suggest Eplerenone, an aldosterone antagonist inhibits release of PAI-1 and may have a 
role to play in endogenous fibrinolysis. 
In the absence of direct thrombin inhibitors and limited data on reliable fibrinoytic markers, it 
was difficult for us to measure the levels of different fibrinolysis markers in vitro. A reliable 
marker of fibrinolysis is required to assess the efficacy of endogenous fibrinolysis, and larger  
trials will help us delineate which markers and medications are most effective in enhancing 
fibrinolysis and improving cardiovascular outcomes. 
 
Statistically underpowered to detect a significant effect in subgroups 
 
The study was underpowered to investigate thrombotic and thrombolytic status in certain 
subgroups of patients due to the small number of patients and events in subgroups such as: 
STEMI, diabetes mellitus, renal impairment, and smokers.  Larger studies with greater 
number of events would be required to study the effects of these clinical parameters in these 
subgroups of patients. 
Future work around this subject involves use of GTT in different patient populations. Studies 
are currently ongoing in elective and emergency PCI patients, renal patients, in patients with 
atrial fibrillation and in patients on newer antiplatelet agents like direct thrombin inhibitors.  
Further larger studies will need to be validated in homogenous patient cohorts to avoid any 
bias in data interpretation, and all studies need to be adequately powered to help us reach a 
statistically significant conclusion. Measurement of various thrombotic and fibrinolytic 
markers will help understand the concept of thrombosis and thrombolysis, and microscopic 
observation of the injected blood at different levels in the GTT tube help in determination of  
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the mechanism underlying OT and LT. Comparison of various point of care assays will help 
determine the ideal and most reliable and physiological platelet function test.  
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Case report form 
 
 
 
 
STUDY NO  THROMBOLYSIS  
HOSPITAL NO  THROMBOLYSIS DATE/TIME  
INITIALS  DIPYRIDAMOLE  
DATE OF BIRTH  INSULIN  
AGE  METFORMIN  
SEX  OTHERS  
DIABETIC  DATE OF ADMISSION  
SMOKER  STEMI  
HYPERTENSION  THROMBOLYSED  
PRIOR CAD  TROP POSITIVE  
RENAL DISEASE  PEAK TROPONIN  
CREATININE  DYNAMIC ECG CHANGES  
PVD  LAST EPISODE CHEST PAIN  
STROKE/TIA  ANGIOGRAM RESULT  
BLEEDING DIATHESIS  INTERVENTION AND STENT  
ASPIRIN  HAEMOGLOBIN  
DATE ASPIRIN STARTED  RBC  
CLOPIDOGREL  PLATELETS  
DATE CLOPIDOGREL STARTED  CREATININE  
STATIN  UREA  
ACE I/ ARB  DATE OF TESTING  
BETA BLOCKER  TIME OF TESTING  
NITRATE  LAST DOSE ASPIRIN/ CLOP  
CLEXANE  GTT OT  
CLEXANE LAST DOSE  GTT LT  
WARFARIN  VERIFY NOW BASE  
WARFARIN LAST DOSE  VERIFY NOW PRU AND % 
 
ININHIBITION 
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